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Abstract
Alpha2 macroglobulin (a2M) is a major blood protein (2-4mg/ml in adult
blood) with a molecular weight of 725kD. Recent reports have indicated that
this molecule may bind a variety of cytokines. Such interactions could have
important implications with respect to the activity and quantitation of
cytokines in vivo and in vitro. The aim of the present study was to establish if
a2M bound a number of previously unstudied cytokines of immunological
importance, and if so, did this influence their immuno- and bio-reactivity. The
cytokines in question were recombinant derived human IL2, TNFa and IFNy.
The initial studies were qualitative in nature employing G200 Sephadex, FPLC
on Superose 6B, zinc affinity chromatography on Sepharose, and native and
SDS PAGE. The aim of these studies was to separate preincubated a2M and
cytokine, and thus to identify cytokine that had bound to the serum protein.
From this work it was apparent that IL2, TNFa and IFNy bound to a2M. For
all 3 cytokines the binding was stronger with a2M-methylamine (a2Mm), a
chemically altered form of a2M that has a physiological equivalent.
Subsequent biochemical studies were carried out using a2Mm. To analyse the
quantitative interaction of cytokines with a2Mm, a novel radioimmunoassay
system was developed using anti-human a2M polyclonal reagent as the
capture antibody. In addition, the zinc affinity Sepharose system that had been
used in earlier qualitative studies was adapted to a tube system to permit
batch analysis of a2Mm-cytokine interactions. These techniques revealed a
binding affinity for IL2 with a2Mm of Kcj=2.1-2.5xlO'6M, while that of TNFa
with a2Mm was 1^=0.96-1.36xlO~6M. Furthermore, IL2 bound non-
specifically whereas TNFa showed a specific interaction with the serum
protein. The relevance of such interactions was studied by determining the
effect of a2M on commercial cytokine immunoassays. It was found that a2M
and its derivatives may mask or enhance the detection of a number of
cytokines, the effect being dependent on the cytokine and on the source of the
kit. The influence of a2Mm on the bioactivity of IL2 and TNFa was examined
in lymphoproliferative and antiproliferative assays respectively. These studies
revealed that the complexing of TNFa with a2Mm ablated its bioactivity,
whilst that of IL2 was maintained when complexed with the protein. In
conclusion, the results presented corroborate previous work in the literature
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The following list of abbreviations appear in the main body of this thesis.
AD - Alzheimer's Disease
aM - alpha macroglobulin
a2M - alpha 2 macroglobulin
ARDS - adult respiratory distress syndrome
bFGF - basic fibroblast growth factor
BAC - bovine adrenocortical cells
BSA - bovine serum albumin
CF - cystic fibrosis
cisDDP - cisdichlorodiamineplatinum
CNS - central nervous system
EDTA - ethylenediaminetetraacetic acid
EGF - epidermal growth factor
5HT - 5 hydoxytestosterone
IFNy - interferon gamma
ILlp - interleukin lbeta
IL2 - interleukin 2
IL4 - interleukin 4
IL6 - interleukin 6
IL8 - interleukin 8
- dissociation constant
LDL - low density lipoprotein
LRP - LDL-related protein
LMW - low molecule weight
MAF - macrophage activating factor
MIF - macrophage inhibitory factor
NGF - nerve growth factor
PZP - pregnancy zone protein
PAGE - polyacrylamide gel electrophoresis
PBS - phosphate buffered saline
PDGF - platelet derived growth factor
RA - rheumatoid arthritis
RIA - radioimmunoassay
SDS - sodium dodecyl sulphate
TEPP - thiol ester plasma proteins
TGFp - tissue growth factor beta
TNFa - tumour necrosis factor alpha
Section 1:
Introduction
1.1: Alpha 2 macroglobulin
1.1.1:An introduction to oQM
Alpha 2 macroglobulin (a2M) is a 725kDa protein found at a concentration
of 2-4mg/ml in human plasma (Ganrot and Schersten 1967; Tunstall,
Merriman, Milne and James 1975). It is also present in extravascular
fluids such as in synovial fluid and in neurological tissue (Teodorescu,
Gaspar, Spear, Skoskey and Ganea 1984; Strauss, Bauer, Ganter, Jonas,
Berger and Volk 1992). a2M's activity as a proteinase inhibitor has been
extensively researched (Barrett and Starkey 1973; Barrett, Brown and
Sayers 1979, see Sec. 1.6 and 1.7). It appears in the circulation as an open
cylinder that interacts with proteinases resulting in a conformational
change of the a2M molecule (Fig. 1.1.1, see Sec. 1.6 and 1.7). The
conformational change results in a shift in mobility under the conditions of
polyacrylamide gel electrophoresis (PAGE) giving rise to the designations
of slow (native) and fast (converted) a2M. The conformational change
entraps the proteinase and reveals a binding site for the a2M receptor.
Under normal conditions, the a2M-proteinase complex is rapidly removed
from the circulation via cells bearing the a2M receptor.
It has become apparent that a2M may have a role within the immune
response (James 1980; Borth 1992, see Sec.1.8.). This may be
implemented by its inhibitory effect on proteinases. In the literature, a
novel function has been proposed: namely that a2M may bind cytokines
and thus modify their activity in vivo (reviewed in James 1990, see
Sec. 1.9). Herein this proposition is examined.
1
(A)Nativea2M(B)Converted2M
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1.2: a2M in health and disease
1.2.1: a2M in health
In healthy adults, a2M is present at a plasma concentration of 2-4mg/ml,
ofwhich a2M-proteinase complexes normally constitute 0.2-0.8% (Abbink,
Nuijens, Eerenberg, Huijbregts et al 1990; Zucker, Lysik, Zarrabi, Fiore,
and Strickland 1991; Birkenmeier and Stigbrand 1993). The level of a2M
varies with age and between the sexes (see Table 1.2.1.). Age variation is
attributed to the increased requirement of a2M as a proteinase inhibitor
during development, thus its levels are highest in the foetus at late
gestation, and remain high through to the end of puberty (Ganrot and
Schersten 1967; Tunstall et al 1975). Hormonal regulation of a2M
synthesis may partly account for the increased concentration seen in
females (Ganrot and Schersten 1967; Tunstall et al 1975). However, the
difference between the sexes continues beyond the menopause.
a2M functions as a proteinase inhibitor and a binder of cytokines and
growth factors (reviewed in James 1990; Borth 1992, see Sec. 1.6, 1.7 and
1.9). By these roles it can contribute to the pathogenesis of a number of
diseases as illustrated in Table 1.2.2., and discussed below.
1.2.2: Role of a2M in reproductive organs
In the male and female reproductive systems, a2M has a significant
function as a proteinase inhibitor and a binder of growth factors. In the
ovaries, such functions are required for tissue remodelling during ovulation,
development of the corpus luteum and in pregnancy (Gaddy-Kurten,
Hickey, Fey, Gauldie, and Richards 1989; Curry, Mann, Estes, Jones
1990). In the testes, a2M is the major proteinase inhibitor restricting the
damage of proteinases produced by degenerating spermatozoa as they






Birth 3 N/M N/M
0-1 4 N/M N/M
1-3 4.25 N/M N/M









Table 1.2.1: The mean serum concentration of a2M in different
age groups
Serum a2M concentration was measured for 12 age groups. Levels in
childhood and puberty were higher than in adult life possibly reflecting
the use of cx2M in control of growth in pre-adult life. Female adults
consistently had a higher concentration than men. N/M indicates data
not measured. Figures derived from Ganrot and Schersten (1967).
Disease Characteristics
Ehlers-Danlos Syndrome - a2M deficiency
- cutaneous hyperelasticity,
hyperextensible joints
Cystic Fibrosis - functional a2M deficiency
- error in bait region or in receptor
recognition domain
Rheumatoid Arthritis - increased a2M levels locally
- a2M-proteinase complexes form
- decreased clearance of complexes




- increased a2M levels locally
- binds proteinase and maintains activity
- leads to lung injury
Venous Ulceration - a2M, and other macromolecules leak
into dermis
- inhibit wound repair and tissue
maintenance
Cancer - variable effects dependant on tissue,
disease stage, individual patient
- effects involve interactions with
proteinase, cytokines, or cytoskeleton
Alzheimer's Disease - increased levels locally
- present in amyloid plaques and in
microglial cells
- function in disease pathogenesis unclear
Gingivitis - increased levels locally
- may act to inhibit proteinase activity
Table 1.2.2: The role of a2M in a range of disease states
a2M has been reported to be involved in the pathogensis or recovery from
a number of diseases. Its activity may be due to association with
proteinases, cytokines, or with cytoskeletal proteins as discussed in
Section 1.2.
et al 1990). a2M also limits the action of proteinase dependent
seminiferous tubule remodelling, and maintains TGF(3 and other growth
factor and cytokines in an inactive/latent state limiting their activity to a
small area of epithelium.
Foetal and maternal levels of a2M have been found to be inversely
proportional to foetal birth weight (Goldenberg, Tamura, Oliver, Cutter et
al 1991; Oliver, Goldenberg, Neel, Tamura et al 1993). It has been
proposed that the increased a2M concentration may be linked to an
immune response against a bacterial infection in the foetus, the infection
also resulting in growth retardation of the foetus. In addition, pregnancy
zone protein (PZP), a high molecular weight a-globulin, of similar form to
a2M, rises in pregnancy from trace levels to lmg/ml by the third trimester.
This protein is further discussed in Sec.1.5.
1.2.3: Deficiency of a2M
Complete absence of a2M is thought to be a lethal deletion. Examination
of 100,000 different sera did not find an individual devoid of a2M (Laurell
and Jeppsson 1975). It has been proposed that absence of a2M may
cause death of the foetus, indicating that it is a crucial requirement for the
developing embryo.
Deficiencies of a2M have been recorded (Mahour, Song, Adham, and
Rinderknect 1978; Bergqvist and Nilsson 1979; Stenberg 1981). Low
levels of a2M are found in some patients with Ehlers-Danlos syndrome,
where it may contribute to cutaneous hyperelasticity and hyperextensible
joints observed in this condition (Mahour et al 1978). In contrast to
deficiencies of other proteinase inhibitors, for example a2 anti-plasmin, al
anti-trypsin and anti-thrombin III which predispose the patient to lung
disease, liver dysfunction, and thrombosis, a2M deficiency can be
3
asymptomatic (Stenberg 1981). However, a low concentration of a2M is
observed in a number of other conditions including multiple myeloma,
pulmonary embolism, and extensive trauma.
1.2.4: Cystic Fibrosis
In cystic fibrosis (CF), a pseudodeficiency occurs where, due to defective
proteinase trapping or receptor recognition, a2M does not inhibit and clear
proteinase effectively (Wilson and Fudenberg 1976; Shapira, Martin, and
Nadler 1977; Marynen, Van Leuven and Cassiman 1983). The
pseudodeficiency may arise from an inherited error in the bait region of the
a2M molecule rendering proteinases unable to cleave it and resulting in
decreased proteinase trapping and therefore decreased clearance (see
Sec.1.6 and 1.7). Alternatively, polyamine derivatives, present in high
levels in the plasma of CF patients, may bind to the thiol ester causing
closure of the trap and inhibiting further interaction with proteinases
(Wilson and Fudenberg 1976). In addition, the a2M-receptor recognition
domain may be defective in CF patients resulting in abnormal levels of
proteinase bound to a2M compared to control sera (Marynen et al 1983).
In such circumstances, the level of endocytosis of a2M-proteinase can be
decreased by 20%, with the result that a proportion of bound proteinase
remains active and in the circulation or tissues for longer.
1.2.5: Role of a2M in disease
In normal health, the principle function of a2M appears to be as a
proteinase inhibitor. It traps and inhibits members of all 4 endoproteinase
classes, and may function when other inhibitors are exhausted (Barrett
and Starkey 1973; Travis and Salvesen 1983, see Sec.1.6 and 1.7). The
enzyme protein complex binds to receptors expressed on a range of cells,
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especially hepatocytes. This binding occurs via a neoantigen receptor
recognition domain on the converted protein and results in endocytosis of
the complex (see Sec.1.6.7).
In disease states, the levels of a2M synthesised may change, and as levels
of proteinase rise the amount complexed to a2M requiring clearance from
the circulation or tissues increases. The efficient inhibition of proteinase
requires not only rapid binding by inhibitor, but also rapid clearance since
proteinases can remain active against small substrates when bound to
a2M (Barrett and Starkey 1973; Levine, Sherry, Strickland and Ilowite
1993). The rate of clearance of a2M-proteinase is a particular problem in
rheumatoid joints, and possibly in adult respiratory distress syndrome as
discussed below.
1.2.6: Rheumatoid arthritis
In adult and juvenile rheumatoid arthritis (RA), the concentration of anti-
proteinase activity within the synovial joint increases (Teodorescu et al
1984; Borth, Dunky and Kleesiek 1986; Levine et al 1993). Specifically,
increases in a2M-proteinase complex concentration are seen, and these
have been correlated with increased levels of neutrophils and of neutrophil
elastase activity. The key role of neutrophils in RA is highlighted by the
increase in their concentration from 5% to 90% of the cells in the RA joint,
and they have been implicated as major mediators of tissue destruction in
RA (Abbink, Kamp, Nieuwenhuys, Nuijens et al 1991). a2M may enhance
the activity and half life of neutrophil elastase, and possibly of other
proteinases in synovial fluid by two means (Abbink et al 1991; Teodorescu
et al 1984; Levine et al 1993):
(i) a2M traps proteinase and unlike other inhibitors, the interaction does
not inactivate the proteinase; small substrates still have access to them.
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Thus, when neutrophil elastase is bound by a2M it retains some activity.
In this context it should be noted that 74% of neutrophil elastase activity
in the RA joint has been reported to be associated with a2M (Levine et al
1993).
(ii) a2M can undergo the aforementioned conformational change by direct
cleavage of a second bond, an internal thiol-ester (see Sec. 1.1.1 Fig. 1.1.1,
Sec.1.6 and 1.7). The cleavage of the thiol-ester can be mediated by
oxygen reactive species produced by neutrophils, and apparently can
account for 90% of the total conformationally altered a2M levels observed
(Levine et al 1993; Shatcher, Maayan and Feinstein 1973).
Thus, neutrophils produce elastase which can be bound by a2M and
remain active, and whose clearance rate as a complex with a2M is
decreased because of the overload of inactive, receptor-recognised a2M
produced by oxygen reactive species. It was found that up to 46% of a2M
present in RA synovial fluid is inactive, arising due to interactions with
proteinase or with oxygen species (Abbink et al 1991). The neutrophil
elastase bound by a2M is protected from inactivation by other proteinase
inhibitors.
In addition, a2M binds ILlp and IL6 retaining the cytokines bioactivity
(Teodorescu, McAfee, Skosey, Wallman et al 1991; Matsuda, Hirano,
Nagasawa and Kishimoto 1989). This may also contribute to the
pathogenesis of RA and is further discussed in Sec. 1.9.
1.2.7:Adult respiratory distress syndrome
The interaction of a2M with neutrophil elastase has also been implicated
in adult respiratory distress syndrome (ARDS) (Wewers, Herzyk and
Gadek 1988). There are increased numbers of neutrophils in ARDS lung
lavage fluid. In normal patients less than 5% of their lavage cells are
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neutrophils, but in ARDS this increases to 60-90% of the total cell count
(Abbink et al 1991; Wewers et al 1988). Simultaneously, protein levels
increase, and there is a marked rise in neutrophil elastase activity which
has been shown to be associated with a2M. Thus, it appears that a
parallel scenario to RA occurs in the lung in ARDS with an influx of
neutrophils producing proteinase whose activity may be maintained by
a2M. The a2M-proteinase complexes may be cleared thus defending the
lungs against injury, but there is evidence to suggest that the complexes
promote lung injury (White, Janoff, and Godfrey 1980; Wewers et al 1988).
The increased levels of a2M could be leaking from the vascular system due
to the increased permeability associated with ARDS, or may be
synthesised by macrophages that infiltrate the area during ARDS (White
et al 1980).
1.2.8: Cancer
It is presently uncertain what role a2M plays in the control and
development of cancers. The concentration of a2M varies according to the
tissue and stage of cancer, and with considerable individual deviations
(Twining and Brecher 1977; Saksela, Vaheri, Schleuning, Mignatti and
Barlati 1984a; Saksela, Wahlstrom, Meyer, and Vaheri 1984b; Burtin,
Chavanel, Andre-Bourgaran, and Gentile 1987; Matoska, Wahlstrom,
Vaheri, Bizik and Grofova 1988; Bizik, Lizonova, Grofova, Matoska et al
1989).
Changes in a2M concentration appear to be local to the tumour site,
suggesting it is acting as a local defence protein remote from plasma a2M
(Zucker et al 1991; Saksela et al 1984b). For example, variations in a2M
levels are observed during the development of cervical cancer.
Examination of cervical epithelia at a number of stages of dysplasia
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reveals an inverse correlation between a2M concentration and the disease
stage. Furthermore, in truly neoplastic tissue no a2M synthesis or uptake
can be detected (Saksela et al 1984b). Differences between individual
patients were found in human melanomas where a2M production varied
considerably. In one study, a2M levels were found to correlate positively
with a poor prognosis, suggesting the inhibitor may contribute to the
pathogenesis of the disease (Matoska et al 1988). This may have been due
to a2M maintaining the proteolytic activity of bound molecules, similar to
its proposed role in RA and ARDS.
In contrast, the interaction of a2M with growth factors and cytokines may
inhibit tumour development (see Sec. 1.9). For example, a2M is a selective
growth disadvantage in certain melanomas in vitro where its presence has
been found to increase the tumours doubling time (Bizik et al 1989). a2M
is known to bind PDGF and to restrict its activity, therefore it has been
proposed that it retards the growth of tumours by inhibiting PDGF activity
(Huang, Huang and Deuel 1984; Bizik et al 1989).
A loss of a2M function may occur as its synthesis is switched off in
transforming cells. A decrease in a2M levels may contribute to tumour
development due to a change of surface properties, and loss of cell adhesion
and morphology (Saksela et al 1984a; Twining and Brecher 1977; Zardi,
Carnemolla, Cagnasso and Santi 1980). A positive correlation between
a2M and fibronectin was reported by Zardi et al (1980), implying a role for
a2M with respect to fibronectin, a protein active in maintenance of cell
morphology, cytoskeletal structure and adhesion. The physical changes
observed in transformed cells may occur due to the uncontrolled activity of
proteinases that function at the cell surface, and may arise due to a
decreased production of a2M and a number of other inhibitors.
There is a range of proteinase inhibitors present at tumour sites, and a2M
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may be part of a network. It may be acting as a "back-up" inhibitor, for
example inhibiting plasmin activity when its principle inhibitor a2 anti-
plasmin is at a low concentration (Burtin et al 1987). These and other
proteinase inhibitors deserve further investigation as to their pleiotropic
effects at tumour sites (Troll, Frenkel and Wiesner 1984).
1.2.9: Venous Ulceration
a2M, and other macromolecules, may have a role in venous ulceration
(Falanga and Eaglstein 1993). It is known that venous hypertension
precedes this condition, but the subsequent pathogenesis is unclear. a2M,
fibrin, and other macromolecules leak into the dermis during hypertension,
and ulcers are characterised by extravasation of fibrinogen and a2M. a2M
and other macromolecules may "trap" growth factors and other
stimulatory or haemolytic substances in the dermis. Thus, repair of the
wound that forms during ulceration and maintenance of tissue integrity is
restricted. TGFp and TNFa are bound by a2M which may inhibit their
activity (Danielpour and Sporn 1990; Wollenberg, LaMarre, Rosendal,
Gonias and Hayes 1991, see Sec.1.9). Though abundant in ulcers, wound
fluid does not contain the expected stimulatory activity attributable to
TGFp and TNFa, indicating restriction of the activity of these molecules.
The effects of a2M, and other macromolecules, may therefore be
implicated by binding to growth factors and altering their concentration or
sequence of release, thus affecting the growth factor "language" of repair
(Sporn and Roberts 1988).
1.2.10: Alzheimer's Disease
a2M may have a role in the development ofAlzheimer's disease (AD). It
is present at increased levels in central nervous system (CNS) tissue in
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AD patients. It appears that a2M may immunomodulate microglial cells
in an inflammatory response. This is supported by the observation of a2M
staining in neuritic plaques, although in vitro production of a2M by
neuroblastoma cell lines have contradicted these findings (Ashall and
Goate 1994; de Strooper, Van Leuven and Van den Berghe 1992). a2M
has previously been purported to be an inhibitor of secretase, a proteinase
required for the normal cleavage of amyloid precursor protein, a significant
protein in AD (Strauss et al 1992). Inhibition of secretase results in
aberrant cleavage of the protein to form p-amyloid which is found in high
concentrations in AD plaques. However, it appears that a2M and other
proteinase inhibitors do not influence the disease progression at the point
of secretase (de Strooper et al 1992).
1.2.11: Gingivitis
In the buccal cavity, gingivitis can be induced by cessation of brushing for
10 days (Giannopoulou, Di Felice, Andersen and Cimasoni 1990). The in
vivo study of a2M production in the gingival sulcus was based upon an in
vitro observation of a2M synthesis by cultured gingival fibroblasts
(Condacci, Cimansoni, Rey and Baehni 1988). The study revealed a 6 fold
increase in a2M levels in the gingival sulcus that corresponded to the
development of inflammation. Albumin levels increased 2 fold therein, and
neither protein increased in concentration in the serum. Due to its size it is
unlikely that a2M could move freely from the serum to the buccal cavity
membranes, indicating that a2M found locally under normal and
inflammatory conditions was produced by local cells and by infiltrating
leucocytes.
10
1.3: Synthesis of a2M
1.3.1: Hepatic synthesis of cSM
As with most plasma proteins, the primary site of a2M synthesis is
believed to be the liver, specifically hepatic and Kupffer cells (Laurell and
Jeppson 1975). However, a number of other cells are known to produce
a2M including lymphocytes, cultured human fibroblasts, monocytes,
human alveolar macrophages, gingival fibroblasts, cultured bovine adrenal
cortical cells, and cells of the testis and ovaries (Tunstall and James 1974;
Mosher and Wing 1976; Hovi, Mosher and Vaheri 1977; White et al 1980;
Straight, Jakoi, McKee and Snyderman 1988; Condacci et al 1988;
Giannopoulou et al 1990; Kirshner, Corcoran and Erickson 1989; Cheng et
al 1990; Gaddy-Kurten et al 1989; Curry et al 1990).
1.3.2: Extra-hepatic synthesis of aZM
Local synthesis of a2M may be outwith the control of the hepatic system,
as demonstrated in various disease states. For example, as discussed
previously, in RA and in cancer a2M levels have been found to rise in
synovial fluid or at the tumour site, but plasma levels remain normal
(Levine et al 1993; Zucker et al 1991, see Sec. 1.2). The synthesis of a2M
at extra-hepatic sites serves a range of functions including local control of
proteolysis (see Sec. 1.2). There is also evidence that in some tissues a2M
may regulate growth factor and cytokine activities (see Sec. 1.9).
In bovine adrenocortical cells, TGFp and a2M form a feedback loop each
modulating the synthesis and activities of the other (Kirshner et al 1989;
Shi, Savona, Gagnon, Cochet et al 1990; Keramidas, Chambaz and Feige
1992,see Sec. 1.9). In addition, it appears that hormonal control of
synthesis occurs in the ovaries and testis (Gaddy-Kurten et al 1989;
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Curry et al 1990; Cheng et al 1990). It has been suggested that there is
very little control over a2M synthesis normally (Mosher 1983). Beyond
these details the factors that induce or inhibit a2M production in humans
are not well documented.
It has been shown that there is a positive correlation between proteinase
and a2M secretion in fibroblast like cells: it may be that a2M is
synthesised to inhibit proteinase activity and limit it to the
microenvironment in which it was produced. There are a range of in vivo
sites at which this correlation is evident, such as in the RA joint, in the
alveolar space, and in the buccal cavity (see Sec. 1.2). Therefore, it may be
proposed that at non-hepatic sites the stimulus for the production of
proteinase and inhibitor may be one and the same.
Thus, it can be concluded that a2M is primarily produced by the liver, but
local synthesis can occur both constitutively and in disease states. In
addition, there is evidence of exchange between the vascular and tissue
pools of a2M (Zucker et al 1991).
1.3.3:The a2Mgene
The a2M gene is located on chromosome 12 (Kan, Soloman, Belt, Chain et
al 1985). Control elements have been identified in the rat, for example the
HP1 element, a metal response element, a potential Spl binding site and a
transcription initiation site in the 5' flanking region of exon 1 which is
homologous to IL6 response elements (reviewed in Borth 1992). IL6 has
been identified as an acute phase stimulator of a2M synthesis in rat liver,
and to induce a2M synthesis in a murine neuroblastoma cell line
(Warburton, Gusterson and O'Hare 1993; Ganter, Strauss, Jonas,
Weidemann et al 1991; see Sec. 1.2).
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1.4: a-Macroglobulins in other species
1.4.1: Detection ofaM in other species
a-macroglobulins (aM's) have been recognised in a number of species
(Starkey and Barrett 1982a; Starkey, Fletcher and Barrett 1982; Starkey
and Barrett 1982b; Saito and Sinohara 1985; Feldman and Pizzo 1985;
Bjork, Lindblom and Lindahl 1985; Sottrup-Jensen, Borth, Hall, Quigley
and Armstrong 1990). Starkey and Barrett conducted a definitive study
by examining a large range of vertebrates for the presence of a papain
binding protein with a2M-like characteristics (Starkey and Barrett
1982a). Their premise was that due to its important role as a human
proteinase inhibitor a2M would probably be found in other species therein
conducting similar functions. All major vertebrate taxa were found to have
a 725kDa protein that could bind papain restricting the enzyme's activity
to small substrates. Invertebrates, specifically arthropods, were also
examined: not all were found to be positive for a2M, although Limulus
polyphemus, the horse shoe crab, was shown to have a form of aM. These
results indicate that human a2M has homologous proteins throughout a
wide range of organisms, as illustrated in Table 1.4.1.
Limulus aM was found to interact with proteinase and with methylamine
in a similar manner to aM in higher organisms. However, its molecular
weight is in the region of 550kDa, thus it is trimeric as compared to the
725kDa tetrameric human a2M. Fish, specifically plaice, were found to
contain a 360kDa aM that can interact with proteinase or with
methylamine, but which did not show a conformational change (Starkey
and Barrett 1982a and b; Starkey et al 1982). Starkey and Barrett
speculated that a transition of aM from a dimer to tetramer form and
ability to change conformation must have occurred during evolution.
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and Barrett as illustrated in Table 1.4.1. The most striking features are
the range of species in which aM have been found, and that many species
have 2 or more distinct forms of the inhibitor.
1.4.2: Homology amongst aMs
Sequencing studies and amino acid composition analysis have been carried
out on a number of aM's, and as expected homology is apparent (Sottrup-
Jensen, Folkersen, Kirstensen, and Tack 1984, Feldman and Pizzo 1986,
Sottrup-Jensen 1987, Spycher, Arya, Isenman, and Painter 1987).
Conserved sequences have been found to be at the N terminus, bait region
and thiol ester, and at other sites throughout the molecule (see Fig.1.4.1.)
1.4.3: Evolution of aM
Frog alM and bovine a2M seem to be proteins at evolutionary crossroads
in the development of the tetramer of higher vertebrates (Feldman,
Gonias, Ney, Pratt and Pizzo 1984; Feldman and Pizzo 1985; Bjork et al
1985; Feldman and Pizzo 1986). They exhibit a range of characteristics
that make them less efficient as proteinase inhibitors than the aM found
in higher species. These various features of lower species aM's, such as
dimer form, no conformational change, no receptor recognition domain, low
trypsin binding efficiency, contrast to those of higher organisms such as
rats and humans. In the latter, aM is usually present as a tetramer whose
conformational change alters upon efficient interaction with proteinase
activating the inhibitor, exposing the receptor recognition domain,
entrapping the proteinase and resulting in clearance of the inhibitor from
the circulation via the a2M-receptor (Feldman, Gonias and Pizzo 1985).
Monomer and dimer aM are present in a number of species, as indicated in
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and Gauthier 1985; Saito and Sinohara 1985; Moncino, Roche and Pizzo
1991). For example, rat allg is similar to the monomer subunit of human
a2M, and has an internal thiol ester bond. It traps proteinase in a similar
mechanism to human a2M but does not limit access to substrates
(Esnard et al 1985). Unlike dimers and tetramers, covalent binding is
essential for proteinase interaction with monomers (see Sec. 1.7).
1.4.4: Ovostatin
The thiol ester bond is a characteristic feature of aM's and it is vital to the
activity of the related complement proteins C3 and C4 (see Sec. 1.5, 1.6,
and 1.7). Nevertheless, some forms of aM exist without this bond. Hen
plasma has a thiol ester containing a2M, but in hen egg white, as in other
avian and amphibian eggs, there is a distinct second form (Nagase, Harris,
Woessner and Brew 1983; Nagase and Harris 1983). This protein,
ovostatin, has no internal thiol ester but is otherwise similar to other aM
proteins and its activity against proteinases does not seem to be perturbed
by this absence. The complement protein C5 also has a structure similar
to the monomer chain of a2M but the cysteinyl and glutamyl residues of
the thiol ester bond are absent (Sottrup-Jensen 1987, see Sec. 1.5).
1.4.5: Role of aM as a defence protein
aM has been identified in diverse species and it has been suggested that it
could be a primitive defence molecule for inhibiting proteinase (Barrett
1981; Sottrup-Jensen 1987; Matsuda et al 1989). Indeed, the lobster
Homanus americanus has a trimeric form of a2M but apparently no thiol
ester containing complement proteins, such as C3 and C4 (Spycher and
Painter 1991). In lower species, a2M may form part of a "primitive"
defence system from which its "modern day" counterparts in higher
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organisms have evolved, principally a2M, its homologues, and the
complement proteins C3, C4, and C5 (Sottrup-Jensen, Stepanik,
Kristensen, Lonblad et al 1985). Furthermore, the Limulus lineage and
vertebrates diverged at least 550 million years ago, indicating that the
function of a2M is ancient and evolutionarily conserved (Quigley and
Armstrong 1983a and b).
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1.5: Thiol ester plasma proteins
1.5.1: The thiol ester plasma proteins in humans
Human blood contains two a-macroglobulins, namely a2M and PZP (see
Sec. 1.4 Table 1.4.1). These proteins contain an internal thiol ester bond,
but they are not unique in this respect. The complement proteins C3 and
C4 have also been identified as thiol ester plasma proteins (TEPP) the
bond being critical to their activities (Fig. 1.5.1; Tack, Harrison, Janatova,
Thomas and Prahl 1980; Janatova and Tack 1981; Sottrup-Jensen 1987).
These proteins can be grouped by a number of common features:
(i) Slow inactivation by amines (Gordon, Whitehead and Wormall 1926;
Tack et al 1980; Janatova and Tack 1981; Sand, Folkersen, Westergaard,
and Sottrup-Jensen 1985; Van Leuven, Cassiman and Van den Berghe
1982).
(ii) Rapid covalent binding of the proteinase activated form of the TEPP to
another protein or to a cell surface (Law 1984; Salvesen and Barrett 1980;
Sand et al 1985).
(iii) The appearance of titratable -SH groups during these reactions
(Janatova and Tack 1981; Sand et al 1985; Barrett et al 1979).
(iv) Specific conformational change with recognition by a cell surface
receptor (Janatova, Lorenz, Schechter, Prahl and Tack 1980a; Jantova,
Tack and Prahl 1980b; Janatova and Tack 1981; Van Leuven, Cassiman
and Van den Berghe 1986a; see Sec. 1.6 and 1.7).
1.5.2: Homology
A comparison of available sequence data has enabled alignment of
homologous regions and has lead to the conclusion that these proteins
come from a single ancestral gene (Sottrup-Jensen et al 1985; Sottrup-































































































Figure 1.5.1: Chemical structure and reactions of the internal thiol ester bond in
the thiol ester plasma proteins
The internal thiol ester bond of all thiol ester proteins can react with primary amines such as
methylamine (A). a2M reacts with lysine sidechains of entrapped proteinases (B).
Complement proteins C3 and C4 react through the cleaved thiol ester with polysaccharides,
membrane components, and immune complexes (C). The thiol ester can also be denatured
forming an internal pyroglutamic acid ring (D). In each case a free -SH group appears which
is available to react with other proteins. Taken from Sottrup-Jensen 1987.
and subsequently cleaved to produce their secreted form. The single pro-
protein chain of each complement protein compares to the primary
structure of the a2M monomer at several points (see Sec.1.4. Fig.1.4.1).
The key features are:
(i) N terminus: the terminal 40 or so residues are homologous.
(ii) The bait region sequence: the bait region is found in the a chain of C3
and C4. In addition, the bait region of the a2M monomer aligns with the
sequence of pro-proteins of C3 and C4 within which they are cleaved to
form the a-(3 chains of the secreted protein. C4 has a second cleavage
point towards the COOH terminus and its secreted form is therefore
trimeric.
(iii) Internal thiol ester bond: a residue sequence of approximately 150
amino acids containing the thiol ester bond is very homologous between
the proteins (Swenson and Howard 1980; Tack et al 1980; Thomas,
Janatova, Gray and Tack 1982; Sand et al 1985; Sottrup-Jensen et al
1985; Sottrup-Jensen 1987).
Overall there are long stretches of identity, interspersed with regions of low
homology that provide each protein with a unique tertiary structure and
function. Analysis of the primary structures of the TEPP's indicated
approximately 60% homology between a2M, C3 and C4, and 68% between
a2M and PZP (Sottrup-Jensen 1987). In addition, the complement protein
C5 had homologous regions but did not contain the cysteine and glutamyl
residues that constitute the thiol ester bond. This is similar to ovostatin
the aM in hen egg white that has aM-like proteinase inhibitory activity,
but lacks a thiol ester bond (Nagase et al 1983; Nagase and Harris 1983;
see Sec.1.4).
1.5.3: Distinct features amongst TEPP
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Despite the high degree of primary structural homology, the TEPP do have
distinct features. PZP and human a2M exist as single chains that dimerise
and can form tetramers (Sand et al 1985; Barrett et al 1979). C3 and C4
are a heterologous dimer and trimer respectively formed from the cleavage
products of a single chain (Sottrup-Jensen 1987). In keeping with their
function, C3 and C4 contain an anaphylatoxin site, and they also have an
extension beyond the C terminus of the aM gene. Disulphide bridges are a
key feature of human a2M which contains 11 intra and 2 inter disulphide
bridges per chain, whereas C3 has 3 such bridges. Approximately 10% of
the weight of a2M is carbohydrate which is distributed between 8 diverse
sites on the molecule (Sottrup-Jensen, Stepanik, Kristensen, Wierzbicki et
al 1984b; see Fig. 1.4.1). The carbohydrate residues may be an
evolutionary conserved feature being employed in lower species as a
mechanism of clearance (Sottrup-Jensen et al 1984b). C3 has 3
carbohydrate attachment sites which would account for much less of its
mass (Sottrup-Jensen 1989).
1.5.4: Internal thiol ester bond
For both the aM and complement TEPP's, activation of the thiol ester site
is critical to their function. However, the complement proteins have a
narrow substrate specificity for their activation cleavage site, whereas
a2M and PZP have broad substrate ranges (Sottrup-Jensen 1987; Sand et
al 1985; Barrett and Starkey 1973; Salvesen and Barrett 1980). Fig.1.5.1.
illustrates the thiol ester bond and the reactions that it can undergo in
aM's and in the complement proteins.
With respect to substrates, a2M and PZP diverge somewhat: their ranges
do overlap but the interaction rates with particular proteinases differ
between the 2 inhibitors indicating a variation in their specificity (Sand et
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al 1985). The bait region sequences of a2M and PZP are not identical
which explains the disparity in reactivity. Due to the variation in
substrate, and also that PZP is normally only available in pregnancy, it
has been proposed that PZP may have a distinct role in the body from that
of a2M, possibly to clear proteolytic activity arising from increased cell
turnover. PZP has been reported to be immunosuppressive and may act
to protect the immunologically privileged state of the foetus (Stimson
1972; Stimson and Eubank 1972; Sand et al 1985). PZP and a2M have
been found on the surface of syncytiotrophoblasts suggesting protection of
the maternal-foetal interface by clearing proteinase, or by binding and
eliminating growth factors therefore controlling growth of the maternal
foetal unit (Lim and Halbert 1976; Lim, Halbert and Spellacy 1976; Sand
et al 1985).
1.5.5: The nascent state
The activation of the thiol ester bond in TEPP's results in a nascent state
in which the glutamyl residue can react rapidly with available nucleophiles
(see Fig.1.5.1 and Sec.1.7). Activation results in clearance of TEPP's from
tissues or from the circulation. For a2M and PZP this involves a
conformational change and exposure of the receptor recognition domain
(see Sec.1.6 and 1.7). The receptor recognition domain of both proteins can
bind to the a2M receptor, expressed by a range of cells, resulting in
receptor mediated endocytosis of the protein-proteinase complex.
Activation of the thiol ester is required for the covalent interaction of C3
and C4 with cell surface antigens such as CR1 and also with immune
complexes (Sottrup-Jensen 1987; Tack et al 1980; Janatova and Tack
1981; Law 1984). As with the aM's, C3 and C4 can be inactivated by
reaction with methylamine due to cleavage of the thiol ester bond by the
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amine (Barrett and Starkey 1973; Sand et al 1985; Tack et al 1980;
Janatova and Tack 1981). However, for the aM's, proteinase inhibition
requires trapping within the dimeric functional unit of the inhibitor and
does not rely upon the subsequent covalent interaction of proteinase and
glutamyl residue (Sand et al 1985; see Sec. 1.7). Nevertheless, the thiol
ester does have a pivotal role in the conformational change of a2M and
PZP that is required in trapping. Thus, the thiol ester is central to the
functions of all the TEPP either for trapping of proteinases due to a
conformational change in the aM's, or for covalent binding of C3 and C4 to
cell surface molecules and to immune complexes.
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1.6: The structure of a2M
1.6.1: The tetrameric form of a2M
Human a2M is a tetrameric protein composed of identical subunits. The
monomers form disulphide bonded pairs which noncovalently bond to form
the tetramer (Jones, Creeth, Kekwick 1972; Frenoy, Bourrillon, Lippoldt,
and Edelhoch 1977; Barrett et al 1979). Upon interaction with proteinase
or primary amine, the intersubunit interactions change, so that in the
reacted form there are an increased number of noncovalent links between
the monomers and the molecule appears more compacted (Fig. 1.1.1,
Barrett et al 1979; Feldman et al 1985).
The alteration in intersubunit interactions is due to a conformational
change, which has been detected by circular dichroism, sedimentation
velocity measurement, electrophoresis and electron microscopy (Barrett
and Starkey 1973; Bjork and Fish 1982; Feldman et al 1985; Boisset,
Taveau, Pochon, Tardieu et al 1989; Delain, Pochon, Barray and van
Leuven 1992). In addition to the overall structural change certain
chemical groups are revealed, as illustrated in Fig. 1.4.1 and 1.5.1. It is
possible to titrate a2M with trypsin or methylamine to reveal 4 sulphydryl
groups per a2M tetramer, that is one sulphyryl group per cleaved thiol
ester bond (Salvesen, Sayers and Barrett 1981; Swenson and Howard
1979). Within a2M is the "bait region" which is a sequence of residues that
can be cleaved by most endoproteinases resulting in activation of the thiol
ester bond and conformational change. Methylamine and other primary
amines elicit the conformational change by activating the thiol ester bond
directly. The conformational change is accompanied by exposure of the
receptor recognition domain required for clearance of a2M from the
circulation (Sottrup-Jensen, Gliemann and Van Leuven 1986).
Physical changes in the structure of a2M have been examined by a
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number of means. The most direct technique has been electron
microscopy which has revealed quite clearly the change in a2M tertiary
structure upon incubation with proteinase or primary amine (Fig. 1.6.1;
Schramm and Schramm 1983; Feldman et al 1985; Delain et al 1992). In
the native protein, a2M is an open Cyrillic H form which becomes
compacted during the conformational change.
1.6.2: Primary structure
The primary structure of a2M was fully elucidated by Sottrup-Jensen et
al, although previously certain regions had been examined (Sottrup-Jensen
et al 1984b; Swenson and Howard 1979). From the primary structure a
number of key sites can be distinguished including positions of
carbohydrate attachment and disulphide bridges, as illustrated in Fig. 1.4.1.
As previously emphasised, some 10-11% of the mass of a2M (725kDa) is
attributable to carbohydrate which is bound at 8 sites on the molecule (see
Sec.1.5.3). The carbohydrate chains bound are very heterogeneous. Of
the 24 cysteine residues in the monomer sequence, 22 form intrachain
bridges, one is required for the internal thiol ester bond (cys949), and one
forms an interchain bridge with a neighbouring monomer (cys447). There is
very little intrachain sequence homology indicating that it is unlikely that
the primary sequence of a2M arose by gene duplication.
1.6.3: Secondary structure
Based on the primary sequence data, 47.8% p structure and 8.6% a helix
were predicted for the secondary structure of a2M (Sottrup-Jensen et al
1984b; Welinder, Mikkelsen and Sottrup-Jensen 1984). This corroborated
well with a previous report (Bjork and Fish 1982). Furthermore, the
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Figure 1.6.1: Electron micrograph image of alpha2M
The image presented is formed of a series of images of
alpha2M-chymotrypsin by Boisset et al (1989). The long
arms of the molecule can be distinctly identified;
compare to Fig.1.1.1. Boisset et al indicate that the
central domains represent the proteinase.
appearance of hydrophobic and hydrophilic sequences indicated a domain
structure with exposed and shielded regions as expected of a
macromolecule.
1.6.4: Quaternary structure
Feldman et al proposed the classical model of a2M (Fig. 1.1.1; Feldman et al
1985). The model is overtly similar to images seen in EM studies, namely
a hollow cylinder with lateral arms, one short pair and one long pair in each
half of the molecule (Fig. 1.6.1; Delain et al 1992). Each monomer
contributes one long and one short arm. The dimensions suggested agree
favourably with later work in which the functional unit of a2M, that is a
dimer that acts to trap and inhibit a proteinase, was designated as the
basket-like halves of the protein (Roche, Salvesen and Pizzo 1988; Chen,
Wang, Yuan and Feinman 1992). The monomers that compose these
functional units are non-covalently bonded, the disulphide bonds forming
across the X-axis of the molecule (Roche et al 1988).
Feldman et al's model predicted the bait region and thiol ester to be
internal, central, and adjacent to each other (Feldman et al 1985). In
addition, they hypothesised that the receptor recognition domain would be
on the external face of the cylinder at the base of the long arms. It was
proposed that the long arms would move inwards to trap the proteinase
upon activation of the thiol ester, positioned at the internal base of the
hinge arms. Concomitantly, the receptor recognition domain would be
revealed facilitating a2M-proteinase complex clearance from the
circulation. Further investigation has confirmed certain aspects of this
model and disputed others. These will be discussed below.
1.6.5: Bait region
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The bait region is a sequence of approximately 27 amino acids in the
middle of the primary structure that presents cleavage sequences that are
suitable for all known endoproteinases (Fig. 1.4.1; Travis and Salvesen
1983; Sottrup-Jensen et al 1984b). Prior to identification of the sequence,
the bait regions presence was predicted due to the interaction of one
proteinase precluding the interaction of a second in the same functional
halfmolecule (Barrett and Starkey 1973). In addition, reaction with all
endoproteinases followed by reductive SDS-PAGE revealed cleavage
products of 85-100kDa (Barrett et al 1979; see Sec. 1.7). These
observations indicated the same or adjacent cleavage sites for the range of
endoproteinases.
Within the bait region, there are "hot" sequences specifically Arg681-Glu686
and Arg696-His699. The proteinase cleaves a2M within the bait region often
within the "hot" sequences resulting in thiol ester activation and a
conformational change of a2M therefore restricting access to the bait
region for other proteinases. Although it is cleaved by proteinases at one
and sometimes a second site within the bait region, no cleavage products
are released from a2M: this is due to a disulphide bridge that spans the bait
region thus keeping the molecule intact (see Fig. 1.4.1; Sottrup-Jensen et al
1984b). The bait region may be able to adapt its conformation to present
a more suitable substrate specificity to a particular proteinase, some
proteinases binding better than others (Sottrup-Jensen 1989; Sand et al
1985).
Upon cleavage of the bait region, the "trap" is sprung: the conformation of
a2M is altered and the proteinase is entrapped and its activity against
large substrates is lost, although its active site is still functional (see
Fig. 1.1.1; Barrett and Starkey 1973). As previously stressed, the
retention of proteolytic activity may be important in disease states, for
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example in rheumatoid arthritis and in adult respiratory distress syndrome
(see Sec. 1.2).
The location of the bait region in the quaternary structure of a2M is
unclear. Feldman's model predicted it to be at the central base of the
interior of the cylinder, and this seems to be the most satisfactory
explanation as judged by EM and fluorescence studies (Schramm and
Schramm 1983; Boisset, Taveau, Pochon, Barray et al 1991; Delain et al
1992). Gonias et al reported that the bait region was at the termini of the
long arms, but this result may be an artifact arising from use of an IgG-
colloidal gold complex which may have been sterically hindered from
accessing the cylinder interior (Gonias, Allietta, Pizzo, Castellino and
Tillack 1988). Differential images of a2M after binding free chymotrypsin,
immobilised chymotrypsin, and methylamine indicated a central location
for the proteinases and implies a central location for the bait region, and
also for the thiol ester site (Boisset et al 1989; Boisset et al 1991).
1.6.6: Internal thiol ester bond
The internal thiol ester bond is notable for two reasons: it is a unique
internal bond of a glutamyl and cysteinyl residue found only in a2M and
related proteins (eg C3, C4, PZP), and it allows primary amines to interact
with native a2M to induce conformational changes that are essentially
identical to those observed with proteinases (See Fig. 1.5.1, Sec. 1.4 and 1.5;
Swenson and Howard 1979; Salvesen et al 1981). The bond is formed
between cys949 and gin952 by post-translational modification that requires
only the energy of folding for its formation (Swenson and Howard 1979;
Pangburn 1992; Gettins and Crews 1993a). Primary amines act as
nucleophiles attacking the electrophilic thiol ester resulting in cleavage of
the bond. The amine reacts with the glutamyl residue, and concomitantly
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free SH groups are observed (Salvesen et al 1981). SH groups are also
observed upon proteinase interaction: bait region cleavage activates the
thiol ester resulting in its cleavage. In early studies, the sites of proteinase
and amine binding in the primary structure were found to be identical, ie
both bind to the glutamyl residue (Swenson and Howard 1979; Van Leuven
et al 1982). Lysine sidechains of the entrapped proteinase may interact to
form covalent bonds with the glutamyl residue, though this is not essential
to proteinase inhibition (see Fig.1.5.1 and Sec.1.7; Salvesen and Barrett
1980; Salvesen et al 1981). In addition, the glutamyl and cysteinyl
residues of the proteinase-cleaved thiol ester can interact with amines, or
with other proteins such as cytokines (see Sec. 1.9; Swenson and Howard
1979; Chu, Rubenstein, Enghild and Pizzo 1991; Chu and Pizzo 1993). One
nucleophile can interact per monomer, and 4 SH groups can be titrated per
tetramer indicating that there are 4 thiol ester sites in the complete
molecule (Swenson and Howard 1979; Salvesen et al 1981; Salvesen and
Barrett 1980; Van Leuven et al 1982).
It has been proposed that the thiol ester is a conformational lock (Howard,
Swenson and Eccleston 1983). In the native molecule, stability is
maintained, but cleavage of the bait region releases tension in the molecule
resulting in cleavage of the thiol ester and so conformational change.
Primary amines attack the bond directly and a similar conformational
change occurs, although it is much slower, taking 2-3 hours, compared to
lOOmsecs with proteinases (Van Leuven et al 1982; Gonias, Reynolds and
Pizzo 1982).
Structural predictions proposed that the thiol ester site would be located at
the loop of a (3 hairpin, and shielded in the native molecule and therefore
unable to bind large amines (Welinder et al 1984). However, in the
quaternary structure of a2M, its location is unknown: the model of
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Feldman et al suggested it to be at the base of the "hinge" arms.
Subsequently other groups proposed the thiol ester bond to be at the distal
ends of the arms (Feldman et al 1985; Osada, Nishigai and Ikai 1988;
Schramm and Witke 1988). As mentioned above, electron micrograph
images of a2M and proteinase indicate a central position for the
proteinase, suggesting a similar site for the thiol ester bond (Fig. 1.6.1;
Boisset et al 1989; Boisset et al 1991). More recently, the thiol ester in
native a2M has been distinguished by using activated PLA2, a small
glycoprotein with 10 lysine residues and no proteinase activity which acts
as a nucleophile to bind gin952 (Boisset, Pochon, Chwetzoff, Barray et al
1992a). In a separate study the sulphydryl group of cys949 has been
located by cryoelectron microscopy (Boisset, Grassucci, Penczek, Delain et
al 1992b). Both investigations have indicated central locations in the
interior of a2M for the thiol ester.
In addition, it is interesting to note that the thiol ester is susceptible to
cleavage by heat, due to freeze/thaw activity or to prolonged storage
(Barrett et al 1979; Harpel, Hayes and Hugli 1979; Howard, Vermeulen
and Swenson 1980; see Fig.3.1.2).
1.6.7: Receptor recognition domain
Neoantigens on a2M can be detected after conformational change (Barrett
et al 1979). The increased rate of a2M clearance from the circulation is a
direct result of the exposure on the molecule of the receptor recognition
domain (Barrett and Starkey 1973; Imber and Pizzo 1981; see Sec.1.7).
Papain extraction cleaves a 20kDa C terminal fragment that has receptor
recognition activity, and is capable of blocking a2M-trypsin binding to
murine macrophages (Sottrup-Jensen et al 1986). A similar fragment
that binds to the a2M receptor on fibroblasts was isolated (Van Leuven,
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Marynen, Sottrup-Jensen, Cassiman and Van den Berge 1986). It was
found at the termini of the long arms, contrary to Feldman's earlier
prediction of a position at the external base of the hinge arms (Sottrup-
Jensen et al 1986; Feldman et al 1985; see Sec. 1.4). Delain et al proposed
that the prediction of Feldmann et al over-simplified the conformational
changes that occur in a2M upon activation by proteinase or methylamine
(Delain, Barray, Tapon-Bretaudiere, Pochon et al 1988). They went on to
suggest that upon thiol ester cleavage globular domains may unfold to
build the lateral walls of the molecule, and to expose the C terminus
containing the receptor recognition domain. Furthermore, a cis-
Dichlorodiamineplatinum (cisDDP) sensitive site has been found:
inactivation of it with cisDDP decreases the receptor binding (Gonias and
Pizzo 1981; Pizzo, Roche, Feldman and Gonias 1986; Enghild, Thogersen,
Roche and Pizzo 1989). The implication is that the complete recognition
domain is contained within a larger sequence than was initially identified,
the total region covering the C terminal 40kDa fragment.
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1.7: a2M as a binding protein
a2M is able to interact with a range ofmolecules. The associations are of
three forms, namely trapping, covalent binding, and adherence
interactions. These are discussed below.
1.7.1: Trapping interaction
a2M is unique amongst proteinase inhibitors: it does not inhibit active
sites, but operates a trap mechanism to limit substrate access to the
active site (see Fig.1.1.1 and Sec.1.6.). This concept was conceived by
Barrett and Starkey (Barrett and Starkey 1973). They proposed that
endoproteinases cleave a specific sequence within a2M resulting in a
conformational change of the serum protein and irreversibly enclosing the
proteinase. A range of observations were the foundation for this model:
(i) Upon interacting with a2M, endoproteinases retain their activity
against small but not large substrates indicating that their active site is
still functional but access is restricted.
(ii) Only active endoproteinases can be inhibited; exoproteinases, non-
proteolytic hydrolases and inactive endoproteinases are not effected,
implying that an internal cleavage reaction is involved in the inactivation
process.
(iii) The range of endoproteinases inhibited by a2M covers all four classes
which suggests a common sequence for cleavage.
(iv) Previous electron microscopy studies had indicated a conformational
change of the a2M molecule upon interacting which would be consistent
with a trapping mechanism involving protein rearrangement (Morelis,
Ambrosioni, Got and Fontanges 1969).
(v) a2M that has interacted with one proteinase cannot bind with a second.
This is due to restricted access to the cleavage site upon trap closure.
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Further to the evidence of Barrett and Starkey, in subsequent
investigations reductive SDS-PAGE of a2M-proteinase complexes revealed
fragments of 85-100kDa, indicating adjacent or identical cleavage sites for
all endoproteinases (Barrett et al 1979; Travis and Salvesen 1983; see
Sec.1.6).
Barrett and Starkey thus proposed a sensitive region within a2M that is
especially susceptible to cleavage by a large range of endoproteinases (see
Sec. 1.6). They termed it the bait region and suggested that cleavage would
be accompanied by conformational change enclosing the proteinase, thus
the "trap" is sprung. Subsequently, the bait region has been identified: it is
composed of 2 very sensitive areas which offer a substrate specificity
appropriate to most endoproteinases (Sottrup-Jensen et al 1984b; see
Sec.1.6).
1.7.2: Biological consequences ofproteinase trapping
The conformational change that occurs as the trap is sprung exposes the
receptor recognition domain, located at the termini of the trap arms
(Delain et al 1988; see Sec.1.6). The result ofbinding is rapid clearance of
a2M-proteinase complexes via the a2M receptor which is expressed on a
number of cells (Imber and Pizzo 1981; see Sec.1.6.7). Under normal
circumstances, a2M-proteinase complexes will be cleared rapidly (Barrett
and Starkey 1973; Imber and Pizzo 1981). However, as discussed before,
in some disease states clearance can be retarded because of an excessive
concentration of conformationally fast a2M (Abbink et al 1991; see
Sec. 1.2). The retention of proteolytic activity against small substrates as
a result of trapping then assumes greater importance, as does the
carrying of cytokines and growth factors (see Sec. 1.9).
In addition to inhibiting proteinases and removing them from their
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environment, the interaction of a2M-proteinase with the receptor may-
modulate the receptor cell's functions. For example, binding to
macrophages induces intracellular signalling cascades with increases in
intracellular calcium concentration, and changes in inositol phosphate and
cAMP levels (Misra, Chu, Rubenstein, Gawdi and Pizzo 1993). There is
also evidence to suggest that a2M may deliver antigen to macrophages
through endocytic pathways (Chu and Pizzo 1993; Moestrup 1994). The
antigen is then processed and presented as normal. From a2M delivery
experiments with hen egg lysozyme, Chu and Pizzo proposed that in vivo
cc2M may target antigen in sites of inflammation (Chu and Pizzo 1993).
1.7.3: Clearance of a2M
Although native a2M is removed from the circulation, its half life is
decreased from hours to minutes upon interacting with proteinases or
primary amines (Imber and Pizzo 1981; Barrett and Starkey 1973). The
conversion of a2M by proteinase or primary amine exposes the receptor
recognition domain which can bind with available a2M receptor expressed
on cells (Imber and Pizzo 1981; Delain et al 1988). The critical step for
receptor recognition domain exposure is the cleavage of the thiol ester
bond, the interaction of the proteinase with the bait region merely
facilitating this event (Van Leuven, Cassiman and Van den Berghe 1981;
Imber and Pizzo 1981; Van Leuven et al 1982). The presence of other
molecules bound to a2M, for example hen egg lysozyme or insulin, does not
alter the rate of a2M binding and uptake (Chu and Pizzo 1993). This may
be of significance when considering the role of a2M as a cytokine binder,
maintaining or clearing activity in vivo (LaMarre, Hayes, Wollenberg,
Hussaini et al 1991)
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1.7.4: The a2M receptor
As previously indicated, the a2M receptor is expressed by a range of cells,
most importantly liver cells, hepatocytes and Kupffer cells, which take up
80% of injected a2M (Moestrup and Gliemann 1989). Other cells including
fibroblasts, monocytes/macrophages, smooth muscle cells, neurones, and
astrocytes account for local removal of a2M and ligands from interstitial
and cerebrospinal fluids (Imber and Pizzo 1981; Van Leuven et al 1986b;
Straight et al 1988; reviewed Moestrup 1994). In blood, the a2M receptor
(CD91) is expressed only by monocytes/macrophages and is therefore a
marker protein for these cells (Moestrup 1994, Moestrup 1995; James,
Milne and Donaldson 1985). In addition, there is 97% identity between the
murine and human receptor, and homologus residues in other species have
been identified (Enghild et al 1989; Van Leuven, Stas, Raymakers,
Overbergh et al 1993; Moestrup 1994).
The receptor is the largest member of the low density lipoprotein (LDL)
receptor superfamily, and is probably the oldest: it is expressed in a lower
organism, Caenorhabdites elegans, than other family members (reviewed in
Moestrup 1994). The low density lipoprotein receptor, very low density
lipoprotein receptor, and gp330 constitute the rest of the family.
The a2MR is composed of 2 chains: a, 515kDa, and (3, 85kDa which are
homologous to LDL-related protein (LRP; Herz, Hamann, Rogne,
Myklebost et al 1988; Moestrup and Gliemann 1989; Kristensen,
Moestrup, Gliemann, Bendtsen et al 1990). Other ligands for the a2MR
are pVLDL with apoE, and a2MR-associated protein (RAP) both of which
compete with a2M (fast) for binding to the receptor (Kristensen et al 1990;
Strickland, Ashcom, Williams, Battey et al 1991; Hussain, Maxfield, Mas-
Oliva, Tabas et al 1991). RAP is a 40kDa protein associated with the a
chain of the receptor (Strickland et al 1991; Moestrup and Gliemann 1991;
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Herz, Goldstein, Strickland, Ho and Brown 1991). The in vivo role of RAP
is unclear but its inhibitory effects implies a modulatory function with
respect to cc2M-a2MR binding (Moestrup and Gliemann 1991; Herz et al
1991).
Binding of a2M by its receptor is calcium dependent (Moestrup and
Gliemann 1989; Moestrup, Kaltoft, Sottrup-Jensen and Gliemann 1990).
There are 8 or more calcium binding sites on the receptor which
demonstrate positive cooperativity. In the absence of calcium no a2M can
be bound: it appears that calcium is required for the appropriate receptor
conformation. As the pH is decreased, calcium is released thus releasing
a2M: this is important in the endocytic vesicle where a2M and its receptor
will therefore be uncoupled in the acidic environment (Moestrup et al
1990).
The affinity of a2M for its receptor is increased by the binding of 2 receptor
recognition domains of a single a2M molecule to 2 cellular receptors. Thus,
a binding affinity of 40pM is observed when 2 receptor recognition domains
are involved, and of 2nM, when 1 receptor recognition domain is bound
(Delain et al 1988; Moestrup and Gliemann 1989; Moestrup and Gliemann
1991). It may be that the requirement for 2 receptors modulates binding
to induce interaction with the a2MR located in coated pits where it is at a
higher density, thus aiding endocytosis.
1.7.5: Covalent interactions
As previously indicated, a2M and related proteins contain a unique internal
thiol ester bond (see Figs.1.4.1 and 1.5.1, Sec.1.5 and 1.6). This is an
electrophilic centre that is activated during proteinase cleavage of the bait
region. In the native protein, the thiol ester is sterically shielded but can
be contacted by small primary amines which act as nucleophiles to cleave
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the bond, and then bind to the released glutamyl residue (Swenson and
Howard 1979; Van Leuven et al 1981). In a similar manner, lysine
residues on an entrapped proteinase can interact with the glutamyl
residue after cleavage of the thiol ester has occurred (Salvesen and
Barrett 1980; Salvesen et al 1981). The bonds formed are non-disulphide
covalent in nature (Salvesen and Barrett 1980). The interactions that
occur at the thiol ester bond are illustrated in Fig. 1.5.1. The covalent
interaction with the thiol ester bond is secondary to the trapping
interaction of proteinases, and does not occur with all proteinases (Barrett
and Starkey 1973; Salvesen and Barrett 1980; Howard et al 1983). For
aM's that are monomelic the covalent binding of proteinase is essential to
its inhibition, as seen for rat alI3 (Moncino et al 1991, see Sec.1.4). The
covalent interaction involving the thiol ester residues are also important
for the function of complement proteins C3 and C4 in binding to cells, and
to complement substrates (Fig.1.5.1, Sottrup-Jensen 1987, see Sec.1.5).
The activation of the thiol ester by a proteinase can allow other
substrates, such as bEGF and insulin, to covalently bind with either the
glutamyl or thiol residues of the bond (Chu et al 1991; Chu and Pizzo 1993;
Gettins and Crews 1993b). It has been suggested that the role in vivo for
the thiol ester in dimeric and tetrameric aM's may be to capture small
proteins with increased activity during the conformational change, that is
when a2M is in the nascent state (Chu and Pizzo 1993, see Sec.1.6). In
vivo both cysteinyl and glutamyl residues may be available for binding,
although glutamyl is very reactive and may undergo rapid hydrolysis.
Furthermore, Travis and Salvesen speculated that soya bean trypsin
inhibitor (SBTI), a 21kDa inhibitor which can be degraded by trypsin, may
define the limits of size or shape for access to fast a2M (Travis and
Salvesen 1983). Thus, proteins of size and shape smaller than SBTI may
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have access to the interior of fast form a2M and could interact with cys949
or gin952 residues. It has been suggested that in interactions in the
nascent state a2M may be able to non-selectively bind proteins and
peptides that express nucleophilic amino acids (Chu and Pizzo 1993). To
this end, a2M has been identified as an SH-reactive agent (Schlesinger,
McEntire, Wallman, Skosey et al 1989).
1.7.6: Adherence interactions
The macromolecular state of a2M enables it to interact with a range of
molecules by adherence, rather than by more specific interactions
(Barrett 1981). For example, a2M is the primary zinc binding protein
carrying 40% of the plasma zinc (Kurecki, Kress and Laskowski 1979). In
addition, the 8 carbohydrate chains can bind the mitogens concanavalin A
and PHA (Sottrup-Jensen et al 1984b; Barrett 1981). Such non-specific
interactions may be of importance within the immune response. a2M can
also interact hydrophobically, for example with endotoxin and LPS (Barrett
1981).
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1.8: a2M as an immunomodulator
Proteinase inhibitors, especially inhibitors of serine proteinases, are
recognised as having immunosuppressive activity in vitro (Petersen,
Ejlersen, Moestrup, Jensen et al 1989; Hubbard, Hess, Hsia and Amos
1981; Dickinson, Shenton, Alomran, Donnelly and Proctor 1985). a2M
shows immunomodulatory effects on a number of immunogical events
which may be attributed to:
(a) Its proteinase inhibitory activity
(b) Binding to its receptor
(c) Activity with respect to molecules of immunological importance
including cytokines.
1.8.1: oc2M synthesis and clearance within the immune system
There are a range of cells of the immune system reported to synthesize
and secrete a2M, including macrophages and monocytes (see Sec. 1.3). In
addition, a number of cells, including monocytes, carry receptors for a2M
(see Sec.1.7). Thus there exists the potential for a source of cc2M and a
mechanism for its clearance in the immune system and in diseased tissue.
It has been suggested that a2M may dysregulate the immune response
(Heumann and Vischer 1988). Various methods have been proposed as to
how it may do so, or how it may play a positive role in the immune system,
as discussed below.
1.8.2: Roles ofnative and fast form cc2M in the immune response
The two forms of a2M have distinct biological properties: the native form
has a half life in the circulation of 24 hours, can bind proteinases and has a
very low affinity for the a2M receptor (Imber and Pizzo 1981; Barrett and
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Starkey 1973). Fast a2M, inactivated by proteinase, oxygen reactive
species, or by chemical means, cannot bind proteinase, has a much
shorter half life in the circulation, and is removed via the a2M receptor.
This distinction may be of importance with respect to the
immunomodulatory effects of a2M.
There are different immunological effects attributed to each form of the
protein. For example, native a2M has immunosuppressive potential as
observed in LAK cell lysis assays (Petersen et al 1989). It was found that
a2M bound to molecules with trypsin and chymotrypsin-like activity on
the LAK cell surface. Petersen et al proposed that interaction with
proteinases and their probable inhibition was the mode of suppression
used.
Both forms of a2M suppress the mixed lymphocyte response (Hubbard et
al 1981). However, the dose response observed was stronger with a2M-
proteinase. It has been found that monocyte activity can be increased by
fast a2M, and that the native protein has no effect on the chemotactic
activity of the cells (Forrester, Wilkinson and Lackie 1983). a2M-
proteinase interferes with the T cell proliferation response to antigen in a
dose-dependent manner. This effect is partly because of residual trypsin
activity against IL2, but is also mediated through macrophages
(Mannhalter, Borth and Eibl 1986; Heumann and Vischer 1988; see
Sec.1.9).
The effects of a2M-proteinase may be significant in cases were there are
increased levels of the complexes (see Sec. 1.2.6). As discussed before, in
disease states where there is an excessive proteinase release there may be
a resultant increase in a2M-proteinase complexes as other inhibitors
become exhausted, or, as in rheumatoid arthritis, clearance may be
inhibited (Harpel 1977; Burtin et al 1987; Sec. 1.6 or 1.7). The change to
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a2M as a principle inhibitor may result in modulation of the immune
response as noted above or by other immune mechanisms, for example
altering NK activity or antibody dependent cell-mediated cytotoxicity.
These events have been observed to be affected by a2M-trypsin
(Dickinson et al 1985).
Fast form a2M inhibits the change in cell morphology of macrophages
during antigen presentation, therefore suppressing T cell activation
(Roche, Hoffman and Pizzo 1990). It was reported that fast form a2M
could have a specific, dose-dependent and receptor-mediated
immunomodulatory effect on murine macrophages (Hoffman, Pizzo and
Weinberg 1987). Subsequently, it was reported that a2M mediates its
effect by preventing the normal IFNy induced change in morphology of the
macrophage (Roche et al 1990). The consequence of the a2M activity is a
decrease in the density of la on the macrophage surface, and therefore a
reduction in T cell activation (Roche et al 1990). In addition, a2M binding
to the a2M receptor expressed on macrophages results in various
intracellular changes, for example increased intracellular calcium levels,
and changes in inositol phosphate and cAMP levels (Misra et al 1993; see
Sec.1.7.2). This and antigen delivery to macrophages can increase T cell
activation.
1.8.3: Influence of a2M on molecules of the immune system
Further to the proteinase and cellular effects attributed to a2M, it may
also inhibit molecules of specific immunological importance. For example,
a2M has been found to inhibit in vivo and in vitro the activity of
deglycosylated ricin A chain (Ghetie, Uhr and Vitetta 1991). Defensins,
inflammatory mediators, are bound by fast a2M (Ganz and Lehrer 1994;
Panyutich and Ganz 1991). a2M may constitute a mechanism for
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regulation and containment of these and other molecules in inflammation.
The pathogenesis of RA may therefore be further influenced by a2M acting
in this capacity, in addition to its role as a proteinase inhibitor, cytokine
binder, and mediator of chemotaxis (see Sec.1.2.6).
Thus it appears that a2M can mediate a range of effects on the immune
system. In vivo, local circumstances may dictate which effects are
paramount. Furthermore, a2M has been attributed as being a carrier of
cytokine activity, either to maintain or clear it from the circulation and
tissues. This will be discussed in Section 1.9.
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1.9: a2M-cytokine interactions
1.9.1: Early studies of a2M-cytokine binding
Early studies of a2M indicated that it has an immunomodulatory function
(reviewed James 1980, see Sec. 1.8). In some cases, the activity can be
attributed to a2M's role as a proteinase inhibitor. For example, a2M was
found to inhibit esterases resulting in increased activity of migration
inhibitory factor on macrophages (Remold and Rosenberg 1975). However,
there is also evidence that it has growth inhibitory properties that are not
due to proteinase activity, but can be attributed to small bioactive
molecules, suggesting that a2M can act as a carrier protein of biological
activity (Koo 1982). a2M has been identified as a carrier molecule of a
range of biological molecules apart from proteinases, including insulin and
a number of cytokines and growth factors (Hoffmann, Ristow, Veser and
Frank 1973; Remold and Rosenberg 1975; McDaniel, Laudico and
Papermaster 1976; Koo 1982; Chu et al 1991).
Table 1.9.1 summarises the principle cytokines and growth factors
examined, and the characteristics and consequences of the interactions.
1.9.2: Affects ofcytokines on a2M activity
In a number of cases, the activity of a2M, rather than the associated
cytokine, is affected. For example, CSF1, IL6 and TGFp have each been
reported to alter a2M activity (Hussaini, Srikumar, Quesenberry and
Gonias 1990; Ganter et al 1991; Shi et al 1990). CSF1 acts on bone
marrow macrophages to increase a2M receptor expression leading to
increased clearance of fast a2M (Hussaini et al 1990). A change in
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TGFpl stimulates bovine adrenocortical cells (BAC) to secrete a2M (Shi et
al 1990). The response to TGFpl can be inhibited by an anti-RNA POL II
reagent which indicates that stimulation occurs at the protein synthesis
level. TGFpl binds to both slow and fast forms of a2M, and remains active
on a range of cells including BAC when bound by a2M. Collectively these
results suggest that there may be an autocrine loop operating to control or
to enhance TGFpl activity in BAC (Keramidas et al 1992).
Like TGFpl, IL6 is known to be bound by a2M, but the free form of the
cytokine has itself been found to effect a2M production (Matsuda et al
1989; Ganter et al 1991). In the CNS, a2M may act as an acute phase
protein (see Sec. 1.2.10). The report that IL6 can induce a2M synthesis in
a murine neuroblastoma cell line has lead to speculation that IL6 and a2M
may have roles in the pathogenesis of Alzheimer's Disease (Ganter et al
1991).
Inhibition of a cytokine's activity may also be induced without contact of
a2M and cytokine as reported for IFNy and a2M on murine macrophages
(Hoffmann et al 1987; Roche et al 1990; see Sec. 1.8).
1.9.3: PDGF binding to oQM
PDGF is a potent polypeptide growth factor released when platelets are
activated, namely during blood coagulation or after blood vessel injury
(Huang et al 1984). It is also a chemoattractant for inflammatory cells
and for cells required at sites ofwound repair. PDGF was found to bind to a
plasma protein, subsequently identified as a2M, which could clear the
growth factor thus limiting its activity to the site of local injury (Huang,
Huang and Deuel 1983; Huang et al 1984). It can bind to either form of
a2M, using disulphide bonds, and retains about 50% of its mitogenic
activity upon binding though it loses its antigenicity. Non-covalent and
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reversible association of PDGF and a2M has also been demonstrated, and
it is not clear which report, if either, is entirely correct (Crookston, Webb,
Wolf and Gonias 1994). The binding of 125-I PDGF to native or fast form
a2M is inhibited by cold PDGF, and only binding to the fast form can be
blocked by TGFp, bFGF, and IL6. These results indicate that binding is
specific, and that the binding site is not shared with the other cytokines
tested. PDGF remains bound by a2M dining and after the conformational
change (Bonner, Goodell, Laskey and Hoffman 1992). Thus, if bound to
slow a2M, PDGF could be maintained in the circulation until the
conformational change occurs and then be cleared via the a2M receptor.
By these means the growth factor is prevented from acting outwith its
local site of release from activated platelets.
However, as noted above, PDGF has been reported to retain some activity
when bound to a2M (see Sec. 1.2.8). The consequences of this are seen with
fibroblasts where the presence of a2M appears to synergistically increase
their PDGF induced growth (Bonner, Badgett, Osornio-Vargas, Hoffman
and Brody 1990). In contrast, in melanomas the presence of a2M has
been found to decrease the rate of disease development and this effectmay
be due to the inhibition of PDGF activity by a2M (Bizik et al 1989; see
Sec. 1.2.8). In conclusion, it appears that the in vivo consequence of the
interactions between PDGF and a2M may be more complicated than
present in vitro findings indicate.
1.9.4: TGFp-a2M interactions
Similar to PDGF, TGF(3 is composed of 2 polypeptide chains, is localised in
platelets, and has a high disulphide linkage content. Early studies
indicated that TGFp was bound covalently to a2M, resulting in a decrease
in the cytokines activity and loss of its antigenicity (O'Connor-McCourt
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and Wakefield 1987; Huang, O'Grady and Huang 1988). Binding of
radiolabeled TGFp can be blocked with the cold growth factor, but is
unaffected by PDGF, EGF and insulin. This corroborates the earlier report
that TGFp did not effect PDGF binding (Huang et al 1984). There is
evidence that TGFp activity increases in melanoma cell lines where a2M is
absent, as observed with PDGF (Lizonova, Bizik, Grofova and Vaheri
1990; Bizik et al 1989). These results may have implications in vivo for
the control of TGFp activity by a2M. Subsequent investigations have
shown TGFp2 to be more strongly bound by a2M than is TGFpl
(Danielpour and Sporn 1990; LaMarre, Wollenberg, Gauldie and Hayes
1990). The bioactivity of TGFp2 is inhibited to a much greater extent than
that of TGFpl. These results suggest that there is differential control of
TGFpl and p2 activities in vivo by a2M.
As mentioned above, TGFpl increases a2M secretion by bovine
adrenocortical cells (BAC) (Shi et al 1990). a2M-TGFpl complexes have
been shown to be bioactive on BAC, in contrast to the negation of activity
seen in other cell lines, such as lung carcinoma cells and melanomas
(Keramidas et al 1992; O'Connor-McCourt and Wakefield 1987; Huang et
al 1988; Danielpour and Sporn 1990). BAC cells may contain an effector
that can mediate release of the active growth factor from a2M. It has
been suggested that a2M may be a latent carrier of TGFpl activity, and
that it is being released in its active form in the acidic conditions of the
lysosome (Keramidas et al 1992). It is unlikely that the BAC cells are
using this to provide them with active TGFpl since all cells have
lysosomes. The unique component of BAC is unclear, but may be an
enzyme in or on the surface of the cells. In addition, there is evidence of
a2M enhancing TGFpl activity on smooth muscle cells, possibly requiring
the a2M receptor for activity (Stouffer, LaMarre, Gonias and Owens 1993).
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1993).
1.9.5: In vivo activity ofPDGF and TGFp
Injection of PDGF or of TGFp results in their binding to a2M in vivo
suggesting the in vitro binding and effects attributed to PDGF and TGFp
interacting with a2M may have an in vivo equivalent (Crookston, Webb,
LaMarre and Gonias 1993). It has been found that TGFpl injected
intravenously is removed via the liver, the principle site of a2M clearance,
and that the level of clearance can be increased to more than 90% if TGFp
is injected bound to a2M (LaMarre et al 1991). However, there is
contradictory evidence to suggest that endogenous TGFpl is cleared from
the circulation via its own ubiquitous receptor (Philip and O'Connor-
McCourt 1991). Binding of TGFp by a2M may be importance to maintain
the growth factor in a latent state to protect it from proteinases and also
from clearance via its own receptor. It may be carried in the circulation by
a2M until it is required, for example at a disease site, at which time it may
be activated, possibly by the binding of proteinases by a2M leading to
TGFpl release.
1.9.6: The binding ofother cytokines to a2M
Unlike PDGF and TGFp, some cytokines and growth factors bind only to
fast form a2M, whilst others interact preferentially with nascent a2M
(Table 1.9.1; Dennis, Saksela, Harpel, and Rifkin 1989; Borth and Luger
1989; Wollenberg et al 1991; Chu et al 1991; Gettins and Crews 1993b).
The glutamyl residue of the activated thiol ester bond is rapidly lost by
reaction with a lysine side-chain of a proteinase, a primary amine, water,
or with nucleophile residues on proteins or peptides (Chu and Pizzo 1993;
see Sec. 1.7). There is evidence that EGF and insulin may bind to the gin952
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residue (Chu et al 1991; Gettins and Crew 1993b).
ILlp is believed to interact with the cysteinyl residue of the cleaved bond
(Borth and Luger 1989; Borth, Scheer, Urbansky, Luger, Sottrup-Jensen
1990a; Borth, Urbanski, Proaska, Susani and Luger 1990b; Teodorescu et
al 1991). For ILlp, the cysteine residue that forms a disulphide bridge with
a2M was identified as cys8 (Teodorescu et al 1991). In addition, ILlp may
use histidine to bind (Borth and Luger 1989; Borth et al 1990a). The
interaction of radiolabeled ILlp can be blocked by a 20 fold excess of cold
ILlp, but not by IL2 nor by IFNy (Borth et al 1990a). Gettins and Crew
proposed that the short half life of the nascent state of a2M is such that
binding of ILlp, insulin, or EGF in vivo may not be plausible (Gettins and
Crews 1993b). However, if cytokine is in situ during activation of a2M,
binding to the nascent residues may be more feasible (Chu et al 1991; Chu
and Pizzo 1993). Furthermore, the binding of ILlp by a2M appears to
have a role in rheumatoid arthritis (Teodorescu et al 1991; see Sec. 1.2.6):
D-penicillamine, active in the treatment of rheumatoid arthritis, is able to
inhibit the binding of ILlp to a2M in the reagents therapeutic range. a2M
levels rise in synovial fluid of RA patients, and in the disease state fast
form a2M is not rapidly cleared (Abbink et al 1991; see Sec. 1.2.6). In
addition, ILlp when bound to a2M retains its bioactivity (Borth and Luger
1989; Borth et al 1990a; Teodorescu et al 1991). a2M-ILlp complexes
may therefore form in vivo in the inflammatory state, thus the complexes
could actively operate in the synovial fluid. ILlp is 15-17kDa in its active
form, and it may therefore be possible for it to access the trap after it has
been sprung. In a similar way to ILlp, IL6 is bound by fast form a2M and
retains its bioactivity (Matsuda et al 1989). The effect of such
interactions may be to protect the cytokines from proteinase activity
whilst allowing their continued bioactivity.
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There is evidence ofbinding to fast form a2M still leaving a cytokine open
to proteinase inhibition. Stimulation of CTLL-20 by IL2 is inhibited by
addition of a2M-trypsin (Borth and Teodorescu 1986). The inhibition
results from degradation of IL2 by bound trypsin. It may be that a2M
acts as a catalyst bringing together IL2 and trypsin in close proximity.
The binding of TNFa by a2M has been detected at a qualitative level
(Wollenberg et al 1991; James, van den Haan, Lens and Farmer 1992). In
addition, it was reported that the cytokine retained its bioactivity when
bound. However, in these previous studies the separation of bound and
free cytokine and the subsequent application of "bound only" cytokine to
the cell line was not reported. This is further discussed in Sec. 1.10, Sec.4.3
and Sec.4.4.
1.9.7: Overview of the literature on oQM-cytokine studies
The most obvious characteristic of the interactions of a2M with cytokines
is that there is no distinct pattern of binding: some bind to slow form a2M,
others to fast form, some to both, using non-covalent, disulphide covalent,
or other covalent interactions, with or without the loss of bioactivity and
antigenicity. It is apparent that a2M does have the capacity, due to its
size and to its hollow trap formation, to interact with a range ofproteins, in
a diverse manner and with a range of consequences.
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1.10: The current project background and strategy
1.10.1: Background to the current study
As outlined above, the binding of a diverse range of cytokines by a2M has
been examined (see Sec. 1.9). However, many of the previous publications
report studies of a2M-cytokine complexes at a qualitative level only.
Furthermore, in examining their bioactivity they did not remove cytokine
not bound by a2M. Thus, in attempting to confirm and extend previous
studies on a2M-cytokine interactions, quantitative and bioactivity studies
were of importance.
The cytokines examined herein were IL2, TNFa and IFNy. All three had
been examined in association with a2M previously, but in limited studies
(see Sec.1.8.3 and Sec. 1.9.6). Investigations of TNFa were the most
extensive, but had no quantitative analysis and an incorrect assay of
bioactivity (Scuderi, Dorr, Liddil, Finley et al 1989; Wollenberg et al 1991;
James et al 1992). IL2 and IFNy had been examined on the basis of
interference by a2M on their bioactivity, but not on the premise of protein-
cytokine interactions (see Sec.1.8.3). These cytokines have key roles in
the immune response. In addition, these cytokines are of special interest
to the Wilkie Laboratories with respect to their roles in anti-tumour
immunity. They have well defined structures and functions, and
associations with their receptors, as outlined below.
1.10.2: Interleukin 2
Interleukin 2 (IL2) is a 15.5kDa T cell derived cytokine. It is an O-
glycosylated globular protein, with a tertiary structure of 4 a helical
bundles similar to those for GM-CSF and IL4, and the recently discovered
IL15 (Robb, Kutny, and Chowdhry 1983; Bazan 1992). IL2 is produced by
antigen or mitogen activated T cells, and can by autocrine or paracrine
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means stimulate T cell proliferation (Morgan, Ruscetti and Gallo 1976;
Gillis, Ferm, Ou and Smith 1978; Leonard, Depper, Kanehisa, Kronke et al
1985). It also affects monocytes by increasing their cytotoxic activity, and
it can stimulate resting B cells to proliferate and differentiate to form
activated B cells producing IgM (Malkovsky, Loveland, North, Asherson et
al 1987; Tigges, Casey, and Koshland 1989).
The IL2 receptor is composed of at least three chains: a (tac, p55), (3 (p75),
and y (p65) which can associate in different ways to form a receptor of
variable affinity and activity (Ringheim, Freimark and Robb 1991;
Takeshita, Asao, Ohtani, Ishii et al 1992). In structure, the a chain is
homologous to complement control protein, while p and y are members of
the cytokine receptor family (Leonard et al 1985; Takeshita et al 1992).
The a chain binds IL2 with a of ~10_8M, but is unable to transduce the
signal (Ringheim et al 1991; Semenzato, Pizzolo and Zambello 1992;
Takeshita et al 1992). p chain binds IL2 with a Kj of 10~9M, and an ap
dimer can form with a of 10'10M for IL2. The y chain alone cannot bind
IL2 but can associate with the p chain to form a receptor with a of ~10-
9M. An ccPy receptor with a of ~10"nM appears to be the complete
receptor (Ringheim et al 1991; Takeshita et al 1992; Nakamura, Russell,
Mess, Friedmann et al 1994). The y subunit is found in other cytokine
receptor complexes, for example in those for IL4, IL7 and IL15 (Bazan
1990; Giri, Ahdieh, Eisenmann, Shanebeck et al 1994; Noguchi,
Nakamura, Russell, Ziegler et al 1993a). The IL15 receptor also contains
the p subunit, and the cytokine has been found to share structural
features, such as the 4 a helical bundle, and biological properties with IL2
(Grabstein, Eisenman, Shanebeck, Rauch et al 1994). The importance of
the y receptor chain was highlighted by Noguchi et al who showed that its
gene was at the same locus as that for X-linked severe combined
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immunodeficiency (Noguchi, Yi, Rosenblatt, Filipovich et al 1993b).
Soluble IL2 receptors have also been identified in culture, such as those of
HTLV-I positive cell lines, B cell lines, normal PBMC activated with plant
lectins, and also in vivo in patients with Hodgkin's disease, with non-
Hodgkin's lymphoma, or with metastatic solid tumours (Rubin, Kurman,
Fritz, Biddison et al 1985; Lissoni, Barni, Rescaldani, Rovelli and Tancini
1989). It is not clear why receptor secretion occurs, but it has been
proposed that it could serve an immunoregulatory function during growth
and development.
1.10.3: Tumour necrosis factor a
Active TNFa is trimeric formed of 17kDa monomers placed edge-to-face in
a "jelly roll" motif similar to those observed with TNFp and CD40L
(Aggarwal, Kohr, Hass, Moffat et al 1985a; Farrar and Smith 1992; Eck
and Sprang 1989). It is produced as a pro-protein with a membrane
anchor, from which the active protein is cleaved (Kriegler, Perez, DeFay,
Albert and Lu 1988). The membrane protein is biologically active and may
bind with a TNFa receptor expressed on another cell to activate the
receptor's cell. Alternatively, the membrane bound TNFa could be bound
by a soluble TNF receptor and transduce a signal itself.
TNFa was originally named because of its necrotic effects on tumours
such as that observed with a methylcholanthrene induced murine sarcoma
(Carswell, Old, Kassel, Green et al 1975; Gray, Aggarwell, Benton,
Bringman et al 1984). However, it is now recognised as having a wide
range of effects (reviewed by Le and Vilcek 1987; Vilcek and Lee 1991). It
is a pro-inflammatory cytokine, along with IL1 and IFNy (Dinarello,
Cannon, Wolff, Bernheim et al 1986). In the inflammatory state, it is
produced by infiltrating macrophages (Aggarwal et al 1985a). It can also
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be synthesised by T cells, B cells, NK cells, LAK cells etc. (reviewed in
Vilcek and Lee 1991).
TNFa can have beneficial effects; for example, it protects the host against
bacterial infections, and acts as a mediator of inflammatory reactions and
necrosis of tumours (Vilcek and Lee 1991). However, in sepsis and in
chronic infections it is also known to mediate wasting (Cerami, Ikeda, Le
Trang, Hotez and Beutler 1985; Beutler, Greenwald, Hulmes, Chang et al
1985). The biological activities of TNFa include T cell activation,
activation of neutrophils, and induction of IFN(32, of c-myc and c-fos, and of
IL1 synthesis (reviewed in Vilcek and Lee 1991). It is able to activate a
range of genes and proteins including those for a number of cytokines and
their receptors, cellular adhesion molecules, and MHC proteins. This
spectrum of activities and the presence of its receptors on many cell types
enables TNFa to have a central role in the immune system. Furthermore,
it can regulate its own production, and can act synergistically with IFNy
(Halloran 1993).
There are two receptor types, p55 and p75 both ofwhich bind TNFa and (3,
with a in the region of 10_10M (Aggarwal, Eessalu, and Hass 1985b;
Smith, Davis, Anderson, Solam et al 1990; reviewed in Le and Vilcek 1987;
and in Vilcek and Lee 1991). Unlike the IL2 receptor, p55 and p75 operate
independently (Vilcek and Lee 1991). Thus, p55 is expressed more widely,
p75 is restricted to cells of haematopoeitic lineages. Both are members of
the NGF receptor family characterised by extracellular cysteine repeats
(Farrar and Smith 1992; Mallett and Barclay 1991). However, TNFa
forms a separate ligand family from NGF (3, along with TNFp and CD40L
(Farrar and Smith 1992).
Soluble receptors are present in normal human urine and serum, possibly
to control TNF bioactivity in vivo (Olsson, Lantz, Nilsson, Peetre et al
1989; Engelmann, Aderka, Rubinstein, Dalia et al 1989). The trimer cone
form of active TNFa inserts its narrow end into the soluble receptor, each
subunit contributing crucial residues in association with its adjoining
subunits (Banner, D'Arcy, Janes, Gentz et al 1993). It is thought that the
membrane bound receptorwill operate in the same manner.
1.10.4: Interferon y
IFNy is a 17kDa glycosylated protein present as a dimer in its active form
(Ealick, Cook, Vijay-Kumar, Carson et al 1991). It is synthesised by
activated T cells and by NK cells, and has a range of effects in vivo
(reviewed in Halloran 1993). It induces MHC I and II expression on
macrophages indicating a specialised role for it in the immune response
(Basham and Merigan 1983; Langer and Pestka 1988). IFNy is a pro¬
inflammatory cytokine involved in inhibition and activation of macrophage
migration. It can induce synthesis of TNF a, also a pro-inflammatory
cytokine, and synthesis of the TNF receptor. It was initially identified as
an anti-viral agent, and hence was classified as an interferon (Wheelock
1965). In addition, IFNy can augment its own production by T cells
(Morris 1988).
The active IFNy dimer is composed of 2 identical subunits to form a
globular protein (Ealick et al 1991). Each subunit comprises six a helices,
and no (3 sheet. There are extensive intersubunit contacts in the dimer: for
example, the first four a helices of one subunit form a cleft to
accommodate the COOH terminus of the other subunit. The NH2 and
COOH termini of opposing subunits are adjacent and together contact the
receptor.
The IFNy receptor is composed of an a and a p subunit (Ucer, Bartsch,
Scheurich, Berkovic et al 1986; Auget, Dembic and Merlin 1988; Soh,
52
Donnely, Kotenko, Mariano et al 1994). The a subunit binds IFNy, and the
(3 "accessory" subunit transduces the signal. Both receptor subunits are
members of the type II cytokine receptor family (Bazan 1990). The IFNy
receptor is expressed on most cell types, and values in the range 10"9-
10"1:LM have been identified for various tissues (Ucer et al 1986; Langer
and Pestka 1988; Fischer, Wiegmann, Bottinger, Morens et al 1990).
Fischer et al (1990) observed post-translational regulation of the IFNy
receptor by GM-CSF, and proposed that GM-CSF may enhance
membrane associated proteinases resulting in release of soluble IFNy
receptor. Soluble receptors have been identified in urine (Novick,
Engelmann, Wallach and Rubinstein 1989).
1.10.5: Investigations on the qualitative binding ofcytokines by a2M
Qualitative studies have previously been employed to examine a2M-
cytokine interactions. Within the present investigations, qualitative
binding analysis was carried out using three column techniques, namely gel
filtration on G200 Sephadex, fast performance liquid chromatography
(FPLC) on SuperoseSB and zinc affinity chromatography on Sepharose, in
corroboration with native polyacrylamide electrophoresis (PAGE). The
bonds involved in interactions were examined by SDS-PAGE. IFNy was
found to bind poorly, and it was noted in column work and by TCA analysis
of IFNy samples that it was of poor quality. Thus, subsequent work
focused on IL2 and TNFa.
1.10.6: Quantitative investigations of a2M-cytokine interactions
Almost all previous studies of a2M-cytokine interactions have been carried
out by qualitative analysis (see Sec. 1.9). In this study two novel
quantitative assays were established. A radioimmunoassay (RIA) was
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developed in which a2M, preincubated with radiolabeled cytokine, was
bound by a rabbit anti-a2M polyclonal antibody. Separation of a2M-bound
cytokine from free was achieved by addition of a donkey anti-rabbit IgG
polyclonal antibody attached to solid phase followed by separation on a
sucrose gradient.
a2M can be isolated in highly purified form from serum or plasma on zinc
affinity columns, and this methodology was also used for qualitative
analysis (Kurecki et al 1979). The zinc affinity method was adopted to
create a tube based assay system for the quantitative study of a2M-
cytokine binding. As with the RIA, the zinc affinity "tube method" used
a2M as the separating molecule. Thus, corroborative values for the
binding of IL2 and TNFa with a2M were available, and the assays may
subsequently be used to examine more cytokines.
1.10.7: The effect of complex formation with a2M on cytokine
immunoassays
It has been noted by a number of groups that cytokines may lose their
antigenicity upon complexing with a2M, that is they lose their capacity to
interact with specific antisera (see Sec.1.9 Table 1.9.1). In diagnostics
and in analysis of tissue culture supernatant any such decrease in
antigenicity due to the presence of a2M could cause a depression of the
observed cytokine concentration. To investigate this further, cytokine
assay kit standards were incubated with a2M prior to application to the
assay. The resultant change in the position of the standard curve, due to a
specific a2M effect or to a more general protein effect was observed in a
number of instances. The implications of the change in the cytokine
standard curve will be discussed.
1.10.8: The effect ofcomplex formation on the bioactivity ofcytokines
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The effect of the binding of cytokines by a2M on their bioactivity is of
importance as regards their activity in vivo, and also for possible effects in
culture. In this study, in contrast to previous work published by other
groups, a2M-cytokine complexes were separated from unbound cytokine
on G200 or zinc affinity columns prior to application to prepared cells.
Bioactivity of a2M-cytokine complexes were examined on cultures of
peripheral blood lymphocytes and the L929 cell line for IL2 and TNFa
respectively.
1.10.9: A briefsummary of the findings of the present study
Qualitative studies indicated an interaction of IL2, TNFa and IFNy with
a2M. Development of quantitative assays revealed values in the
micromolar range for IL2 and TNFa binding with a2M. Furthermore, it
was found that the bioactivity of IL2 was maintained upon binding,
whereas that of TNFa was negated. With respect to cytokine
immunoassays, a2M had positive and negative effects upon a number of






2.1.1: Alpha 2 macroglobulin
a2M was donated by Behringwerke, Marburg, Germany, and was 82.6%
pure as judged by electrophoresis, the principle impurities being albumin
and immunoglobulins.
Alternatively, a2M was prepared from serum or plasma by zinc
chromatography according to the method of Kurecki et al (1979). Briefly,
fast-flow chelating Sepharose 6B (Pharmacia) was prepared by washing
with lOOmM phosphate buffer pH6.5 to remove preservative, and packed
into a 16x180mm glass column. The Sepharose was equilibrated to pH8.0
using lOOmM phosphate buffer containing 800mM NaCl and was then
charged by applying ZnCl2 at 5mg/ml until zinc was detectable in the
eluate by precipitation with 2M IN^COg. Zinc that was not bound to the
column matrix was washed off using lOOmM phosphate buffer pH6.5
containing 800mM NaCl.
Serum or plasma was then applied to the column. Serum was obtained by
allowing fresh human blood to clot overnight at 4°C. Plasma was
separated from the cellular components of fresh heparinised blood (sodium
heparin 50U/50ml of fresh blood) by centrifugation at 800g for 30 minutes.
Unbound protein was removed using the pH6.5 buffer containing NaCl
until the optical density of the eluate at 280nm read zero. Bound a2M was
recovered using lOOmM pH4.5 acetate buffer containing 800mM NaCl.
The fractions containing protein were pooled as the a2M peak and
concentrated approximately 20 fold to 20-30mg/ml using an Amicon™
concentrating chamber. Aliquots were stored at -70 °C until required. The
Sepharose was regenerated by stripping the column of ZnCl2 with 50mM
EDTA pH7.0 containing 800mM NaCl, then re-equilibrated and charged
with ZnCl2 as before.
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2.1.2: a2M-methylamine preparation
a2M-methylamine (a2Mm) was employed in binding investigations due to
its reported similarity to proteinase converted a2M (Bjork and Fish 1982;
Boisset et al 1991).
Behringwerke a2M (50mg/ml; l-2ml) was dialysed for 6 hours or overnight
at room temperature in 1 litre of 50mM TrisHCl pH8.2 containing 200mM
methylamine (Sigma Chemical Co.). The methylamine-treated a2M was
subsequently dialyzed twice overnight against 60mM PBS pH7.2
containing 150mM NaCl to remove the unbound methylamine. The
optical density at 280nm of the a2Mm was read. It was then aliquoted and
stored at -70°C.
2.1.3: Preparation of oQM-plasmin
a2M (Behringwerke, 4mg) was incubated at 37°C with plasmin (Kabi,
0.2mg). After 21 hours, Trasylol (Bayer, 20pl) was added to inhibit the
enzymic activity of plasmin. a2M-plasmin was stored at -70°C until
required.
2.1.4: Radiolabeled cytokines
Radiolabelled cytokines were purchased from a number of sources as
follows:
(^I) interleukin2 (^I IL2) with a specific activity of >600Ci/mmol was
purchased from Amersham International, UK. It had been prepared by
iodination of the natural sequence of recombinant human IL2 using sodium
(^I) iodide by the chloramine-T system, and had a radiochemical purity at
the time of production of 5% free (^I) iodide as determined by reverse
phase HPLC.
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S-f^O-iodotyrosol IFNgamma C125! IFNy), purchased from Amersham
International, UK, had a specific activity of >675Ci/mmol. It had been
prepared from recombinant human IFNy by the chloramine-T system
using sodium (125I) iodide, and had a radiochemical purity of <5% free f125!)
iodide at initial analysis.
Human recombinant tumour necrosis factor a f125! TNFa), that had been
labelled by the Bolton-Hunter method, was purchased from New England
Nuclear Research and had a specific activity of >30|iCi/(j.g. The
manufacturer indicated that free iodine was less than 5% at the time of
preparation, as determined by thin layer chromatography.
These cytokines were diluted in 0.1% (w/v) BSA, aliquoted and stored at -
70°C IFNy and TNFa) or -20°C (^I IL2), as recommended by the
manufacturers. Cytokines were tested by TCA precipitation for the
presence of free iodine both upon arrival and at the end of storage of a
given batch (as Sec.2.2.2). Batches were used within four weeks of their
production date.
2.1.5: Unlabelled cytokines
Unlabelled cytokines, for use in competition studies and in bioassays, were
obtained from a number of sources, as follows:
Recombinant des-alanyl-1, serine-125 IL2 was a gift from Euro-Cetus BV
It was provided at a specific activity of l.SxlOTJ/mg. One unit was
designated as the amount of IL2 required to produce half maximal
tritiated-thymidine incorporation in cultured HT-2 cells.
Human recombinant TNFa, of specific activity 6xl05U/ml and protein
concentration of 20qg/ml, was also a gift from Euro-Cetus. One unit was
defined as the amount of TNFa required to mediate half maximal
cytotoxicity with L929 cells in the presence of actinomycin D.
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Recombinant IFNy, of specific activity >2xl07U/mg, was purchased from
Boehringer Mannheim. It was judged >99% pure by HPLC. One unit was
defined as the amount of IFNy required to produce the equivalent antiviral
activity to that expected by one unit of the NIH IFNy reference standard.
These unlabelled cytokines were aliquoted and stored at -20°C.
2.1.6: Radioisotopes
Iodine-125 supplied as sodium (^I) iodide in dilute sodium hydroxide solution
with a specific activity of 14.4mCi/pg of ^-I at the activity date, and
methyl 3H-thymidine with a specific activity of 85Ci/mmol were purchased
from Amersham International
2.1.7: Antibodies
Rabbit anti-human a2M IgG was purchased from Sigma. It was
reconstituted at a protein concentration of 9mg/ml in deionised water.
Aliquots were stored at -20°C.
Donkey anti-rabbit IgG serum was supplied by the Scottish Antibody
Production Unit (SAPU), (Law Hospital, Lanarkshire, Scotland).
Immediately upon arrival, the IgG component of the serum was extracted
as outlined below (see Sec.2.2.4).
2.1.8: Tissue culture media
All tissue culture media were purchased from Gibco BRL.
RPMI medium, pH 6.9-7.4, was supplemented with 10% (v/v) heat
inactivated foetal calf serum. The RPMI contained 1.2g/100ml of a







2.2.1: Incubation of oQM with cytokines
a2M, derivatives of a2M, or control proteins were mixed at the required
concentrations with labelled and/or unlabelled cytokine, and incubated for 2
hours at 37°C prior to use in all systems.
The time and temperature of incubation were determined by PAGE (see
Sec.2.3.4 - 2.3.6 for methodology). To examine the required time for
incubation, a series of samples were set up at intervals over 4 hours prior
to application to PAGE. To find the optimal temperature, protein-cytokine
mixtures were incubated at a range of temperatures for 2 hours, then
applied to the gel. For each study, the positions ofproteins on the gels were
detected by Coomassie blue staining after electrophoresis, and the
positions of the cytokines were determined from autoradiographs of the
gels. From this information, protein bands were cut from the dried gel and
counted for the presence of radiolabelled cytokine using an LKB Wallac
1260 Multigamma II gamma counter.
2.2.2: TCA precipitation
Once a protein has been labelled with radioisotope a number of events may
occur which result in breakdown of the labelled product. It is therefore
necessary to know the stability of the radiolabelled molecule in order to
assess the accuracy of results. To this end all radiolabelled material
(commercially and in-house prepared) was routinely tested to assess the
percentage of label bound to the protein. This involved mixing 10pl of
sample of known counts per minute (cpm), lOOpl of foetal calf serum as a
carrier protein (Gibco BRL) and 3ml of 20% (w/v) tri-chloroacetic acid
(TCA). The precipitate was recovered by centrifugation at 350g for 10
minutes and the percentage of counts associated with the precipitate were
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determined using a gamma counter.
2.2.3: Iodination of a2Mm
Radiolabeled a2Mm was required for establishing a radioimmunoassay
that was used for quantitative analysis of ».2M-cytokine binding.
Preswollen Sephadex G25 (~50ml; Pharmacia) was allowed to settle and
the fines removed by gentle pipetting. The Sephadex was resuspended in
50mM phosphate buffer pH7.5 and packed into a 16x250mm glass
column. The same buffer was used throughout unless otherwise indicated.
a2Mm was diluted to a concentration of lOmg/ml in 250mM phosphate
buffer pH7.5 and mixed with 5pi of chloramine T (2.5mg/ml) and 2pi of
^iodine (sodium O25!) iodide solution) for 15 seconds in a Nunc cryotube.
Cysteine-HCl, lOOpl at 0.625mg/ml, was added to stop the reaction, and
883pl of potassium iodide (5mg/ml) applied to increase the volume to 1ml.
This solution was pipetted directly onto the column. The reaction tube was
washed twice with 1ml volumes ofbuffer, each time the 1ml was applied to
the column, thus providing a cold carrier. A constant head of pressure was
then maintained using the buffer. An initial void volume (Vo) of 3ml of
eluate was collected, and thereafter 1ml fractions. A sample of the
reaction mixture and all fractions from the column were assessed for the
presence of ^iodine using the LKB gamma counter. In addition, fractions
were examined by TCA precipitation for the level ofbinding of iodine to the
protein. Those fractions containing high levels of radiolabelled protein were
pooled, ahquoted and stored at -70°C. The radiolabelled a2Mm was used
within 4 weeks ofproduction.
2.2.4: Preparation ofsolid-phase bound secondary antibody
Donkey anti-rabbit IgG bound to Sephacryl was employed to facilitate the
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separation of bound and free cytokine in the aforementioned
radioimmunoassay, and was prepared thus:
(i) Donkey anti-rabbit IgG fractionation: Donkey anti-rabbit IgG serum
was heat inactivated at 56°C for 30mins. To one volume of the serum, one
volume of prewarmed (37°C) 28% (w/v) Na2S04 was slowly added while
stirring. The precipitate formed was centrifuged at 5000g for 15 minutes,
and resuspended in half the original serum volume of 150mM NaCl. An
equal volume of 28% (w/v) Na2S04 was added and the precipitate
centrifuged as before. The pellet was resuspended in 150mM NaCl and the
solution dialysed overnight against 100 volumes of lOOmM NaHCOg
pH9.0. This prepared serum could be stored for up to 6 months at 4°C
without losing its activity.
(ii) Preparation of oxidised Sephacryl: Superfine Sephacryl S1000
(Pharmacia; 30ml) was allowed to settle and the fines removed by gentle
pipetting. It was washed with 2 litres of distilled water on a sintered glass
funnel (number 2 porosity). The washed gel was resuspended in 100ml of
5mM sodium m-periodate (Sigma Chemical Co.) in lOOmM sodium acetate
pH5.0 in a glass stoppered tube. It was rotated for 1 hour at room
temperature. The reaction was quenched by the addition of 5ml of 10%
(v/v) glycerol with further mixing for 1 hour. The oxidised Sephacryl was
then washed with 2 litres of lOOmM NaHCOg pH9.0 and stored in 1
volume of the buffer at +4°C for up to 6 months.
(iii) Binding of donkey anti-rabbit IgG to oxidised Sephacryl: Oxidised
Sephacryl (15ml) was resuspended in 20ml of the prepared donkey anti-
rabbit IgG solution and rotated overnight at room temperature. The
Sephacryl with bound IgG was recovered on a glass sinter, resuspended in
50mM PBS pH7.5, and the fines removed after settling. Following washing
with the same buffer, the precipitate was resuspended in 100ml of 50mM
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PBS pH7.5 containing 500mg of sodium borohydride and allowed to react
for 30 minutes. The Sephacryl was then washed 4 times with 250mM
citrate pH4.0, and 5 times with 250mM Tris-HCl pH8.5 containing 1%
(v/v) Tween20, and 2% (v/v) horse serum. The Sephacryl with bound
donkey anti-rabbit IgG was resuspended in 20ml of PBS pH7.2 containing
1% (v/v) Tween20, 2% (v/v) horse serum, and 0.01% (v/v) merthiolate, and
stored at +4°C for up to 4 weeks.
2.2.5: Preparation of a2Mm-cytokine complexes for use in bioassays
a2Mm (17.5nmoles), preincubated with IL2 (175pmoles), was applied to
G200 Sephadex columns (outlined in Sec.2.2.1 and 2.3.2). a2Mm was
eluted in the void volume in PBS pH7.2. Bound IL2 co-eluted with it.
Subsequently, free IL2 was eluted from the column. All fractions were
retained at -70°C until required. Prior to use, samples were filtered
through a 0.22pm Acrodisc filter.
a2Mm (80.1mg), preincubated with TNFa (~4ug) as indicated above, was
applied to columns of zinc charged Sepharose (see Sec.2.2.1 and 2.1.1).
Free cytokine was washed off the column in pH6.5 phosphate buffer with
800mM NaCl, and the eluate collected in fractions of 3ml for subsequent
analysis. Acetate buffer, pH4.5 lOOmM with 800mM NaCl was then used
to strip the column of bound a2Mm. Eluate was collected in fractions for
subsequent analysis for the presence of cytokines. All fractions were
stored at -70°C for up to 6 months. The column was regenerated as
previously described (Sec.2.1.1).
2.2.6: Preparation ofperipheral blood mononuclear cells
10ml of fresh heparinized blood was gently layered onto 7ml of Ficoll
(density: 1.077) and centrifuged at 450g for 20 minutes. The interface of
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Ficoll and plasma, composed of the buffy coat containing mononuclear
cells, was removed using a sterile Pasteur pipette. These cells were
washed twice in 20ml of sterile 60mM PBS pH7.2 containing 150mM NaCl
by centrifugation at 350g for 10 minutes. The supernatant was discarded
and the cells resuspended in medium and counted for subsequent use.
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2.3: Analysis of qualitative binding of cytokines bycx2M
2.3.1: Methods employed in qualitative analysis
Within the course of these studies, the binding of cytokines to a2M was
analysed on two levels employing a range of techniques. This section
details the examination of the qualitative nature of the interactions by
means of gel exclusion chromatography using G200 Sephadex, fast
performance liquid chromatography (FPLC) on Superose 6B, and by
PAGE. These systems separate molecules on the basis of size: they are
therefore ideal techniques for assessing the binding of cytokines to a2M due
to the very different masses of these molecules (15-25kDa compared to
725kDa). Zinc affinity chromatography on Sepharose was also used to
qualitatively assess binding on the premise that it separates a2M from all
contaminants, including unbound cytokine. In addition, sodium dodecyl
sulphate- (SDS-) PAGE was used to study the types of bonds involved in
the binding of cytokines by a2M.
2.3.2: G200 Sephadex gel filtration
G200 Sephadex (20g dry weight) was preswollen in 500ml of 60mM PBS
pH7.2 containing 150mM NaCl by heating to 100°C for 5 hours. This
buffer was used throughout. The Sephadex was washed in buffer, allowed
to settle, and the fines removed by gentle pipetting. It was then degassed.
The gel was packed into glass columns (dimensions: 25x520mm) in the
presence of the same buffer. Alternatively, the swollen gel could be stored
indefinitely at +4°C until required.
a2M-cytokine preparations were applied to the column using a Pharmacia
LKB Pump P-1 in the presence of buffer. Elution was performed with the
PBS buffer, the eluate being automatically monitored by a UV detector.
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Fractions (l-5ml volume) were collected and subsequently analysed for the
presence of labelled cytokine and for protein content.
2.3.3: FPLC
FPLC works on a similar principle to the G200 system but employs higher
pressures and therefore operates more rapidly. Thus, the time between
application of the sample to the column and the time of collection of the
final tube containing radioactive material was one hour compared to
twenty hours with the G200 system. It was hoped that this much faster
separation would enable the increased throughput of a2M-cytokine
complex samples.
The particular system employed was a Pharmacia Superose™6 column
connected to a Pharmacia Liquid Chromatography Controller LCC 500.
The column was equilibrated with 2 column volumes of degassed 0.22pm
filtered 60mM PBS pH7.2 containing 150mM NaCl. All separations were
performed in this buffer. Protein-cytokine complexes, pre-incubated as
indicated above (Sec.2.2.1), were passed through a 0.22pm filter to remove
aggregates which might block the column. Approximately 200pl of the
complex solution was applied to the column. Buffer was applied to the
column at a rate of 0.5ml/minute for 1 hour with a maximum pressure of
1.5MPa. Eluate was collected in one minute fractions using a Pharmacia
FraclOO, and was monitored for the presence of protein by use of an
integral UV unit and pen tracer. Fractions were subsequently analysed for
the presence ofprotein and radiolabeled cytokine.
2.3.4: PAGE and SDS-PAGE
Polyacrylamide gel electrophoresis was chosen for the study of a2M-
cytokine interactions for a number of reasons. In addition to providing the
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effective separation of a2M-cytokine complexes and free cytokine, this
technique enabled the resolution of the native and fast forms of a2M, as
previously discussed (Sec. 1.1.1). Furthermore, in the presence of SDS and
mercaptoethanol, the bonds involved in the a2M-cytokine interactions
could be investigated.
2.3.5: PAGE equipment
All equipment used was from Pharmacia UK. Buffers and stock solutions
were prepared as indicated in Appendix A. Glass plates were thoroughly
cleaned with detergent, wiped down with alcohol to remove any
contaminants and then clamped together with 1.5mm spacers.
2.3.6: Native gel electrophoresis
5% running acrylamide gels were prepared by the recipes listed in
Appendix A. Atmospheric oxygen inhibits the polymerisation of
acrylamide. To eliminate this effect, solutions were degassed prior to the
addition of the polymerisation catalyst, ammonium persulphate (10% w/v;
Sigma Chemical Co.). The running gel solution was gently pipetted into the
gap between the upright plates to within 3cm of the top of the plates. A
layer of distilled water (~2mm deep) was gently applied on top of the
running gel to further block the effects of atmospheric oxygen.
Polymerisation was complete within 1 hour. The layer of water was
discarded and a comb inserted. The stacking gel was then applied by
pipette. The stacking gel was prepared as in Appendix A. A narrow band
of distilled water was layered on top of the gel. After 1 hour, the comb was
removed and simultaneously distilled water was pipetted into the wells.
The water was removed using a syringe and the wells flushed with fresh
distilled water. This process cleared the wells of any unpolymerised
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acrylamide. The wells were then filled with Tris-glycine electrode buffer
(pH8.3) in preparation for sample loading.
Samples of protein (0.5-2mg/ml; 7-28pmoles) and/or cytokine (20jiCi/ml;
O.lpmoles) were prepared as required. Loading buffer (see Appendix A)
was added to each sample as 4pl per 20pl of sample. Samples were then
applied to the wells. The gel was submerged in electrode buffer pH8.3 (as
above) and a constant current of 60mA was applied for 2.5 hours.
Proteins were fixed to the gel by incubation for 1 hour in a 25% (v/v)
methanol, 10% (v/v) acetic acid solution. The gel was stained using a
0.25% (w/v) Coomassie blue (Sigma Chemical Co.), 10% (v/v) methanol
solution for 30 minutes. Excess dye was removed over an 8 hour period at
37°C using a 10% (v/v) acetic acid solution with several changes of fluid.
The gel was then dried onto filter paper using a Bio-Rad slab gel drier.
For the detection of radioactive cytokines, the dried gel was applied to an x-
ray plate (Agfa Curix RP1 X-Ray Film) at -70°C in a film tray (Appligene,
Illkirch). The autoradiograph was developed and fixed using the solutions
described in Appendix A. The positions of radiolabelled cytokine on the gel
were located by comparison with the autoradiograph.
2.3.7: SDS-PAGE
SDS-PAGE reducing gels were prepared in a similar manner to native gels.
However, the composition of the buffers and the recipes for the running
and stacking gels differed from those used for the native gels. These are
listed in Appendix A. Proteins were diluted in sample buffer containing 2%
(w/v) SDS (Sigma Chemical Co.) and 5% (v/v) mercaptoethanol (Sigma
Chemical Co.). The technical aspects of the preparation and performance
ofboth gel types were the same. Where required, samples were suspended
in boiling water for 3 minutes.
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2.4: Quantitative analysis of oc2M-cytokine binding
2.4.1: Methods employed in quantitative analysis
In order to study the interaction of a2M with the cytokines at a
quantitative level, it was necessary to develop methods that could process
large quantities of samples to allow subsequent mathematical analysis of
the binding. Two approaches were adopted which permitted the separation
of bound and free ligand. These involved either the use of antibody or of
zinc affinity chromatography to separate bound and free radiolabeled
cytokine from a2M. These methods are outlined below. All buffers are
listed in Appendix A.
2.4.2: Radioimmunoassay protocol
RT30 tubes (Costar) were incubated overnight at 37°C with l%(w/v) BSA,
0.02% (v/v) Tween20 to block protein binding sites on the plastic.
Radiolabeled cytokine was added to these preblocked tubes and incubated
for 2 hours at 37°C with lOpg of a2Mm. lOOpl of rabbit anti-human a2M
antibody at 1/100 dilution was then added (Sigma, protein concentration
9mg/ml). After overnight incubation at +4°C, lOOpl of Sephacryl bound
donkey anti-rabbit IgG antibody (prepared as Sec.2.2.4) was added
followed by incubation for one hour on a shaking platform (1000+/-
lOOrpm).
To each assay tube, 1ml of prewash was added to suspend the Sephacryl,
followed by 2ml of wash (see Appendix A). The wash was underlayered
through the prewash layer thus suspending the prewash-Sephacryl layer
above it. After 30 minutes, the Sephacryl had settled under gravity
forming a pellet in the base of the tubes. The supernatant was removed
and the washing procedure repeated once. The pellet was then transferred
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to clean tubes and assessed for the presence of radiolabeled material using
the LKB gamma counter.
2.4.3: Zinc affinity tube-based batch assay
Sepharose was equilibrated and charged with zinc by the method of
Kurecki et al as outlined in Sec.2.1.1 (Kurecki et al 1979). The process
was performed overnight at room temperature in a rotating 50ml
centrifuge tube. The charged gel was recovered by centrifugation (200g, 10
minutes), and washed with lOOmM pH6.5 phosphate buffer containing
800mM NaCl. Sepharose was subsequently used in a 1:1 ratio with this
buffer.
a2M-cytokine complexes were applied to 1ml of the zinc charged
Sepharose slurry in Eppendorf tubes. These were rotated for 1 hour to
ensure complete adsorption of a2M to the Sepharose. The tubes were
centrifuged as above, and the pellet retained. The gel was further washed
by resuspension in the same phosphate buffer and centrifuged as before.
The supernatant formed in each wash was collected and the radioactivity
measured using the LKB gamma counter.
The a2M-cytokine complexes were then eluted from the zinc affinity gel by
rotating the Eppendorf tubes for 1 hour in the presence of lOOmM acetate
buffer pH4.5 with 800mM NaCl, and centrifuged as before. The presence
of eluted a2M with bound cytokine in the resultant supernatant was
determined using the LKB gamma counter. The Sepharose was
regenerated as before (see Sec.2.1.1).
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2.5: Effects of a2M on cytokine assays
2.5.1: Assays examined
The techniques outlined above were designed for the study of possible
interactions between a2M and cytokines. It was also desirable to examine
the influence such interactions would have on cytokine assays. To this
end, the effect of a2M on commercial cytokine assays was determined, and
the activity of a2M-cytokine complexes in bioassays was assessed.
2.5.2: Influence ofa2M in cytokine immunoassays
Cytokine immunoassay kits were purchased from or donated by a number
of sources as indicated in results (see Sec.3.7 Table 3.7.1). All were two
site assays, and the protocols followed were as specified by the
manufacturers.
Assay standards were prepared as per the normal protocol and sufficient
reserved for forming the standard curve. The remaining solution for each
standard was incubated for 2 hours at 37°C in a 1:1 ratio with a2M, its
derivatives or with a control protein (BSA), the final concentration for the
proteins being in the range 0.5-5mg/ml. The standard-protein mixtures
were applied simultaneously and in the same manner as the normal
standards to the immunoassay plates. All samples were applied in
duplicate. Results were read as optical densities using a Dynatech MR700
Microplate reader set at the appropriate wavelength.
2.5.3: Assay for IL2 activity by lymphoproliferation tests
IL2 bioactivity was assessed by LPA assays on human peripheral blood
lymphocyte preparations isolated as described (see Sec.2.2.5). The cells
were suspended at 106 cells per ml in complete RPMI-10%FCS. The cell
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suspension was applied at 100|il per well to a 96 well plate (flat bottom,
Costar). The volume of each well was made up to 200pl by addition of
medium (RPMI-10% FCS), with or without stimulants such as PHA
(Sigma, 5pg/ml), IL2 or IL2 complexed with a2Mm at the appropriate
concentrations. The cells were incubated for 4 days at 37°C in a 5% CO2
atmosphere, then pulsed for 18 hours with methyl 3H-thymidine (3HT) at
0.5|iCi/well. The cells were harvested using a semi-automatic cell
harvester (Skatron). The discs which bound the released DNA were then
placed in individual scintillation vials with 2ml of Vickers scintillation
cocktail and the quantity of 3HT incorporation measured in a Tri-Carb
1900CA liquid scintillation counter.
2.5.4: TNFa bioassay
L929 cells are fibroblast cells that are particularly sensitive to TNFa, and
are routinely used in the bioassay of this cytokine. For the purposes of
testing the effects of a2M on the bioactivity of TNFa, L929 cells were
grown according to the following protocol.
For passage, cells were trypsinised using trypsin-EDTA (O.SgP1 trypsin
and 0.2gH disodium EDTA) in 60mM PBS pH7.2 containing 150mM NaCl
at 37°C for 90 seconds and resuspended in RPMI-10%FCS. They were
recovered by centrifugation at 130g for 5 minutes, and resuspended to
lOmls. 4mls of these cells were added to 6mls of complete medium and
grown for 2 days to confluence.
Prior to each assay, the confluent cells were trypsinised as before,
resuspended to a density of4xl06 cells/ml, and seeded into the inner wells of
96 well plates at lOOpl per well. Cells and medium were omitted from 5
wells, which were used as blanks in assessing the optical density ofwells at
the end of the assay. The plates were incubated overnight at 37 °C to allow
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the cells to form a monolayer. Medium was then aspirated from the wells.
For the formation of a TNFa standard curve, 50|il ofmedium was placed in
all wells required, then 50pl of TNFa of known concentration in the first
wells of the series. The TNFa was then diluted across the plate from these
initial wells by doubling dilution, and 50pi of fluid discarded from the final
wells of the series. For the testing of samples of unknown TNFa
concentration, aspirated medium was replaced with 50pl of unlabelled
TNFa and/or a2Mm, prepared as above (see Sec.2.2.5). All conditions were
tested at least in duplicate. Control wells in which 50pi ofmedium alone
was applied to the cells were also set up. 50pl of actinomycin D (Sigma,
8pg/ml), an RNA polymerase inhibitor, was added to all wells to prevent
cell proliferation allowing a clearer assessment of the anti-proliferative
effects of TNFa. The cells were incubated for 18 hours at 37°C, 5% CC>2-
To each well lOpl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (Sigma, 5pg/ml) was applied, and the plates incubated for a
further 2 hours at 37°C. The supernatant was then discarded, and
prewarmed (37°C) propan2ol-0.4% (v/v) IN HC1 applied at lOOpl/well and
the plates incubated for 45 minutes at 37°C. The optical density in each




3.1: Sources and purity of a2M
3.1.1: Sources and purity of a2M and its derivatives
As previously described in Sec.1.1.1, a2M exists in 2 conformations that
are differentiated by PAGE, as illustrated in Fig.3.1.1. It is evident that
the native protein (lanes 1 and 6; purchased from Behringwerke) and that
derived from plasma (lanes 3 and 7) migrated more slowly than the serum
derived (lanes 5 and 9) and methylamine-treated forms (lanes 4 and 8). As
mentioned before, it is on the basis of such migration patterns that
classically the slower proteins are referred to as "slow form", and the
others as "fast form". In Fig.3.1.1, no contaminants are seen in the
preparations indicating a high level of purity for each of the preparations.
Nevertheless, at higher concentrations of a2M some contaminants may
be visible.
Storage of the Behringwerke a2M for 6 months at -70°C resulted in the
conversion of some of the protein to the fast conformation (Fig.3.1.2). This
protein had not been subjected to freeze-thawing. This phenomenon has
been observed elsewhere and is proposed to be due to the autolytic
cleavage of the thiol ester bond (Barrett and Starkey 1973; see Sec.1.6).
When this age-converted protein was examined by FPLC on Superose 6B
for its potential to bind to 125-I IL2, it bound similar levels of the cytokine
as fast forms of a2M (see Sec.3.3 and Fig.3.3.3d).
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Figure 3.1.1: Slow and fast forms of a2M on PAGE
Samples of a2M (10|il, 2mg/ml in lanes 1, 3, 4, and 5, lmg/ml in lanes 6,
7, 8, and 9) were applied to a 5% PAGE gel, run at 50mA for 2 hours.
Note the migration pattern: a2M and a2M (plasma) ran slower than
a2Mm and a2M (serum).
3.2: Time course and temperature studies
3.2.1: Investigation of the optimal a2M-cytokine incubation conditions
Prior to binding studies, native PAGE was used to determine optimal
conditions for the interaction of a2M and cytokines. An initial time of
incubation of 2 hours was established based on previous investigators'
studies (Wollenberg et al 1991; Teodorescu et al 1991), and a range of
temperatures analysed (-70°C to +65°C). Fig.3.2.1 illustrates the
resultant autoradiograph for the study with IFNy. It is apparent that
+37°C provided the optimal temperature with this cytokine. A similar
finding was established with IL2 (Figure not shown).
Time courses were set up with incubations commencing up to 4 hours prior
to running reactants on a gel: Fig.3.2.2 indicates that 2 hours was sufficent
time for the interaction of 125-IIL2 with a2Mm; a similar result was found





























Figure 3.2.1: Temperature study for the interaction of 125-I IFNy
with ot2Mm
Samples of a2Mm (lOpl, 2mg/ml) and 125-I IFNY(~105cpm) were
incubated for 2 hours at a range of temperatures, applied to a 5% PAGE
gel, and run for 2 hours at 50mA. After staining for proteins, the gel
was dried and laid down with an x-ray plate at -70°C for 7 days, then




Figure 3.2.2: Time course study for the interaction of 125-I IL2
with a2Mm
Samples of a2Mm (10pl, 2mg/ml) and 125-I IL2 (~105cpm) were
incubated for 2 hours, applied to a 5% PAGE gel and run for 2 hours at
50mA. The gel was stained for proteins, dried and laid down with an X-
ray plate for 7 days at -70°C, then the gel was developed. Note the
increase in intensity of the band associated with a2Mm as time of
incubation increased.
3.3: Qualitative column studies of the binding of cytokines by
a2M
3.3.1: G200 Sephadex and FPLC Superose 6B Studies
The binding of radiolabeled IL2 and IFNy by a2M was examined by
applying incubated mixtures of protein and cytokine to G200 Sephadex
and FPLC Superose 6B columns. The columns permit separation of free
cytokine from that bound to protein on the basis of size. The columns were
calibrated with molecular weight marker proteins in order to assess the
molecular weights of eluting material (see Appendix C)
3.3.2: G200 studies of the binding ofcytokines by a2M
In the G200 studies, it was apparent that the various forms of a2M
examined bound IL2 and IFNy (Figs.3.3.1 and 3.3.2). Cytokine binding by
albumin could also be detected but at a lower level. Transformation of the
data to indicate the percentage of eluted protein-associated cytokine
revealed a distinct binding pattern relating to the form of a2M: the fast
forms of the protein (ie methylamine treated, or serum derived) bound
more cytokine than the slow native form (illustrated in peak A in Table
3.3.1 and 3.3.2). For example, it was found that a2M bound 8.2% of the
IFNy that eluted from the column, whereas the fast forms of a2M bound
16.7-25.9% of the eluted cytokine (Table 3.3.2). In contrast, albumin
bound only 6.7% of the available cytokine. A similar pattern was observed
with IL2, with serum derived a2M 67.9% of the eluted cytokine was bound,
with native a2M 28.6%, while albumin bound only 24.6% (Table 3.3.1).
Contrary to expectations, plasma derived a2M also bound levels of
cytokine similar to the fast forms of a2M. For example, a2M from plasma
bound 32.4% of eluted IFNy as compared to the serum derived form of the































































Figure 3.3.1: The binding of 125-I IL2 to human a2M as revealed by
filtration on G200 Sephadex
125-I IL2 (94fmoles) preincubaved with protein (21nmoles «2M, 224nm
BSA) (2 hours, 37"C) was applied to a G200 Sephadex column
(16x52mm, flow rate 6.6ml/hour) for the separation of bound and free
cytokine. The presence of radioactivity and of protein in the resultant
fractions was measured. Note the association of radioactivity with the





























































Figure 3.3.2: The binding of 125-I lFNy to human «2M as revealed by
G200 Sephadex.
125-1 IFNy preincubated with protein (21nm «2M, 224nm BSA; 2 hours,
37°C) was applied to a G200 column (16x52mm, flow rate 6.6ml/hour). The
eluate was assessed for the presence of protein and of radiolabel. Note the
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from plasma may have arisen by age-conversion of the protein due to
autolytic cleavage of the thiol ester bond (see Sec.3.1 Fig.3.1.2).
Fast form a2M generated by incubation with plasmin was also examined
(Fig.3.3.2f). However, G200 studies with that preparation revealed that
considerable degradation had occurred yielding polypeptides of a2M of
various molecular weights and binding variable quantities of 125-I labelled
cytokine. On the basis of this observation, subsequent work was
performed with fast form a2M prepared by methylamine treatment, or
derived from serum as described in Sections 2.1.2 and 2.1.1.
3.3.3: FPLC studies of the binding of a2M and cytokines
FPLC studies corroborated the G200 findings indicating that IL2 coeluted
with a2M (see Fig.3.3.3). A similar binding pattern was found to that seen
with G200 (Table 3.3.3): for example, native a2M was found to bind 10.0%
of eluted IL2, whereas the fast forms of the protein bound 34.1-36.7%
(peak A in Table 3.3.3). This was observed with methylamine treated,
serum derived and age-converted a2M. In contrast, albumin bound only
3.4% of the cytokine.
3.3.4: Elution profiles ofprotein and radioactivity from columns
Calibration of the columns, see Appendix C, indicated that when a2M was
run on G200 or on FPLC it eluted as a protein peak in the void volume, and
that albumin eluted later as would be expected: this can be seen in the
protein profiles in Figs.3.3.1-3.3.3. The ^-iodine radiolabeled cytokine
eluted in 3 principle peaks: peak A co-eluted with protein (ie either a2M or
albumin) and was presumably due to the interaction of protein with whole
radiolabeled cytokine. Peak B eluted in the molecular weight band of







































Figure 3.3.3: The binding of 125.J 1L2 to human u2M as revealed by
filtration on Superose 6 B FPLC
125.1 IL2 preincubated in the presence of protein (a2M 21nmoles, BSA
224nmoles) was applied to a Superose 6B FPLC column (flow rate 0.5ml/min) to
separate bound and free cytokine. Resultant fractions were assessed for the
presence of radioactivity and for protein concentration. Note the association of
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low molecular weight region and would have consisted of degraded cytokine
and free ^-iodine. Variation in the size of peaks B and C is evident in
Fig.3.3.1-3.3.3 and Tables 3.3.1-3.3.3. This was due to degradation of the
radiolabelled cytokine during storage. This pattern of three peaks was
confirmed by TCA precipitation studies which revealed that counts in the
third peak were not associated with intact protein (see Sec.3.9 Fig.3.9.1).
It should also be noted that routine studies on stored labelled cytokines
indicated that degradation of these products regularly occurred (see
Sec.3.9. Table 3.9.1).
3.3.5: Zinc affinity Sepharose column studies
a2M and cytokine interactions were further investigated by separation of
mixtures of these materials by zinc affinity chromatography on
Sepharose. A phosphate buffer was used to elute material that did not
bind with the zinc, specifically cytokine. Acetate buffer was then used to
elute a2M that had interacted with the zinc. Any a2M-associated cytokine
was also eluted at this point.
From Fig.3.3.4, it can be seen that an appreciable amount of labelled IL2
coeluted with a2M and with a2Mm in the acetate buffer. In the absence of
protein, no IL2 was present in the acetate wash. These findings imply
that the m-l IL2 eluted in the acetate wash had interacted with the serum
protein. Analysis of the amounts of protein and cytokine eluted revealed
once more that a2M bound less of the available IL2 than a2Mm (Table
3.3.4). The general finding was that 10 fold less a2Mm, than a2M, was
required to bind lfmole of IL2. For example, for the cases illustrated,
0.24nmoles of a2M bound lfmole of IL2 whereas 0.035nmoles of a2Mm
were required to bind the same amount of cytokine.
























































Figure 3.3.4: Zinc affinity Sepharose study of the binding of 125-1 IL2
by a2M
Preincubated 125-I IL2 and protein (variable amounts, 2 hours, 37°C) were
applied to a Sepharose column to which zinc ions had been bound. In the
presence of phosphate buffer pH6.5, a2M chelated with the zinc, all other
material was eluted (panels a, c, and e). Acetate buffer pH4.5 was then
applied to elute the a2M, and any cytokine that had bound to it (panels b, d
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separation on Sepharose (Fig.3.3.5, Table 3.3.5). Once again it was found
that cytokine eluted in the acetate wash only in the presence of a2M
(Fig.3.3.5b and d compared with Fig.3.3.5f) indicating an interaction of
TNFa with a2M. In addition, a2Mm showed stronger binding to the
cytokine than did the native protein, 28% of eluted TNFa associating with
the methylamine converted protein while only 6.3% bound to native a2M
(Table 3.3.5). Limited OD values were recorded during these studies and it
is therefore not possible to make a more detailed comparison of the binding
of a2M and a2Mm with TNFa from this work. Breakdown products were
found in the double peak in the phosphate wash and were further
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Figure 3.3.5: Study of the binding of 125-I TNFa by a2M using zinc
affinity Sepliarose separation
Preincubated 125-I TNFa and protein (variable amounts, 2 hours, 37"C) were
applied to a zinc chelated Sepharose column. In the presence of phosphate
buffer pH6.5, a2M botmd to the zinc and cytokine was eluted (panels a, c and
e). Acetate buffer pH4.5 was then used to elute the protein and any
associated TNFa (panels b, d and 0. It can be seen that TNFa associated
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3.4: Polyaery lamide gel electrophoresis studies of cx2M-
cytokine interactions
3.4.1: General conclusions of the electrophoresis studies
In addition to gel filtration chromatography, qualitative analysis of the
binding of the radiolabelled cytokines IL2, IFNy, and TNFa to a2M was
carried out by native and SDS polyacrylamide gel electrophoresis (PAGE
and SDS-PAGE). The gels and autoradiographs illustrate that the protein
and these cytokines do bind (Figs.3.4.1-3.4.3). The effects of SDS and
mercaptoethanol on the interaction of the cytokines with a2Mm indicate
that the interaction of IFNy with a2Mm employs non-disulphide covalent
bonds, that of IL2 with the protein uses covalent bonds, and that TNF a is
bound to a2M by non-covalent bonds.
3.4.2: Binding studies with PAGE
Figs.3.4.1-3.4.3 reveal the binding of IFNy, IL2 and TNFa to a2M and its
derivatives. Binding of IFNy is to fast form a2M in all three samples
(Fig.3.4.1). It is apparent that a2M derived from serum and from plasma
was composed ofboth slow and fast forms of the protein, contrary to that
observed previously (see Sec.3.1 Fig.3.1.1). Moreover, the presence of fast
form a2M in the plasma preparation explains the high levels of binding
observed with this preparation in G200 studies with 125-I IFNy compared
to the expected lower levels (see Sec.3.3 Fig.3.3.2b and Table 3.3.2).
125-I IL2 was bound by fast form a2M. Binding was observed with the
lower part of the slow-fast a2M band (Fig.3.4.2). It was not bound by an
equivalent component of plasma, but did co-migrate with a 470kDa protein
in both the a2M and plasma preparations. However, there is not a distinct
protein band at ~730kDa in either plasma preparation, therefore it would
be unlikely that any 125-IIL2 bound to a2M in those preparations would be
81

































Figure 3.4.1a: Study of the binding of IFNy by a2M using PAGE
a2M samples (0.5mg/ml, 16pl) were preincubated with ~105cpm of 125-I
IFNy for 2 hours at 37°C, then run on a 5% PAGE gel for 2 hours at
50mA. The gel was stained for proteins (Fig.3.4.la), laid down with an
x-ray plate at -70°C for 7 days then the x-ray was developed






























Figure 3.4.1b: Study of the binding of IFNy by a2M using PAGE
a2M samples (0.5mg/ml, 16|il) were preincubated with ~105cpm of 125-I
IFNy for 2 hours at 37°C, then run on a 5% PAGE gel for 2 hours at
50mA. The gel was stained for proteins (Fig.3.4.la), laid down with an
x-ray plate at -70°C for 7 days then the x-ray was developed
(Fig.3.4.1b). 125-I IFNy was bound by the faster migrating bands of
a2M.
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Figure 3.4.2a: PAGE study of a2M-IL2 binding
Samples of a2M (2mg/ml, 20pl/well) or of plasma (fresh or stored for 1
month at -70oC, lOpl) were incubated with 125-1IL2 at 37°C for 2 hours,
then run on a 5% PAGE gel for 2 hours at 50mA. The gel was stained
for proteins (Fig.3.4.2a), laid down with an x-ray plate at -70°C for 7
days and the x-ray plate developed to reveal radioactivity bands. 125-I
IL2 bound to purified a2M, and also to protein bands of ~430kDa seen











































































































































Figure 3.4.2b: PAGE study of a2M-IL2 binding
Samples of a2M (2mg/ml, 20jil/well) or of plasma (fresh or stored for 1
month at -70°C, lOpl) were incubated with 125-IIL2 at 37°C for 2 hours,
then run on a 5% PAGE gel for 2 hours at 50mA. The gel was stained
for proteins (Fig.3.4.2a), laid down with an x-ray plate at -70°C for 7
days and the x-ray plate developed to reveal radioactivity bands. 125-I
IL2 bound to purified a2M, and also to protein bands of ~430kDa seen

















































Figure 3.4.3a: PAGE study of a2M and 125-1 TNF a
Samples of a2M, albumin (both at 2mg/ml 20pl/well) or of fresh plasma
(20pl/well) were incubated with 125-I TNFa (~105cpm) at 37°C for 2
hours, then run on a 5% PAGE gel. The gel was stained for protein
(Fig.3.4.3a), laid down with an x-ray plate at -70°C for 7 days, and then
the x-ray was developed (Fig.3.4.3b). Note the interaction of a2M and
!25-i TNFa, and an equivalent molecular weight protein in the plasma
preparations also bound the cytokine.
<N CO
Figure 3.4.3b: PAGE study of a2M and 125-I TNF a
Samples of a2M, albumin (both at 2mg/ml 20pl/well) or of fresh plasma
(20gl/well) were incubated with 125-I TNFa (~105cpm) at 37°C for 2
hours, then run on a 5% PAGE gel. The gel was stained for protein
(Fig.3.4.3a), laid down with an x-ray plate at -70°C for 7 days, and then
the x-ray was developed (Fig.3.4.3b). Note the interaction of a2M and
i25-i TNFa, and an equivalent molecular weight protein in the plasma
preparations also bound the cytokine.
visible on the autoradiograph.
As with IFNy and IL2, 125-I TNFa was found to be bound by a2M
(Fig.3.4.3). However, as has been observed elsewhere and within these
studies (Barrett and Starkey 1973; see Sec.3.1.1), native a2M can undergo
age-conversion during storage as seen in lanes 8 and 9 of Fig.3.4.3. The
plasma preparations do show a very faint protein band of equivalent
molecular weight to a2M, and there is an increased density of radioactivity
on the autoradiograph at those bands (lanes 2 and 3).
3.4.3: Study of the bonds involved in a2M-cytokine interactions using SDS-
PAGE
The bonds involved in these interactions were examined by use of the mild
detergent sodium dodecyl sulphate (SDS) to cleave non-covalent bonds,
and ofmercaptoethanol to cleave disulphide bonds. It appears that IL2 did
not dissociate from a2Mm even in the presence of mercaptoethanol
indicating that the bonds formed had been non-disulphide covalent
(Fig.3.4.4). However, if the gel is overlaid with the autoradiograph the
bands of protein and radioactivity do not appear to align, even in the
presence of denaturant alone which implies that the binding is non-
covalent. This is contradictory to an SDS gel run in the absence of
mercaptoethanol where IL2 was found to remain bound (Fig.3.4.5). Thus,
the bonds between IL2 and a2Mm appear to be covalent in nature, though
it is unclear if they are disulphide or not.
As with the IL2 study, the a2M-TNFa complex appeared to remain intact
in the presence of SDS and mercaptoethanol indicating a covalent non-
disulphide interaction (Fig.3.4.6). However, once again the protein and
radioactivity bands are misaligned when the gel is overlaid with the
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Figure 3.4.4a: SDS-PAGE study of the interaction of a2Mm and
125.J IL2
Samples of a2Mm (2mg/ml, lOpl) and 125-IIL2 (~105cpm) were
preincubated for 2 hours at 37°C. SDS and mercaptoethanol were
added as appropriate, and if required samples boiled for 3 minutes prior
to loading onto a 5% SDS-PAGE. The gel was run for 2 hours at 50mA,
stained for proteins (Fig.3.4.4a), then laid down with an x-ray plate at -
70°C for 7 days. The x-ray was then developed (Fig.3.4.4b). Note that
the radioactivity does not align with the positions of the subunit bands
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Figure 3.4.4b: SDS-PAGE study of the interaction of a2Mm and
125.1 IL2
Samples of a2Mm (2mg/ml, 10pl) and 125-IIL2 (~105cpm) were
preincubated for 2 hours at 37°C. SDS and mercaptoethanol were
added as appropriate, and if required samples boiled for 3 minutes prior
to loading onto a 5% SDS-PAGE. The gel was run for 2 hours at 50mA,
stained for proteins (Fig.3.4.4a), then laid down with an x-ray plate at -
70°C for 7 days. The x-ray was then developed (Fig.3.4.4b). Note that
the radioactivity does not align with the positions of the subunit bands
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Figure 3.4.5a: SDS-PAGE study of the interaction of a2M with
TNFa and with IL2
Samples of a2M or albumin (2mg/ml, 10pl) were incubated with 125-I
IL2 or 125-I TNFa (~105cpm) for 2 hours at 37°C. SDS was added then
samples were loaded onto a 5% SDS-PAGE gel. The gel was run for 2
hours at 50mA, then stained for proteins and dried (Fig.3.4.5a). It was
laid down with an x-ray plate at -70°C for 7 days and then developed
(Fig.3.4.5b). IL2 remained bound to a2Mm dimers formed in the
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Figure 3.4.5b: SDS-PAGE study of the interaction of a2M with
TNFa and with IL2
Samples of a2M or albumin (2mg/ml, lOpl) were incubated with 125-I
IL2 or 125-1 TNFa (~105cpm) for 2 hours at 37°C. SDS was added and
samples loaded onto a 5% SDS-PAGE gel. The gel was run for 2 hours
at 50mA, then stained for proteins and dried (Fig.3.4.5a). It was laid
down with an x-ray plate at -70°C for 7 days and then developed
(Fig.3.4.5b). IL2 remained bound to a2Mm dimers formed in the


















































































































Figure 3.4.6a: SDS-PAGE study of a2Mm-TNFa binding
Samples of a2Mm (2mg/ml, 10pl) were incubated with 125-I TNFa for 2
hours at 37°C. SDS and mercaptoethanol were added as appropriate,
and if required samples boiled for 3 minutes. Samples were then run
on a 5% SDS-PAGE gel for 2 hours at 50mA, followed by staining for
proteins (Fig.3.4.6a). The gel was then dried and laid down with an x-
ray for 7 days at -70°C. The x-ray was developed (Fig.3.4.6b). Note
that the protein and radioactivity bands do not align between these two













































































































Figure 3.4.6b: SDS-PAGE study of a2Mm-TNFa binding
Samples of a2Mm (2mg/ml, 10|il) were incubated with 125.J TNFa for 2
hours at 37°C. SDS and mercaptoethanol were added as appropriate,
and if required samples boiled for 3 minutes. Samples were then run
on a 5% SDS-PAGE gel for 2 hours at 50mA, followed by staining for
proteins (Fig.3.4.6a). The gel was then dried and laid down with an x-
ray for 7 days at -70°C. The x-ray was developed (Fig.3.4.6b). Note
that the protein and radioactivity bands do not align between these two
figures. This is discussed in the text.
TNFa binding to a2M was only very slightly maintained in the presence of
the denaturant implying that the interaction was principally through non-
covalent bonds.
IFNy remained bound to a2Mm in the presence of SDS and
mercaptoethanol, from which it can be concluded that IFNy binds to a2Mm
by means of non-disulphide covalent bonds. The gel and graph are not
shown because the radioactive bands were extremely faint.
It is interesting to note the mobility shift of proteins seen in the presence
of mercaptoethanol as revealed in Fig.3.4.4 and 3.4.6: this may have
occurred because of the protein subunits assuming a different
conformation as disulphide bonds are cleaved.
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3.5: Quantitative analysis of a2M-cytokine binding by
radioimmunoassay
Radioimmunoassay Development
3.5.1: Iodination of a2Mm
Freshly produced a2Mm was iodinated by the Chloramine T method and
used to establish optimal conditions for the radioimmunoassay (RIA).
Labelled a2Mm was separated from unbound ^-iodine on a Sephadex G25
column. TCA precipitation revealed that the labelled fractions 4-7 were
associated with a2Mm (Fig.3.5.1). Those fractions were aliquoted, stored
at -70°C and used within 1 month.
3.5.2: Blocking ofnonspecific binding in assay tubes
Plastic RT30 tubes were employed throughout development and
application of the assay. In order to reduce non-specific adherance of
radiolabelled material to the plastic two blocking solutions were examined
(Table 3.5.1). With both solutions it was apparent that less than 10% of
the radiolabelled protein remained bound to the BSA-treated plastic after
transfer of the reactants to fresh tubes and 2 washings of the original
tubes. One wash provided efficient transfer of material. In all further
experiments, tubes were blocked by treatment with 1% BSA containing
0.02% (v/v) Tween 20.
3.5.3: Optimising primary antibody dilution
A range of dilutions of the primary antibody were tested to establish the
optimal titre. The optimal antibody dilution for subsequent use in the RIA
was that which bound 50% of available radiolabelled ligand. It can be seen
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Figure 3.5.1: Protein and radioactivity profile from the
iodination of a2Mm
Freshly prepared oc2Mm was iodinated by the Chloramine T system
and separated from free 125-iodine on a G25 Sephadex column.
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Figure 3.5.2: Study of the optimal dilution of primary
antibody for use in the radioimmunoassay.
Primary antibody (rabbit anti-human a2M antibody) at a range of
dilutions (1/10-1/1000) was incubated overnight with a2Mm
(lOpg) and 125-I a2Mm (lOOng), following which the components
were incubated with secondary antibody (donkey anti-rabbit IgG
bound to Sephacryl). Bound l-adiolabelled a2Mm was then
separated on a sucrose gradient. Optimal sensitivity is obtained
with an antibody dilution that binds 50% of available
radiolabeled protein. Here it occured in the l'egion of a 1/100
dilution. All conditions were examined in triplicate, and the
study conducted three times with the same result. Values are
mean +/- standard deviation; error bars are included in all cases.
3.5.4: Protein amount
A concentration series of a2Mm was examined to ensure that the
conditions of the RIA were optimal. Thus, the assay was set up as
described in Fig.3.5.3. The optimal amount of protein for the assay
conditions should occur at the steepest part of the resultant curve:
Fig.3.5.3 indicates that 10gg of cold a2Mm fulfilled this criterion.
3.5.5: Checking for non-specific binding
The various components of the RIA were examined for their non-specific
influence upon the assay (Fig.3.5.4). There appeared to be very little non¬
specific binding due to the secondary antibody binding directly with the
radiolabelled ligand. Furthermore, a non-related primary antibody did not
interact. However, it should be noted that when myosin was employed as
the control protein replacing unlabelled a2Mm, the binding of 125-I a2Mm
observed was 17.7%+/-4.6. The low binding may have arisen due to the
antibodies crossreacting with the myosin and thus blocking the binding of
the radiolabelled protein. Alternatively, it may have been caused by the
presence of contaminants in the myosin preparation.
Use of the radioimmunoassay
3.5.6: Binding studies
Radioimmunoassays were carried out as previously described (see
Sec.2.4.2). In brief, this involved incubating a range of concentrations of
labelled cytokine with a fixed amount of a2M. Binding analysis revealed
dissociation constants (Kd) for the interaction of a2Mm with ^-IIL2 and
with ^-I TNFa of 2.1-2.5xlO"6M and 0.96-1.36xl0"6M respectively. These
figures were derived by plotting the quantities of radiolabelled cytokine
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Figure 3.5.3: Protein titration curve for the
development of the radioimmunoassay.
a2Mm (0.1-1000|ig) was incubated with primary antibody
at 1/100 dilution (rabbit anti-human «2M) overnight at 4°C
in the presence of 125-I a2Mm (lOOpg), followed by a 1 hour
incubation at room temperature with secondary antibody
(donkey anti-rabbit IgG bound to Sephacryl). Bound and
free a2Mm were separated on a sucrose gradient, and the
cpm of 125-I a2Mm associated with the Sephacryl pellet
counted. The presence of 10|ig of the protein resulted in the
binding of -28.3% of the available 125-I a2Mm this occuring
on the steepest part of the curve; thus subsequent assays
were carried out with this amount of protein (ie 10(ig)
present. All conditions were tested in triplicate, and the
assay carried out twice. Values are mean +/- the standax*d
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Figure 3.5.5: Radioimmunoassay for the binding of 125-I
IL2 with a2Mm
a2Mm (lOpg) and 125-I IL2 (variable amounts) were incubated
for 2 hours at 37°C in pre-blocked RT30 tubes (1% BSA +
0.02% Tween 20) followed by an overnight incubation at 4°C
with rabbit anti-human antibody. Subsequently, donkey anti-
rabbit IgG bound to Sephacryl S1000 (lOOpl) was added and
the tubes shaken for 1 hour at room temperture (1000+/-
lOOrpm). Material bound to the Sephacryl was then
separated from the unbound by sedimentation through a
sucrose gradient. The presence of radioactivity in the pellet
formed was assessed and from this the quantities of bound
and free 125-IIL2. A strong positive correlation (r2=0.984) was
detected for the binding as studied; a of 2.1pM was
calculated for the interaction as presented above.
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Figure 3.5.6: Radioimmunoassay for the binding of 125-I TNFa
with a2Mm.
a2Mm (10pg) and 125-I TNFa (various amounts) were incubated for 2
hours at 37°C prior to an overnight incubation at 4"C with rabbit
anti-human a2M antibody (1/100 dilution, lOOpl Sigma). Donkey
anti-rabbit IgG bound to Sephacryl (lOOpl) was applied followed by
shaking for 1 hour (1000rpm+/-100). Material bound to the
Sephacryl was separated from the unbound using a sucrose
gradient and the radioactivity in the pellet counted to determine the
amount of bound and free 125-I TNFa. A strong positive correlation
was found in the amounts of cytokine binding to the amount
available (eg, r2=0.964 for the case illustrated). The Kj value for
this example was 0.96pM.
bound against the amount that remained free (Figs.3.5.5 and 3.5.6). The
calculations are described in Appendix C2. It is apparent that ^-I TNFa
binds a2Mm with a Kd approximately half that of m-l IL2 (ie lxl06M
compared to 2xlO"6M) indicating that the interaction with TNFa is the
stronger of the two.
In the ^-I TNF a study, the influence of the primary, secondary, or a non-
related antibody on the binding levels observed were also investigated. It
appeared that they had little effect on binding levels (Fig.3.5.7). For
example, the bound/free value for these interactions was less than 0.1
whereas under normal assay conditions with a2Mm, rabbit anti-human
a2M antibody and secondary antibody being present the value was greater
than 0.2. However, in the absence of a2Mm the amount of ^-I TNFa
carried through to the final count was large.
3.5.7: Specificity studies
In competitive binding studies, the presence of unlabelled IL2 did not
significantly affect the interaction of the labelled cytokine with a2Mm until
the unlabelled ligand was present at a 1000 fold excess (Fig.3.5.8). This
implies that the labelled ligand was binding to a2Mm by a different
mechanism to the cold IL2. In contrast, cold TNFa was more effective at
blocking the binding of labelled TNFa with a2Mm. Thus, in one instance, a
significant decrease was seen with a 1:1 ratio of hot:cold cytokine, but in
general the binding was blocked by at least 50% when a 1:100 ratio of































































Figure 3.5.8: Competitive binding studies of IL2-a2Mm
interactions
Radiolabeled (lOOng) and unlabelled (range of amounts) of IL2
were mixed together in blocked RT30 tubes and incubated with
a2Mm (lOfig) for 2 hours at 37°C prior to the application of lOOpl
of rabbit anti-human a2Mm (1/100 dilution, Sigma). Following
an overnight incubation at 4°C, lOOpl of donkey anti-rabbit IgG
bound to Sephacryl S1000 was added and the tubes incubated
for 1 hour at room temperature with shaking (1000rpm+/-100).
Material bound by the Sephacryl was separated from the free on
a sucrose gradient and the radioactivity in the pellet assessed.
The amount of 12R-I present was read as the quantity of labelled





Figure 3.5.9: A study of the specificity of the binding of labelled
TNFa with a2Mm
125.1 TNFa was mixed with the unlabelled cytokine (range of amounts)
prior to incubation with a2Mm (10|ig) for 2 hours at 37°C. Rabbit anti-
human a2Mm (lOOpl, 1/100 dilution, Sigma) was applied followed by an
overnight incubation at 4°C. Then, donkey anti-rabbit IgG bound to
Sephacryl S-1000 was applied and the tubes were shaken (1 hour, room
temperature). Material bound to Sephacryl was then separated from
the free on a sucrose gradient and the cpm in the resultant pellet
counted.
3.6: Quantitative studies of the binding of cytokines by a2M
using zinc affinity chromatography on Sepharose
3.6.1: Adaptation of the zinc chromatography method
Affinity chromatography using zinc chelated Sepharose is the classical
method employed for the separation of a2M from blood (Kurecki et al 1979;
see Sec.2.1.1). In order to establish a quantitative technique for assaying
cytokine-a2M interactions, the essential methodology of zinc based
separation was exploited: the column system was adapted to enable
analysis of 20-40 samples in 1.5ml Eppendorf tubes.
3.6.2: Assay development
To determine if this technique would be feasible for the investigation of
a2M-cytokine binding, an initial study with IL2 was carried out: a2Mm
(0.276M), BSA (2.98M), or PBS were incubated as normal with IL2
(~1.4xl05cpm; see Sec.2.2.1). The reactants were then applied to
prepared zinc chelated Sepharose for 1 hour, after which the Sepharose
was washed three times in the presence of phosphate buffer pH6.5 and
then three times in acetate buffer pH4.5. The supernatant recovered with
each wash was decanted and counted for the presence of radiolabel. More
radiolabelled IL2 was found in the acetate wash in the presence of a2Mm
than with BSA or PBS (Fig.3.6.1). 24.4% of total recovered counts co-
eluted with a2Mm, 3.3% with BSA, and 2.4% with PBS. In addition, it is
apparent that two washes are necessary and sufficient for the removal of
material from the gel: eg, with the phosphate buffer, one wash eluted
13.6% of the cytokine, a second wash increased the quantity of eluted
material by 5% to 18.6%. The reading taken after a third wash with the
phosphate buffer indicates a slightly lower recovery (17.2%) which would
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Figure 3.6.1: Establishing a protocol for quantitative
analysis using zinc affinity chromatography
a2Mm (0.276 nmoles), BSA (2.98 nmoles), or an equivalent
volume of PBS were incubated with 125-I IL2 (138072cpm) for 2
hours at 37°C. Samples were then applied to prepared zinc
chelated Sepharose with mixing for 1 hour in 1.5ml Eppendorf
tubes. Tubes were then spun (200g, lOmins), the supernatant
decanted and phosphate buffer pH6.5 applied with mixing for 1
hour. The tubes were centrifuged as before, the supernatant
decanted and counted (PI). Washing was repeated twice, the
supernatants being counted together (P2 and P3). This elution
proceedure was carried out with acetate buffer pH4.5 to elute
a2Mm ("Ac" fractions). It is apparent that only in the presence
of a2Mm does IL2 elute in the acetate buffer, and that 2 washes
with each buffer are necessary and sufficient for elution of
material.
counter. However, this pattern ofmaximal recovery after two washes was
seen in all instances and therefore subsequent work was conducted with
two washes of the matrix with the phosphate and acetate buffers.
3.6.3: Binding studies
To assess the quantitative binding of a2Mm with IL2 and with TNFa,
incubations were carried out as normal with 276pmoles of a2Mm and
increasing amounts of cytokine. Figs.3.6.2 and 3.6.3 are representative of
the results from these studies. As had been done with the data from the
RIA, the gradient of the best fit line was calculated for each set of results
and, knowing the concentration of a2Mm available, the Kd value was
calculated (see Appendix C). For IL2 the was found to be 3xlO_5M, and
for TNFa 2xlO"5M.
3.6.4: Specificity studies
It was also of interest to investigate if cold cytokine could block the binding
of 125T IL2 and 125T TNFa by a2Mm. There was a decrease in binding seen
with IL2 and in one of the TNFa studies (Figs.3.6.4 and 3.6.5). It is evident
that blocking was not possible with either cytokine.
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Figure 3.6.2: The interaction of 125-I IL2 with a2Mm
assessed by zinc affinity chromatography
a2Mm (276 pmoles) was incubated with 125-I IL2 (rangel3.2-
344.9fmoles) for 2 hours at 37°C and then applied to prepared
zinc chelated Sepharose in 1.5ml Eppendorf tubes with mixing
for 1 hour at room temperture. Tubes were spun (200g, 10
minutes) and the supernatant discarded. The matrix in each
tube was washed twice with phosphate buffer pH6.5 and then
twice with acetate buffer pH4.5, each time spinning as before.
The supernatant from each wash was retained and the cpm
counted. From the above plot a value of 3xlO"5M was
calculated for the interaction of 125-I IL2 with a2Mm, with an
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Figure 3.6.3: The interaction of 125-I TNFa with a2Mm as
examined by zinc affinity chromatography
a2Mm (276 pmoles) and TNFa (range76.1-585. lfmoles) were
incubated for 2 hours at 37°C and then applied to prepared
zinc chelated Sepharose with mixing for 1 hour in 1.5ml
Eppendorf tubes. Tubes were centrifuged (200g, lOmins) and
the supernatant discarded. The matrix was washed twice in
phosphate buffer pH6.5 and twice in acetate buffer pH4.5,
centrifuging as before and retaining the supernatants for
counting radioactivity present. From this study a value of
2xlO-5M was calculated for the interaction of a2Mm with 125-I


































Figure 3.6.4: Competition of 125-I IL2 and
unlabelled IL2 for binding by a2Mm
a2Mm (267 pmoles) was incubated with 125-I IL2 (52.8
fmoles) and increasing amounts of unlabelled IL2 (ratio
to 125-I IL2 as indicated) for 2 hours at 37°C. Free and
bound cytokine were separated on zinc chelated
Sepharose in 1.5ml Eppendorf tubes. It is apparent that
the binding of 125-I IL2 cannot be blocked with unlabelled
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Figure 3.6.5: Competition of 125-I TNFa and unlabelled
TNFot for binding with a.2Mm
a2Mm (276 pmoles), 125-I TNFa (70.4 fmoles) and unlabelled
TNFa (ratio as shown) were incubated for 2 hours at 37°C.
Bound and free cytokine was then separated on zinc
chelated Sepharose in Eppendorf tubes. It is apparent that
the presence of cold cytokine did not block the binding of hot
cytokine to a.2Mm. BSA was included as a control protein to
indicate non-specific binding.
3.7; The effect of a2M on cytokine immunoassays
3.7.1: Strategy for cytokine immunoassay studies
The interaction of a2M with a cytokine in biological fluid or in tissue culture
supernatant could alter the detection of the cytokine in immunoassay
systems. In order to investigate this, a2M was preincubated with the
cytokine standards in various commercial immunoassay kits which were
then used in the immunoassay according to the manufacturers
instructions. The cytokine standards were incubated alone and assayed as
controls.
Preincubation of cytokine standards with a2M had three possible effects
on the cytokine standard curves, as reported below.
3.7.2: Effects of a2M and albumin on immunoassays
(i) a2Mm can specifically inhibit certain assays. For example, in the
Amersham IL2 kit, the presence of a2Mm caused a down shift in the
standard curve, the decrease was of the order of 26-40% below that
observed with cytokine standards alone (Fig.3.7.1a). A similar shift in the
presence of a2Mm was also seen with the Amersham IL4, Amersham
TNFa, and Medgenix TNFa systems (Figs.3.7.lb, c, and d). In the
MedgenixTNFa system the reduction of the slope was particularly
pronounced when a2Mm (5mg/ml) was present (Fig.3.7.Id). The presence
of albumin caused less of a downshift in each of the standard curves.
(ii) A general protein effect was observed in a number of the kits examined.
Albumin was tested in conjunction with a2M and a2Mm in all kits. In the
Medgenix IL1(3, IL2, IL6 and IL8 kits the standard curve was shifted in the
presence of all the proteins tested (Figs.3.7.2 a-d). For the first three kits
the shift was upward, and for the Medgenix IL8 kit it was downwards. The
size of the shift appears to be independent of the protein tested. A protein
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Figure 3.7.1 a and b: Cytokine immunoassays specifically affected
by a2Mm
a2Mm ( O ), a2M ( o ), and albumin ( A ), all at 5mg/ml, were incubated
for 2 hours at 37°C with prepared cytokine immunoassay standards prior
to application of the standard to the assay. In addition the standard was
applied alone to act as a control ( □ ). In a number of assays examined, it
was found that a2Mm induced a more pronounced downward shift in the
standard curve compared to a2M and albumin.
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Figure 3.7.1 c and d: Cytokine immunoassays specifically affected
by a2Mm
a2Mm ( O ), a2M ( O ), and albumin ( A all at 5mg/ml, were incubated
for 2 hours at 37°C with prepared cytokine immunoassay standards prior
to application of the standard to the assay. In addition the standard was
applied alone to act as a control ( □ ). In a number of assays examined, it
was found that a2Mm induced a more pronounced downward shift in the
standard curve compared to a2M and albumin.
TNFa pg/ml
t-h oq co Tf 10 co
ILip pg/ml
IL2 IU/ml
Figure 3.7.2 a and b: Commercial cytokine immunoassays
affected by the presence of protein.
a2Mm ( o ), a2M ( O ) and albumin ( A ), all at 5mg/ml, were
preincubated for 2 hours at 37°C with immunoassay kit standards
prior to applying them to the immunoassay. The standards alone
were also applied to act as controls ( □ ). In a number of kits
examined it was found that there was a general protein effect upon
the standard curve as illustrated.
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Figure 3.7.2 c and d: Commercial cytokine immunoassays affected by
the presence of protein
a2Mm ( o ), a2M ( O ) and albumin ( A ), all at 5mg/ml, were preincubated for
2 hours at 37°C with immunoassay kit standards prior to applying them to
the immunoassay. The standards alone were also applied to act as controls
( □ ). In a number of kits examined it was found that there was a general
protein effect upon the standard curve as illustrated.
effect was also seen when the Endogen kit for IFNy was examined (not
shown): the standard curve was moved downwards, the effect being
slightly greater in the presence of albumin.
(iii) No effect on the standard curve was seen in some cases. None of the
proteins tested significantly altered the standard curves in the Amersham
kits for IL6 and for IL8, and in the Medgenix kits for IL4 and for IFNy
(Figs.3.7.3 a- d). This result was also found with the Boehringer-Mannheim
kit for TNFa (not shown).
3.7.3: Effect ofa2M concentration on immunoassays
In addition to testing the effect of proteins on the standard curves, the
effect of a concentration range of a2M was examined. Figs.3.7.4 a-d
illustrates four examples of assays showing differing responses according
to the concentration of cc2M incubated with the cytokine standard. In the
Amersham IL4, Amersham TNFa, and Medgenix TNFa kits there was a
decrease in the shift of the standard curve seen in the presence of a2Mm
at lmg/ml as compared to at 5mg/ml (Figs.3.7.4a-c). These three systems
had shown specific responses to a2Mm (Fig.3.7.lb, c and d). In the
Medgenix IL2 system, it was found that the curve shifted upwards more in
the presence of a2Mm at lmg/ml than at 5mg/ml. Intermediate
concentrations ofprotein showed a concentration dependent response.
3.7.4: Standard deviation in assay results
It is apparent from Table 3.7.1 that the standard deviation for most
assays was low. In some cases, there was a shift from the overall trend for
that assay at low concentrations of cytokine causing a greater standard
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Figure 3.7.3a and b: Commercial immunoassays not affected
by the presence of protein
a2Mm ( O ), a2M ( o ), and albumin ( A ) (all 5mg/ml) were
incubated for 2 hours at 37°C with immunoassay kit standards prior
to applying them to the immunoassay. The standards alone were
also applied to act as controls ( □ ). In a number of the kits
examined it was found that none of the proteins had an effect upon
the slope of the standard curve.
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Figure 3.7.3c and d: Commercial immunoassays not
affected by the presence of protein
a2Mm ( O ), a2M ( O ), and albumin ( a ) (all 5mg/ml) were
incubated for 2 hours at 37°C with immunoassay kit standards
prior to applying them to the immunoassay. The standards alone
were also applied to act as controls ( □). In a number of the kits
examined it was found that none of the proteins had an effect
upon the slope of the standard curve.
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Figure 3.7.4 a and b: The affect of increasing a2Mm
concentration on immunoassay standard curves
a2Mm at 5mg/ml ( O ) and at lmg/ml ( ° ) were preincubated with
cytokine immunoassay standards for 2 hours at 37°C prior to applying
them to the assay. Cytokine standards alone were used as controls ( n ).
Note that the inhibitory effects increase with increasing a2Mm
concentration in 3.7.4a and b, and in 4c overleaf.
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Figure 3.7.4 c and d: The affect of increasing cx2Mm
concentration on immunoassay standard curves
a2Mm at 5mg/ml ( O ) and at lmg/ml ( O ) were preincubated with
cytokine immunoassay standards for 2 hours at 37°C prior to applying
them to the assay. Cytokine standards alone were used as controls ( □ ).
Note that the inhibitory effects increase with increasing a2Mm
concentration in Figure 3.7.4c, and in Figures 3.7.4a and b overleaf.
Kit No.repeats
of assay
Effect Effect of Protein on OD Reading
a2Mm 5mg/ml Albumin 5mg/ml
Amersham IL2 10 a2Mm -35.6 (+/-16.7) -14.25 (+/-6.0)
Amersham IL4 2 a2Mm -29.5 (+/-6.4) -9 C+/-2.8)
Amersham TNFa 3 a2Mm -18 (+/-12.3) -5 (+/-21.3)
Medgenix TNFa 1 a2Mm -74.4 (+/-16.6) -3.6 (+/-7.3)
Medgenix IL2 3 Protein +12.4 (+/-14.6) +41.25 (+/-11.1)
Medgenix IL6 1 Protein +39.5 (+/-13.5) +37.7 (+/-19.1)
Medgenix ILlp 2 Protein +38 (+/-8.2) +49.25 (+/-12.9)
Medgenix IL8 1 Protein +18.75 (+/-29.4) +0.3 (+/-18.1)
Endogen IFNy 1 Protein -19.8 (+/-15.1) -17.75 (+/-10.7)
Amersham IL6 4 None +0.5 (+/-17.7) -51 (+/-S.2)
Amersham IL8 1 None + 18.5 (+/-19.6) -3.4 (+/-5.4)
Medgenix IL4 1 None +8.8 (+/-26.6) +8.8 (+/-26.6)
Medgenix IFNy 2 None + 10.6 (+/-6.0) +5.4 (+/-6.2)
BQehringer-
Mannheim TNFa
1 None -6.9 (+/-8.3) -5 (+/-14.2)
Table 3.7.1: Study of the effect of a2Mm and
albumin on the standard curve in commercial
cytokine immunoassays
a2Mm and albumin (5mg/ml) were incubated with
cytokine immunoassay standards for 2 hours at 37°C
prior to their application to the immunoassay. It was
apparent that the cytokine standard curve was in some
instances shifted due to the presence of the a2Mm, or
that the shift was due to a general protein effect. The
number of times an assay was repeated is also indicated.
Calculation of the mean deviations is indicated in
Appendix C3.
3.7.5: Reproducibility of results
Due to financial constraints, not all assays could be tested several times to
ensure that on an interassay basis reproducible results were obtained.
However, for those that were, the data obtained in independent tests with
different batches of protein were consistent. Table 3.7.2 illustrates this for
the Amersham IL2 assay: it is apparent that a2Mm consistently inhibited
the standard curve by 26-40%.
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IL2 standard
Percentage inhibition of standard curve
(pg/ml)
Kit 1 Kit 2 Kit 3 Kit 4
62 30.0 40.1 37.0 42.6
125 32.0 38.7 38.7 30.9
250 34.5 40.9 42.2 34.8
500 32.2 32.2 35.2 31.2
1000 30.5 37.8 34.7 26.4
Table 3.7.2: Percentage inhibition obsei'ved in
Amersham IL2 assays
The percentage inhibition observed when a2Mm was applied
to a range of cytokine standards in 4 identical Amersham
IL2 ELISA kits. a2Mm (5mg/ml) was incubated with
Standards from the kits for 2 hours at 37°C prior to
application to the kit system. It is evident that the decrease
in the standard curve was consistent at various
concentrations of IL2 and between kits.
3.8: Investigations into the bioactivity of IL2 and of TNFa
when bound to a2Mm
3.8.1: Study of the bioactivity of a2Mm-IL2
Complexes of a2Mm-IL2 were prepared by incubation as normal followed
by separation of free and bound IL2 on a G200 Sephadex column (see
Sec.2.2.5). Eluted fractions were tested in a lymphoproliferative assay for
IL2 bioactivity. These studies revealed that IL2 maintained its bioactivity
when bound to a2Mm (Fig.3.8.1). The high molecular weight peak
fractions containing a2Mm-IL2 complexes (Fig.3.8.la) induced higher
lymphoproliferation than did addition of comparable fractions obtained by
separation of IL2 alone (Fig.3.8.1b). It should be noted that a2Mm alone
showed no bioactivity above background levels.
The principal fractions investigated in the bioassay were also analysed for
their IL2 content using an Amersham IL2 immunoassay. Comparison of
Figs.3.8.1 a and b indicates that Fractions 31-48 contain a2M-IL2, and
Fractions 37-48 also contain free IL2. Thus, only Fractions 31-36 appear
to conatin the a2M-IL2 complexes of interest. Fig.3.8.2 indicates that
when using the immunoassay, the levels of complexed IL2 detected in
fractions 31-36 are less than when the bioassay is employed. This
confirms the results from the immunoassay studies showing a2M
interference in the Amersham IL2 immunoassay system (Sec.3.7).
Transformation of the bioactivity data from radioactivity units to pg/ml of
IL2 revealed that the level ofbinding of IL2 by a2Mm was in the range of
362.5 - 2500pg/ml, whereas the range seen in the immunoassay was 50-
2300pg/ml. Conversely, more IL2 was recorded in the bioassay than in
the immunoassay when the lower molecular weight fractions composed of
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Figure 3.8.1: Investigation of the bioactivity of IL2 when associated
with oc2Mm
a.2Mm, IL2 or a mixture of the two was preincubated for 2 hours at 37°C
then passed through a G200 Sephadex column. Eluate was collected as
fractions which were then applied to PBL cells in 96 well plates and grown
for 4 days with a 3H thymidine pulse 18 hours prior to harvesting. Cell cpm
content was assessed in a scintillation counter. Known concentrations of
IL2 were applied in a similar manner to PBL cells to form a standard curve.
It is apparent that when eluate from the a2Mm-IL2 study was applied to
cells there was an increased proliferation seen in the high molecular weight
a2Mm peak (fractions 31-48, panel a) as compared to that observed on G200
gel filtration of IL2 alone. Note also the presence of bioactivity in the free
cytokine containing fractions, especially fractions 79-81, and the absence of
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Fig.3.8.2: Comparison of the concentration of IL2 recorded by
immunoassay and bioassay
a2M-IL2 complexes were formed by incubation at 37°C for 2 hours
prior to separation of unbound cytokine on a G200 column. A
lymphoprolifeative bioassay indicated that IL2 activity was present in
the a2M fractions (31-48) and in the free IL2 fractions (79-96).
Subsequent immunoassay of the fractions indicated that the material
present could be distinguished using the Amersham IL2 immunoassay.
3.8.2: Study of the bioactivity of oc2Mm-TNFa
a2Mm-TNFa complexes were prepared by incubation as normal followed in
this case by separation of bound and free cytokine on a zinc affinity
Sepharose column (see Sec.2.2.5). Free TNFa was eluted by phosphate
buffer pH6.5, and a2Mm with bound TNFa was recovered in acetate buffer
pH4.5. The bioactivity of individual fractions was tested by determining
their cytotoxic activity on the TNFa sensitive cell line L929.
Essentially the fractions recovered in phosphate buffer had TNFa-like
cytotoxicity (ie a2Mm-TNFa and TNFa alone, Figs.3.8.3a and 3.8.3b). In
contrast, those recovered in acetate exhibited comparatively low levels of
cytotoxicity. There was one fraction in the a2Mm alone incubation and
several from the buffer incubation that showed cytotoxicity but this
probably arose due to infection and was not found in those particular
fractions when the bioassay was repeated.
Selected fractions from the a2Mm-TNFa incubation, based upon the
bioassay results (Fig.3.8.3a), were examined for the presence of TNFa by
immunoassay. It was evident that fractions from the phosphate wash
contained a large amount of TNFa, eg in the range 4375-31250pg/ml. The
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Figure 3.8.3: The effect of the interaction of a2Mm with TNFa on the
cytokine's bioactivity
a2Mm (80.1mg) and TNFa (4pg) were preincubated for 2 hours at 37°C and then
passed through a zinc affinity Sephacryl column to separate free cytokine from
that bound to a2Mm. Controls were prepared and run under similar conditions.
Fractions were collected from the column using phosphate pH6.5 to elute TNFa
("P" fractions), or with acetate to elute a2Mm and bound TNFa ("Ac" fractions).
Fractions were applied to prepared L929 cells and their cytotoxicity assessed after
18 hours by use of MTT, levels of cytoxicity being compared to known standards.
Note that the cytotoxicity associated with Ac fractions a2Mm-TNFa is similar to









































Figure 3.8.4: Detection of a2Mm complexed TNFa using an
immunoassay and a bioassay
a2Mm (80.1|ig) and TNFa (4gg) were incubated for 2 hours at
37°C and then separated on a zinc affinity Sepharose column.
TNFa was eluted using phosphate buffer pH6.5 ("P" fractions),
and a2Mm with associated TNFa using acetate buffer pH4.5
("Ac" fractions). Selected fractions were tested for their TNFa
content using an Amersham TNFa immunoassay. All fractions
required dilution to the low range of the kit (l-1000pg/ml). Note
the variation in the detection of TNFa comparing "P" and "Ac"
fractions, and in the two assay systems.
3.9: TCA precipitation studies of radiolabeled cytokines
3.9.1: TCA precipitation studies on cytokine stocks
TCA precipitation studies were conducted on ^-iodine labelled cytokines
on arrival, and subsequently during usage. The aim of these studies was to
establish how much of the label remained attached to intact cytokine.
Degradation of the cytokines may occur during storage due to proteolysis
or radiation induced damage. Such degradation may effect the
interpretation of binding study results.
Table 3.9.1 illustrates the results of studies carried out on a number of
batches of ^-IIL2 and of 125-1 IFNy. The amount of radiolabel that could
be precipitated decreased during the period of storage, implying that the
amount of ^-iodine that was bound to whole cytokine decreased during
that time.
Only one time course TCA precipitation study was carried out with TNF a.
Over a 28 day period the amount of radiolabel that could be precipitated
decreased from 97.7% to 96.5%, a change of 1.2%. This decrease is much
smaller than that seen in the IL2 and IFNy studies suggesting that this
TNFa sample was more stable.
3.9.2: TCA precipitation studies on column radioactivity peaks
On the basis of the above observations, peaks eluted from G200 Sephadex
and zinc affinity Sepharose columns were tested for the precipitation of
the radiolabel therein.
When radiolabeled cytokine alone was applied to G200, radioactivity
eluted in 3 peaks (Fig.3.9.1). Peak 1 eluted in the void volume; it was very
small compared to that seen in the presence of a2M. The second peak of
radioactivity eluted in the region of 20kDa particles, and the third peak

























Table 3.9.1: TCA precipitation studies with batches of 125-I
IL2 and 125-I IFNy
The number of counts associated with intact cytokine were
assessed by precipitation with 20% (v/v) TCA in the presence of
carrier protein on days x and y , at an interval of days (as x-y). The
decrease in the percentage of TCA precipitable counts is recorded
here. Assay of radiolabeled cytokine was repeated at intervals as
indicated ("days between assessments"). It is apparent that during
storage there is a decrease in the amount of radioactivity that can
be precipitated and therefore by implication the amount of 125-
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H ~20kDa eluate
[PI Low molecular weight eluate
Figure 3.9.1: TCA precipitation studies with
cytokine eluted from G200 columns
Cytokines were applied to G200 columns and the eluate
collected. Radioactivity present in peaks from the
column were subjected to TCA precipitation. It was
evident that 125-I in the HMW and 20kDa fractions could
be precipitated but not that in the LMW fractions
suggesting that counts in the latter were due to free
iodine or iodine associated with cytokine degradation
fragments.
eluate indicated that the first two peaks could be precipitated, the third
peak could not.
The peaks from zinc affinity Sepharose columns were analysised by TCA
precipitation. The first phosphate peak and the single acetate peak were
precipitated, the second phosphate peak was not (Fig.3.9.2). In addition,
fractions eluted from zinc affinity columns were passed through G200
Sephadex columns to analyse their size: the first peak from the phosphate
wash was ~20kDa, ie cytokine, and the second phosphate peak was of
molecular weight in the region of peptides or free iodine. The ^-I in the
acetate peak was associated with a substance of a molecular weight in the
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Figure 3.9.2f Study of the precipitation of 125-iodine in
radiolabel peaks from zinc affinity Sepharose columns
a2M and cytokine, incubated at 37°C for 2 hours, were
applied to a zinc chelated Sepharose column and the cytokine
eluted in phosphate buffer pH6.5, the a2M in acetate buffer
pH4.5. There were two peaks of radioactivity in the
phosphate wash. In the first, the counts were precipitated by
20% TCA indicating that they were bound to protein.
Conversely, in the second phosphate peak only a small
proportion of the counts were precipitated indicating that it
contained free 125-iodine or degraded cytokine. The counts in
the acetate peak were almost entirely precipitated with 20%
TCA indicating that they were probably associated with a2M
which is eluted with that buffer.
Section 4:
Discussion
4.1: A summary of the results of a2M-cytokine interactions
The aim of this thesis has been to study the qualitative and quantitative
interaction of cytokines with a2M, and to examine the possible effects of
binding on cytokine bioactivity and immunoassay. Table 4.1.1
summarises the key findings.
4.1.1: Qualitative binding studies
In the initial investigations, binding was examined on a qualitative level
(see Sec.3.3 and 3.4). Column studies revealed binding of 125-I IL2, 125-I
TNFa and 125-I IFNywith native and fast a2M. Binding was greatest with
the fast forms, such as serum derived or methylamine converted a2M.
This was also seen in PAGE studies.
The column work enabled semi-quantitative analysis of the relative
binding of cytokines with a2M. In G200 studies, 125-I IL2 was bound at a
higher level than IFNy. FPLC studies were carried out with 125-IIL2, and
also with 125-I IFNy. The FPLC IL2 data confirmed the binding patterns
observed with the G200 system, ie more cytokine was bound by the fast
forms of a2M. The results from the IFNy column experiments have not
been included: they revealed the heterogeneity of the labelled cytokine and
could not be interpreted to provide binding information. It appeared that
during storage radiolabeled IFNy, and to a lesser extent IL2 and TNFa
were degrading to form labelled peptides, and probably free iodine was also
being released. The heterogeneity of the material is discussed below (see
Sec.4.6, and Sec.3.9).
A "novel" zinc affinity column system was established as an alternative to
the G200 and FPLC columns. It is not entirely a novel system since it
uses the column material and methodology required for separation of a2M
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125-IIL2,125-I TNFa, 125-I IFNy are bound by a2M,
preferably to the fast form
Bonds used are covalent for IL2 and IFNy, TNFa is bound
by non-covalent bonds
125-IIL2 is bound non-specifically by a2Mm with a Kj
of 2xlO-6M
125.1 TNFa is bound specifically by a2Mm with a K^j
of 10-6M
a2Mm can depress or enhance detection of cytokines
in a number of immunoassay systems
a2M, a2Mm and albumin induce a "protein" effect upon
certain cytokine immunoassays
a2Mm-IL2 complex retains IL2-like bioactivity
a2Mm-TNFa complex does not retain TNFa-like bioactivity
Table 4.1.1: Principle observations from this study of
cytokine and a2M interactions
The interactions of a2M with IL2, TNFa and IFNy were examined
at a qualitative and quantitative level using a number of
techniques to reveal binding to a2M, the nature of the bonds
involved, values and specificity. The effect of a2M-cytokine
interactions on detection of cytokine in immunoassays and in
bioassays was also examined.
from plasma or serum (Kurecki et al 1979). The very clean peaks of
cytokine and of a2M eluted by this column make it preferable to the G200
and FPLC systems which tend to retain cytokine giving rise to broad
peaks of radioactivity that were sometimes difficult to interpret (see
Figs.3.3.1-3.3.5). The results obtained with the zinc affinity system
corroborate with those from G200 and FPLC for IL2 with respect to the
levels ofbinding to the various forms of a2M, and distinguish IL2 and TNFa
binding. In zinc affinity columns, more IL2 than TNFa was bound by
a2Mm. This result was subsequently contradicted by the quantitative
assay studies, ie RIA and zinc affinity tube system, and highlights the
problems of such semi-quantitative analysis using columns (see Sec.3.5
and Sec.3.6).
4.1.2: Bonds employed in cQM-cytokine interactions
The bonds used by a2Mm to interact with IL2, TNFa or IFNy were
examined in SDS-PAGE in the presence or absence of mercaptoethanol
(see Sec.3.4.2). TNFa uses non-covalent bonds to interact with a2Mm,
whereas IL2 and IFNy use covalent bonds. It was interesting to see the
unusual pattern of protein and radioactivity revealed in the presence of
mercaptoethanol: it seems that the reductant negates all interactions
between protein and IL2 or TNFa, and that the freed cytokine migrates as
oligomers (see Figs.3.4.4 and 3.4.6). However, IL2 remained bound in the
presence ofSDS alone (Fig.3.4.5). Thus, IL2 binds with a2Mm by covalent
bonds. IFNy binding was maintained in the presence ofmercaptoethanol,
ie binding was nondisulphide covalent. However, the appearance of the
bands on the gel were very weak (not illustrated).
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4.1.3: Quantitative binding studies
The zinc affinity column methodology was subsequently adapted to a tube
based assay (see Sec.2.4.3 and Sec.3.6). It was employed, in corroboration
with a novel RIA, to examine the binding of 125-I IL2 and 125-I TNFa by
a2Mm at a quantitative level. Table 4.1.2 summarises the results of these
studies. It was found in both assay systems that TNFa was bound with a
higher than was IL2, although the difference is small. For both
cytokines, the RIA detected higher K^'s by a factor of 10 compared to the
zinc affinity system. The zinc system did not show specific binding for
TNFa, the RIA did. In both assays, binding of ^-I IL2 was found to be
non-specific. The relationship of the Kfj values for binding with a2Mm to
those for the receptors for the cytokines will be discussed in Sec.4.4.
4.1.4: Influence of a2M on cytokine immunoassays
a2Mm, previously shown to bind a number of cytokines, may influence the
immunoassay of certain cytokines (see Sec.1.9, Table 1.9.1, Sec.3.7).
Table 4.1.3 illustrates the effects observed and summarises possible
mechanisms of interference. These are discussed briefly below.
(i) a2Mm effect on immunoassays: In immunoassay kits from a number of
sources it was found that a2Mm can depress the detection of a range of
cytokines by as much as 75% when present at physiological
concentrations, ie l-5mg/ml (see Sec.3.7 Fig.3.7.1). Although levels of fast
form a2M are normally low in vivo, they do increase in some disease states
as described, and they may then influence the immunoassay of cytokines
(see Sec. 1.2, 1.7.2, 1.7.3, and 4.5).





a2Mm (RIA) 2xl06M 10-6M
a2Mm (Zn2+) 3xl05M 2xl05M
cytokine receptor 10-uM 10-ioM
Table 4.1.2: Dissociation constants for the interaction of
IL2 and TNFa with a2Mm and with their receptors
Dissociation constants for the interaction of 125-I IL2 and 125-I
TNFa with a2Mm were calculated by use of novel RIA and zinc
affinity systems. They are compared here with previously
published values for cytokine binding to membrane receptors.
Receptor data from Ringheim et al 1991, Smith et al 1990, and






-Shields cytokine from antibody by binding
in the interior of a2M, or to neoantigens on
its outer surface
-Protein increases stability of cytokine
-Excess protein mops up enzymes protecting
cytokine from degradation
-May have protein-cytokine interaction,
but no interference results
Table 4.1.3: The effects of a2M, a2Mm, and albumin on cytokine
immunoassays
The presence of a2M, a2Mm, and albumin in cytokine immunoassays
resulted in a depression of the detection of cytokine by a2Mm, or a
more general protein effect observed for all three proteins. In some
assays, no change in the detection of cytokine was seen. There are a
number of possible explanations for these effects as proposed here.
protein, ie a2M, a2Mm or albumin resulted in similar changes in cytokine
detection in a number of immunoassays, indicating a general protein effect
(see Sec.3.7, Fig.3.7.2 and Table 3.7.1). Thus, in addition to a2M
influencing cytokine immunoassay due to its role as a cytokine binder,
there is the potential of it acting simply in a protein capacity to stabilise
the cytokine, or it may interfere with the cytokine-antibody interaction.
Interpretation and consequences of the immunoassay results will be
further discussed in Sec.4.5.
4.1.5: The bioactivity of oQMm-cytokine complexes
The influence of cytokine binding to a2M was examined in bioassays for
IL2 and for TNFa. It was found that IL2 bioactivity was maintained,
whereas that of TNFa was negated. Complexes of cytokine and a2Mm
free of unbound cytokine were prepared by G200 Sephadex (IL2) or on zinc
affinity Sepharose (TNFa). These different procedures may have given
rise to the different results. However, the evidence for the binding of IL2
and TNFa by a2Mm presented here would suggest that the cytokines are
bound differently by a2Mm, and it is therefore plausible that their
bioactivity is differently affected. The effects upon cytokine bioactivity
are interesting with respect to the physiological consequences of binding,
and will be discussed further below (see Sec.4.4).
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4.2: Confirmation and extension of a2M-cytokine
investigations
Investigations of the interaction of a2M with molecules of the immune
system has a history dating back to the 1960's and earlier (see Sec. 1.9;
reviewed in James 1990, and in Borth 1992). The work herein serves to
confirm and extend previous studies as illustrated in Table 4.2.1.
4.2.1: Confirmation
The results presented within this thesis confirm the concept of a2M as a
cytokine binder in vitro (reviewed in James 1990, and in Borth 1992). As
found with other cytokines and growth factors, there is a variation in the
binding with native and fast form protein (see Table 1.9.1; Sec. 1.9). In
addition, the investigation of the bonds involved in the binding of cytokines
by a2M has indicated once more that the macromolecule is capable of
using a range of bonds in such interactions. The results presented also
serve to confirm that TNFa can be bound by a2M, with a preference for
the fast form (Wollenberg et al 1991; see Sec. 1.9).
Previous reports in the literature have indicated that an interaction of
cytokine with a2M could result in a loss of the cytokines antigenicity (see
Sec. 1.9; Table 1.9.1). Within this present work, cytokine standards from
immunoassays were incubated with a2M prior to application to the assay
(see Sec.3.7). In some instances a depression in the level of detected
cytokine was observed in the presence of a2Mm. This may have occurred
due to steric hindrance of antibody-cytokine contact upon binding with
a2M confirming the earlier findings concerning antigenicity.
4.2.2: Extension ofprevious findings




Variability of binding according to conformation of a2M
Variability of bonds used for different molecules
Loss of cytokine antigenicity on binding
Extension
First reports ofIL2 and IFNy binding by a2M
Time/temperature studies
Development of quantitative assays and presentation of values
Assessment of the influence of a2M on cytokine immunoassays
Bioassay of isolated a2Mm-cytokine complex
Table 4.2.1: Observations to confirm and extend a2M-
cytokine studies
The present thesis has served to confirm previous reports of a2M as
a cytokine binder. It has also served to extend the field of research
on a number of fronts relating to the nature and effects of the
interactions. These are here presented in brief.
have served to extend this field of research on a number of fronts. TNFa
has previously been examined with respect to its binding by a2M and for
its hepatic clearance from murine circulation (Wollenberg et al 1991; see
Sec. 1.10). There have been accounts of IL2, TNFa and IFNy activity being
influenced by a2M, purporting an indirect influence on cytokine activity
(Borth and Teodorescu 1986; Scuderi et al 1989; Roche et al 1990; see
Sec. 1.9 and 1.10). Herein however is the first report of IL2 and IFNy
binding by a2M. In addition, these studies extend knowledge of a2M-TNFa
interactions, specifically with respect to quantitative analysis of binding
and the bioactivity of the complexes.
It is surprising to note that there have been few reports of the influence of
time or temperature on a2M-cytokine interactions (Borth et al 1990a).
The length of incubations reported vary from 1.5 to 24 hours, and
temperatures employed from 4-37°C (LaMarre et al 1991; Teodorescu et
al 1991; Bonner et al 1992). Herein, time and temperature studies were
carried out for 125-I IL2 and 125-I IFNy binding to a2Mm, in each case
revealing 37 °C as the optimal temperature, and 2 hours as necessary and
sufficient for effective interactions to occur (see Sec.3.2). Many previous
a2M studies have used these conditions which suggests that other groups
may have examined the influence of time and temperature on the
interaction of cytokines and a2M, but not reported their findings in the
literature.
The development of 2 assay systems to determine values has produced
the first fully quantitative study of cytokine-a2M interactions. The RIA
and zinc affinity studies were developed to provide a means of rapidly
producing sufficient data for quantitative analysis of binding. A recent
study in the literature has examined binding affinities for the interaction of
a2M with a number of cytokines (Crookston et al 1994). Radioactivity
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levels were counted in protein bands from PAGE gels of incubated a2M-
cytokine samples. The binding affinity of the a2M-TNFa interaction, with
a K(j of 7.5x10-7M, is in the range of that calculated with the RIA system,
ie HHM (see Sec.4.1; Table 4.1.1). The RIA and zinc affinity systems
utilize properties unique to a2M to achieve separation of free and bound
cytokine. Therefore these assays may be employed for subsequent
examination of labelled molecules, cytokine or otherwise, to a2M.
Reports in the literature have indicated that binding of cytokines by a2M
can decrease their antigenicity. Herein the first full scale study of the
consequences of the a2M-cytokine interactions on the immunoassay have
been presented. They are discussed in Section 4.5.
The influence ofbinding to a2M on the bioactivity of cytokines has been
investigated prior to this study (see Sec. 1.9; Table 1.9.1). However, many
of the reports did not employ a2M-cytokine complexes separated from
unbound cytokine. Therefore, where reports have been made relating a
maintenance of bioactivity, it may be due to unbound cytokine that would
simultaneously have been applied to the cells. Thus, in this study
cytokine-a2M complexes were incubated as normal, then separated from
unbound material by a column procedure. The column eluate consisting of
a2M-cytokine complexes alone was then tested in the appropriate
bioassay. This result for TNFa is at odds with reports in the literture
(Wollenberg et al 1991; James et al 1992; see Sec. 1.9, 3.8, and 4.3). The
application of bound only cytokine to the L929 cells in the present study




4.3.1: The bioactivity ofTNFabound to a2Mm
There is one principle point of controversy raised by the results presented
herein, namely the in vitro bioactivity ofTNFa bound to a2M. As indicated
above, a study on the bioactivity of TNFa has previously been made
(Wollenberg et al 1991). TNFa activity was reported to be maintained
when the cytokine was bound to a2M. However, a2M-TNFa freed from
unbound cytokine was not used, with the consequence that the bioactivity
detected cannot be unequivocally attributed to a2M-TNFa complex since it
may have arisen from unbound TNFa which would have been present. The
results presented here have shown that the complexes did not have TNF a-
like cytotoxicity, even though the cytokine was present as subsequently
detected by immunoassay (See Sec.3.8).
4.3.2: Examination ofbinding affinities
There are many reports of cytokine-a2M interactions. However,
qualitative techniques have previously been employed (Huang et al 1984;
O'Connor-McCourt and Wakefield 1987; Dennis et al 1989; Borth and
Luger 1989; see Sec. 1.9.1). Nevertheless, many investigators have
assumed a physiological role for such interactions. The use herein of a RIA
and a zinc affinity tube system to examine binding at a quantitative level
permits discussion of the physiological relevance of interactions observed
in vitro. These will be addressed below (see Sec.4.4). It is suggested that
other cytokines may also be investigated by these methods.
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4.3.3: Evidence for the instability ofradiolabeled cytokine
There is evidence that radiolabeled cytokines degrade during storage (Sec.3.9).
This is revealed by TCA precipitation of the original labelled cytokine
preparations, and by G200 Sephadex studies where TCA analysis of the eluted
radioactive peaks revealed that there were three peaks, namely: a high
molecular weight peak greater than 200kDa and a 20kDa peak both of which
could be precipitated by TCA, and a low molecular weight peak that was
principally composed ofmaterial that could not be TCA precipitated.
These results were observed with all three cytokines examined (Fig.3.9.1) and
have generally been assumed by ourselves and others to represent the
precipitation of intact cytokine, either bound to a2M as in the high molecular
weight peak or free cytokine itself. However, on the basis of the studies
presented it cannot be excluded that some of the counts associated with a2M
might be attributable to bound degraded products. The existence of such low
molecular weight products is not only evident from the gel filtration studies
referred to above but has also been confirmed by chromatography and PAGE
studies (Sec.3.9, 3.3 and 3.4). Possible variations in the amounts and
composition of cytokine degradation products in labelled cytokine preparations
may have clouded interpretation of the PAGE and blocking studies reported in
this thesis.
4.3.4: Non-alignment ofprotein and radioactivity bands on SDS-PAGE in the
presence ofmercaptoethanol
It was found that in the presence of mercaptoethanol, the binding of
radiolabeled cytokine by a2M was negated (Figs.3.4.4 a and b, and Figs.3.4.6
a and b). Nevertheless, bands of radioactivity did appear in the 200-250kDa
region of the autoradiographs (Figs.3.4.4 b and 3.4.6b). One reason for the
appearance of these bands may be the binding of radiolabeled cytokine to
proteins of the 200-250kDa mass, present in the cytokine or a2M preparations,
that were not detected by Coomassie blue staining. The introduction of silver
staining or an alternative sensitive technique into the gel protocol may reveal
the presence of such bands. Such proteins have been reported in the literature
as naturally occurring cytokine binding proteins including soluble receptors and
autoantibodies; these could be present in low concentrations in the materials
used and therefore interfere with the assay. However, it should be stated that to
date we have no other evidence for these proteins. Alternatively, aggregation
of the radiolabelled cytokine, or its degradation products may have occurred
leading to the detection of higher molecular weight bands not associated with
o.2M or its reduction products.
4.3.5: The absence ofblocking by cold cytokine of the binding of radiolabelled
cytokine by a2M
In the quantitative zinc binding studies, it was not possible to block the binding
of radiolabelled cytokine by a2M using autologous cold cytokine (Figs.3.6.4
and 3.6.5). However, using the RIA system there was some evidence of
blocking of l2:>-I TNFa binding in the presence of the cold cytokine, which
decreased to 50% in the absence of the cold protein. These results seem to
suggest that there may be two binding sites on a2M for TNFa both of which
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can bind -I TNFa, while only one binds cold TNFa. This may suggest that
125
-I TNFa can bind to a2M via the iodine atom, or by some conformational
structure resulting from the iodination process itself. Cold IL2 did not block
the binding of I25-IIL2 in either system (Figs.3.5.8 and 3.6.4).
These results have significant consequences with respect to the binding of the
radiolabelled proteins and interpretation of such results. As noted above for
TNFa, on the basis of these studies, it is feasible to speculate that the binding
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of -I cytokine may rely upon iodine interacting with the protein, possibly in a
non-specific manner. Furthermore, the identification of breakdown products in
radiolabelled cytokine preparations, as noted previously, may imply that
radiolabeled cytokine fragments, rather than the whole protein are bound. It is
interesting to compare these studies, which employ cold cytokine up to 100 fold
excess over labelled cytokine, to those in the literature where up to 105 excess
of cold cytokine was used to block the binding of the radiolabelled protein
which authors subsequently claimed demonstrated specific binding (Borth and
Luger 1989; Huang et al 1984). Obviously further studies in the area are
warranted.
4.4: Physiological relevance of a2M-cytokine interactions
4.4.1: Binding affinity of a2M-cytokine interactions
The calculation of binding affinities is a relatively novel concept in a2M-
cytokine studies. Previous reports have simply looked for binding, and a
number of papers do not even go so far as to differentiate the form of a2M
bound (Remold and Rosenberg 1975; O'Connor-McCourt and Wakefield
1987; Koo and Stach 1989; see Sec.1.9 Table 1.9.1). As discussed above,
there has been one recent publication that has attempted to address this
problem (Crookston et al 1994; see Sec.4.2.2).
Within the literature on a2M-cytokine interactions, many authors have
discussed the physiological relevance of the binding they detected.
However, their qualitative analysis has used arbitrary concentrations of
protein and cytokine, that may have no physiological equivalent. Herein,
quantitative studies have been presented on the binding of cytokine by
fast form a2M as detected by RIA or zinc affinity tube assays, and these
may be compared to values established for cytokines and their known
cell surface receptors, as illustrated in Table 4.1.2. From Table 4.1.2, it is
apparent that the dissociation constant for binding of IL2 or TNFa to a2M
is much less than that of the receptors for IL2 and TNFa. The disparity in
the values implies that under normal circumstances a2M will not
compete with the membrane receptor for binding. However, in disease
states competition may result as receptor levels fall and the fast form
a2M concentration rises.
The occurrence of a2M-cytokine interactions in vivo and the fate of the
complexes is illustrated in Fig.4.4.1, and is discussed below.
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Figure4.4.1:Schemeofinteractionsfa2Mwithproteina esndyt kin «2Minteractswithp oteina esfo ma2M-proteinaseco l xes.Ibi dcyt kin sn t vea2Md2M- proteinase,de endingothcytokine.Theinteract o sw thcytokinescabin ibit dys luble(S )rm mbraneb u (M.)receptors,orbytherproteinscapablefindingcytoki e .T a2M( a2M-proteinase)c mpl xedcyt k eyb activeorlatent.Intheproteinasef rm,c mpl x sanbl ar dythu2Mr ceptor,raintainedi t veo inactivestate.
4.4.2: a2M-cytokine interactions in vivo
As shown herein, IL2 and TNFa bind in vitro to a2M, principally to the
proteinase or methylamine converted fast form of the protein (see Sec.3.3
and 3.5). In vivo, such interactions could result in clearance of the
cytokine via a2M receptors. However, the highest concentrations of a2M-
proteinase are recorded in disease states such as in the rheumatoid joint
where the clearance system for fast form a2M is overloaded (Abbink et al
1991; see Sec. 1.2.6). Therefore, under such circumstances if cytokines are
bound by a2M-proteinase their bioactivity and bioavailability would be
affected. This would be expressed as an increase in the half life of the
cytokine if bound to native a2M, or to fast form if clearance was restricted.
The cytokine may or may not still be active (see Sec. 1.9 Table 1.9.1). If
clearance of fast form a2M was not restricted the result would be a
decrease in the half life of the cytokine. The evidence presented here
suggests that such binding would result in a loss of TNFa activity, whereas
IL2 would remain active (see Sec.3.8). Such binding may explain reports
of a2M as an immunomodulator in that it may direct its effects through
the cytokines (see Sec.1.8).
In vivo the effects may be different than those observed in vitro. For
example, although a2M-IL2 has been demonstrated to have PBL
proliferative activity in vitro, binding in vivo to the fast form of a2M may
result in clearance. This would result in inhibition of T cell activation.
Furthermore, it has previously been noted that a2M-trypsin can inhibit
IL2 activity due to the retention of activity by the bound enzyme (Borth
and Teodorescu 1986). This highlights that the present findings are for in
vitro circumstances, and in vivo there are additional effects that may be of
importance. Thus, maintenance or negation of bioactivity when bound by
a2M may occur for IL2, TNFa or other cytokines in vivo. As previously
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argued, in a number of disease states such a2M-cytokine interactions
may assume a physiological significance, for example in rheumatoid
arthritis, in adult respiratory distress syndrome, or in venous ulceration
(Abbink et al 1991; Wewers et al 1988; Falanga and Eaglstein 1993; see
Sec.1.2).
4.4.3: a2M's role in relation to cytokine receptors
As previously noted, a2M is the "backup" inhibitor of plasmin assuming a
more significant role when levels of plasmin's primary inhibitor,
antiplasmin drop (see Sec.1.2.8; Harpel 1977; Burtin et al 1987). a2M is
the back-up inhibitor for other proteinase inhibitors. Its activity is
primarily due to its availability, and to the broad spectrum of proteinases
bound by it. Thus, as inhibitor supplies become exhausted a2M takes over.
In a similar fashion to the inhibitor scenario, a2M may have the
opportunity to bind cytokine if the receptor levels are low, or if cytokine
levels are especially high as may occur in disease states. Binding of
cytokines could result in inhibition of contact between the cytokine and its
receptor, and of cytokine clearance via the local or hepatic a2M receptor.
Alternatively, binding may enhance cytokine presentation to the receptor.
In addition, a2M may be in competition or collaboration with soluble
receptors. Indeed, a2M may be one of a range of proteins present in vivo
that have a capacity to retain cytokines, and inhibit or promote their
activities.
Such a role has been proposed for a2M, fibrin and other macromolecules in
venous ulceration (Falanga and Eaglstein 1993; see Sec.1.2.9). The
concept of a2M as a cytokine binder may be considered in terms of its
effects upon the sequence of growth factor availability. As noted before,
Falanga and Eaglstein proposed that in venous ulceration a2M and other
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macromolecules "leak" into the dermis due to hypertension, therein binding
TNFa and TGF(3, and inhibiting their activity (see Sec.1.2.9). They
proposed that alterations of cytokine levels at certain points in the repair
mechanism could occur. Thus, in venous ulceration and under other
circumstances involving cytokine responses it would not be necessary to
clear all of a particular cytokine but by altering its half-life or
bioavailability the function of the cytokine could be dysregulated.
Further evidence for a2M and general protein interference with cytokines
is presented in the immunoassay studies herein (see Sec.3.7, Sec.4.1.4,
and Sec.4.5).
4.4.4: Cytokine-a2M bonds
The binding sites for IL2 and for TNFa on a2M are unclear, as will be
discussed in Sec.4.5. TNFa binds with noncovalent bonds which may be
hydrophobic or ionic in nature. The covalent bonds that IL2 interacts with
may be through the -SH group of the cleaved thiol ester, or they could be
through a histidine residue, ie similar to IL1 (3 (Teodorsecu et al 1991; see
Sec.1.9).
For both cytokines, "in situ" binding in the presence of converter, ie
proteinase or primary amine, would be an interesting study, and may
reveal more data that will be of physiological relevance. Recent reports
have examined the nascent state of a2M that forms upon activation with
proteinases or small nucleophiles (Chu et al 1991; Chu and Pizzo 1993; see
Sec. 1.9). As discussed earlier, nucleophiles can bind the cleaved glutamyl
residue of the thiol ester bond in the nascent state. Cysteinyl residues are
also available after cleavage and could be bound by a wide range of
proteins. Thus, incubation of cytokine "in situ" with a2M during
conformational change may reveal a higher level of binding that reflects
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the in vivo activity of a2M towards cytokines. Nevertheless, it is possible
that small cytokines may gain access to the closed trap: IL2 is active as a
15.5kDa protein and at that size may be able to enter the sprang "trap"
and bind with free cysteinyl residues.
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4.5: Implications of the immunoassay study
Investigation of the effects of a2M on the detection of cytokines by
immunoassay was a logical extension of reports in the literature relating
loss of cytokine antigenicity upon a2M binding (see Sec.1.9 Tablel.9.1). As
illustrated in Table 4.1.3, there were principally three effects observed
when a2M, a2Mm or albumin were incubated with cytokine standards and
applied to immunoassays as discussed below (see also Sec.3.7).
4.5.1: The a2Mm effect
In the presence of a2Mm cytokine detection was depressed in a number of
assays (see Sec.3.7, Fig.3.7.1 and Table 3.7.1). This effect, as was noted for
the Amersham IL2 system, was found to be reproducible at intra and
interassay levels (see Sec.3.7, Table 3.7.2). The decreased detection may
have been due to binding of cytokine to the interior of a2Mm. This is
feasible for small cytokines: when a2M is conformationally altered
molecules in the region of 20kDa or less can still gain access to the cylinder
interior (Travis and Salvesen 1983; Chu and Pizzo 1993; see Sec.1.7.5).
Alternatively, cytokines may bind to a "pocket" on the outer surface of the
cylinder within which they are partially or completely shielded from
antibodies. This concept of an exterior binding site/sites is backed up by
the finding that IL4 and TNFa detection were depressed in some assay
systems but in others no effect upon detection was found (see Sec.3.7,
Table 3.7.1). Detection of IL2 was depressed in the presence of a2Mm in
the Amersham assay, but in the Medgenix system detection was
enhanced. By partial shielding of the cytokines in an external pocket on
a2Mm the epitopes required for some antibodies may be exposed even
after binding, whereas those of others are not. However, it is also known
that the Fab fragment can contact molecules enclosed within
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conformationally altered a2M close to the trap "mouth" (Gonias et al 1988;
Delain et al 1992). Thus, an interaction with a2Mm may be inferred from
an observed change in cytokine detection, but it is difficult to predict from
these results the location of the binding sites.
In addition, it is apparent that native a2M does not alter cytokine
detection as much as a2Mm in the illustrated assays (see Sec.3.7,
Fig.3.7.1). During the conformational change of the native protein
neoantigens are revealed (Barrett and Starkey 1973). Therefore, it could
be proposed that neoantigens present after a2M converts to the fast form
bind cytokines and affects their detection.
4.5.2: Protein effect on cytokine detection
Native and fast form a2M, and albumin were found to influence the
detection of cytokine in some assays (see Sec.3.7, Table 3.7.1 and
Fig.3.7.2). The increased concentration of cytokine detected in some
assays may be due to a better presentation of cytokine to antibodies. This
is understandable for a2M/a2Mm in their capacity as cytokine binders.
The presence of protein, be it a2M, a2Mm or albumin, could increase the
stability of the cytokine being assayed. This would result in detection of a
larger portion of the cytokine present, ie not only that part stable under
normal assay conditions. In addition, excess protein could serve as
substrate which would mop up proteolytic enzymes which could otherwise
digest the cytokine.
4.5.3: No observed effect on cytokine detection
In some immunoassays, no effect by any protein upon the detection of
cytokine was found (see Sec.3.7, Table 3.7.1 and Fig.3.7.3). This does not
rule out an interaction with those cytokines, but it does indicate that if an
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interaction has occurred it does not obstruct cytokine-antibody
interactions, ie that any interaction does not mask the cytokine epitopes
recognised by the antibodies used in the assay.
4.5.4: Conformation of a2M examined in the immunoassays
It was shown within the qualitative studies of this thesis, that IL2, TNFa
and IFNy bind to fast form a2M better than they do to native a2M.
Nevertheless, both conformations were examined in the immunoassay
study: previous reports indicated that some cytokines bind equally well or
better to native a2M (see Sec.1.9, Table 1.9.1). However, in the analysis of
results it is apparent that for the range examined only in the Medgenix IL8
assay did native a2M appear to have a more pronounced effect than the
fast form (see Sec.3.7, Table 3.7.1). It may be that an antigen available in
the native form is required for the interaction of IL8 and a2M, and that it
disappears during the conformational change. There are no reports in the
literature of a2M-IL8 interactions.
4.5.5: Practical consequences of the immunoassay results
The immunoassay data has consequences in the laboratory with respect
to the diagnostic and research appraisals of cytokine levels in biological
fluids, and also in cell culture supernatants which may mimic the in vivo
state. As discussed previously, a2M and a2Mm levels may rise in a
number of diseases, and a range of cells have been identified that
synthesize a2M including lymphocytes, macrophages and fibroblasts (see
Sec. 1.2 and 1.3). In addition, foetal calf serum contains a2M which has
been observed to interfere in some assays (Danielpour and Sporn 1990).
Thus, in practice the cytokine concentration detected by immunoassay
could be altered by a2M or a2Mm at normal or at elevated concentrations.
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The specific effects of a2Mm, and the more general protein influence
observed do raise the question of the reliability of cytokine kits. As
referred to above, soluble receptors of cytokines, and a plethora of other
proteins present in vivo and in vitro bind cytokines and therefore have the
potential to interfere with these assays. Manufacturers do test for cross-
reactivity, but when approached with the present data were reticent to
assume responsibility of problems with their own assays. Medgenix are
attempting to address this problem.
112
4.6: Limitations of these investigations
As with all scientific study, limitations are placed upon the interpretation
of the observations due to the techniques employed, and as a consequence
of the quality and quantity ofmaterials available. The limitations of this
study are discussed below.
4.6.1: Techniques
(i) Column studies: The principle difficulty with the G200 studies was
timescale. Following the normal 2 hour incubation ofprotein and cytokine,
samples were loaded onto a G200 column and the final radioactivity eluted
approximately 20 hours later. Thus, to permit throughput of an increased
number of samples work was carried out on an FPLC system: this reduced
the elution time to 1 hour. However, the recovery from the column of
loaded material was often only 50%. To circumvent the disparity between
applied and recovered counts, calculations relating to all 3 column systems
were based upon total recovered radioactivity (see Appendix C.l).
As indicated above, it was often difficult to distinguish exact boundaries for
peaks of radioactivity eluting from the G200 and FPLC columns (see
Sec.4.1). In this respect the final system that was employed, that is the
zinc affinity column, provided very clean peaks and would be the author's
system of choice for subsequent studies.
(ii) PAGE studies: These provided a guide to binding and indicated the
conformation of preference. However, in some cases the bands of slow and
fast a2M were not sufficiently distinct to determine to which form binding
was occurring (see Sec.3.4). Nevertheless, the column studies did provide
such information, and where available PAGE corroborated the findings of
those systems.
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(iii) RIA/Zinc affinity studies: in establishing the optimal conditions for the
RIA, myosin was employed as a control protein (see Sec.3.5, Fig.3.5.4). In
the presence of myosin with anti-human a2M antibody and solid-phase
bound secondary antibody one would expect a high level of binding of 125-I
a2Mm to the primary antibody and that the primary antibody should bind
to the secondary. It appears that myosin inhibits formation or detection of
one or both of those interactions. This may have been due to a direct
interaction ofmyosin with the primary antibody inhibiting the interaction
with 125-I a2Mm or with the secondary antibody, or due to binding to the
secondary antibody so interfering with the interaction of primary and
secondary antibodies. However, it appears that in the final assay with
cytokine present, and using BSA as a control, such interference does not
occur, thus this problem was peculiar to myosin and does not limit the
interpretation of the final data and calculation ofRevalues.
In addition, the "stickiness" of radioactive material was a constant feature
of all of these studies, and was overcome very effectively in the RIA
system by precoating the tubes with BSA and transferring reactants from
this tube before the final count (see Sec.3.5, Table 3.5.1).
4.6.2: Materials
(i) Sources of a2M and «2Mm: age conversion was noted for a2M stored for
long periods of time, ie for 6 months or more (see Sec.3.1, Fig.3.1.2; Sec.3.3,
Fig.3.3.3d). This phenomenon has been documented previously: the thiol
ester bond undergoes autolytic cleavage resulting in conformational
change of the whole molecule (Barrett et al 1979; see Sec. 1.6.6). In all
quantitative binding studies, the immunoassays and bioassays were
carried out with slow a2M orwith a2Mm prepared from the slow form.
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It was not possible within this study to prepare a2M converted with
proteinases: plasmin was tested, however incubation resulted in
degradation of the a2M molecule (see Sec.3.3, Fig.3.3.2f). a2M-proteinase
and a2Mm are structurally very similar, and it was therefore feasible to
make this substitution (see Sec. 1.6).
(ii) Heterogeneity of radiolabelled cytokine: As discussed above, it was
noted during FPLC studies that 125-I IFNy purchased from Amersham
was very heterogeneous (see Sec.4.1.1). Subsequent examination by TCA
precipitation of 125-I IL2 and 125-I IFNy upon arrival and during storage
indicated that heterogeneity increased during storage (see Sec.3.9, Table
3.9.1). This effect arises because of primary and secondary decomposition
of the labelled molecule (Guide to the self-decomposition of radiochemicals,
Amersham International pic). In addition to TCA precipitation of samples
from cytokine batches, peak fractions of IL2, TNFa, and IFNy from G200
and zinc affinity columns were examined for the precipitation of
radioactivity (see Sec.3.9.2, Figs.3.9.1 and 3.9.2). It was found that 2 out
of 3 peaks of radioactivity eluted from the columns could be precipitated.
Size analysis indicated that one peak was greater than 200kDa, ie in the
range of a2Mm, and the other in the weight range ofwhole free cytokines.
The third peak could not be precipitated: it consisted of low molecular
weight fragments and free ^-iodine. Once this problem was identified,
radiolabelled cytokine was ordered at its production date and used as
rapidly as possible after arrival, ie within a matter of days, in order to
minimise the contamination of the batch with decomposition products.
TNFa was also tested and showed very little degradation.
(iii) Immmunoassavs: Commercial assays for cytokines range in price
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from £300-£400 for a 96 well kit. In most kits, 16 wells are required for the
standard curve. This leaves 80 wells for analysis of samples. Therefore, in
examining the effect of a2M on immunoassay standard curves, consisting
of 4-8 points, there was a distinct limitation as regards the number of
conditions that could be tested and the number of repetitions that could be
made for each one. In addition, though many kits were tested at least
twice, financial restrictions meant that a few were examined once only (see
Sec.3.7, Table 3.7.1).
(iv) Bioassavs: In the IL2 and TNFa bioassay studies, the presence of
cytokine in the a2Mm fractions was measured using the appropriate
Amersham immunoassays (see Sec.3.8, Figs.3.8.2 and 3.8.4). The levels
of IL2 detected in Fractions 37-48 were similar in both the bioassay and
immunoassay. Immunoassay of the a2M-IL2 and of the cytokine alone
fractions detected less IL2 than did the bioassay (Fractions 31-36 and 79-
96 respectively). This implies that the immunoassay does not detect all of
the cytokine that was bioactive. With respect to the a2M-IL2 fractions,
this may be due to the interference of the serum protein on the
immunoassay of the cytokine.
In the assay using L929 cells, the acetate fractions containing a2Mm-
TNFa complex showed slight variations between cytokine levels. However,
in the phosphate wash fractions, where TNFa was present alone, the level
of cytokine recorded by immunoassay was much greater than that in the
bioassay. This result implies that a portion of the TNFa applied was not
bioactive.
4.6.3: Limitations ofObservations
The limitations of techniques and materials discussed above means that,
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as with all scientific study, there are limits as to the interpretation of the
results and conclusions thereof. Corroboration between studies does help,
for example PAGE and a number of column techniques were employed to
investigate binding at a qualitative level, the RIA and zinc affinity tube
assay were used to examine the quantitative nature of binding and its
specificity. All assays were carried out with inter and intra assay
repetition. Thus, by corroboration between techniques, and by repetition




There are seven key areas of study that can be highlighted for future
investigations:
4.7.1: Is binding increased in the nascent state1?
Apart from studies of EGF and insulin, all work with a2M and cytokines
has involved native or fast form protein (see Sec. 1.9, Table 1.9.1). It would
be interesting to see if the binding investigated here or elsewhere is
increased if a2M, cytokine and an "activator", for example proteinase or
methylamine, are present together. In addition, the bonds involved could
be identified, ie do cysteinyl or glutamyl residues interact with the
cytokine?
Furthermore, Chu and Pizzo proposed that a2M may be able to non-
specifically interact with any available nucleophile during the
conformational change (Chu and Pizzo 1993). Their theory could be tested
by competition studies with various cytokines.
4.7.2: What are the Kd values for the binding ofcytokines with a2M?
As noted above, the RIA and the zinc affinity tube assay use a2M, not
cytokine, as their crucial component for separation. Thus, binding affinity
and specificity for the interaction of a2M, be it native, nascent, or fast
form, with other cytokines could be investigated using either system. It
would be especially interesting to investigate PDGF and TGFp both of
which have been reported to associate with a2M in vivo (Crookston et al
1993; see Sec. 1.9). Information from such studies would also permit
further discussion on the physiological relevance of cytokine-a2M
interactions.
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4.7.3: Do bound cytokines retain their bioactivity?
a2M-cytokine complexes previously reported to have altered or maintained
bioactivity in vitro could be reexamined to see if the same result is found
when a2M-cytokine complexes, free of unbound cytokine, are applied to
cells.
The bioactivity studies with IL2 and TNFa could be continued by
examining complexes prepared by the alternative column method to that
presented herein. Results may also be affected if the assay is carried out
in a serum free environment. However, the contribution of a2M from foetal
calf serum in the bioassays herein was in the region of 0.2mg/ml and it is
therefore unlikely to have made a substantial difference to the results.
4.7.4: Do otherproteins influence cytokine immunoassays'?
The immunoassay studies revealed the actions of 2 proteins in cytokine
immunoassays. As discussed above, biological fluids and cell culture
supernatants contain a wide range of molecules that may also influence
cytokine immunoassay (see Sec.4.5). It may be in the researcher's
interest, and in those of the manufacturer, that such matters are
investigated further.
4.7.5: Can oQM-cytokine complexes be identified in disease states?
There is much interest in studies that have indicated hepatic clearance of
cytokines in association with a2M, and the identification of links between
a2M, ILlp and rheumatoid arthritis (LaMarre et al 1991; Borth et al 1990;
Teodorescu et al 1991; see Sec. 1.2, 1.9 and 4.4). However, the majority of
studies concerning a2M-cytokine interactions have been carried out in
vitro. In order to clarify the physiological link it is necessary that a2M-
cytokine complexes formed in vivo be identified. This has been done for
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TNFain plasma (Wollenberg et al 1991; see Sec. 1.9).
4.7.6: Is the interaction reversible?
Under what conditions can the interaction be reversed, eg by decreasing
pH such as in the endocytic vesicle (see Sec. 1.7.4). This could be of
importance with respect to the in vivo significance of a2M-cytokine
interactions.
4.7.7: Does PZP interact with cytokines?
As outlined in Sec. 1.5, humans have other thiol ester plasma proteins
apart from a2M. It may be interesting to study their interaction with
cytokines. This may be especially important for PZP which shares the
tetramer form of a2M and they have definite sequence homology (Sottrup-
Jensen et al 1984). PZP appears in the serum at pregnancy, and may
have a specific role in binding growth factors and cytokines required at
that time (Sand et al 1985).
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4.8: Summary
The present study has confirmed evidence in the literature that a2M is a
cytokine binder. It has extended this field of research on a number of
fronts: prinicipally to investigate such binding at a quantitative level, and
to provide novel information on the effects of a2M on cytokine assays.
There is a growing list of factors that can bind and interfere with cytokine
activity in vivo, which includes soluble cytokine receptor anatgonists and
cytokine auto-antibodies (Klein and Brailly 1995, Bendtzen, Svenson,
Jonsson and Hippe 1990). The findings presented herewith serve to
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A. 1: For general use:




Made up to 1.91itres with distilled water, pH tested as 7.2, then filled to 2
litre level.
A.2: For use in Zinc affinity studies
Stock phosphate buffers
0.2M Na2HP04.12H20 - 71.64g/litre distilled water
0.2M NaH2P04.2H20 - 31.21g/litre distilled water




Check pH, make up to 1 litre with distilled water.
0.1M Phosphate buffer pH6.5 (0.8M NaCl)
155ml 0.2M Na2HP04.12H20
345ml 0.2M NaH2P04.2H20
Check pH, add 46.75g NaCl if required, and make up to 1 litre with distilled
water.
0.1M Acetate buffer nH4,5. 0.8M NaCl
380ml 0.1M sodium acetate (13.61g C2H302Na.3H20/litre water)
620ml 0.1N acetic acid (6.05g/litre distilled water)
Check pH, add 46.75g NaCl.
0.05M EDTA dH7.0. 0.8M NaCl




A3: For use in the preparation ofa2Mm
0.2M Tris stock
24.23g Tris
Made up to 1 litre with distilled water.
0.1N HC1
8.75ml concentrated HC1
Made up to 1 litre with distilled water.
50mM Tris-HCl with 200mM methvlamine
250ml 0.2M Tris
229ml 0.IN HC1
Made up to 900ml with distilled water, adjusted pH to 8.2, added 6.2g
methjdamine, and filled up to 1 litre with distilled water.
A.4: For use in the iodination of oQMm
1M NaoHPQ1.12HoO
358.2g^a2HP04.12H20
Made up to 1 litre with distilled water. Made 0.1M from this by diluting
10ml to 100ml with distilled water.
1M NaH2PQ4.2H2Q
156.05g NaH2P04.2H20
Made up to 1 litre with distilled water. Made 0.1M from this by diluting
10ml to 100ml with distilled water.
0.05M phosphate, pH7.5
42ml 0.1M Na2HP04 (17.799g Na2HP04.2H20 made up to 1 litre)
8ml 0.1M NaH2P04 (15.6g NaH2P04.2H20 made up to 1 litre)
Made up to 90ml, tested pH as 7.5 and filled up to 100ml.




Made up to 190ml with distilled water, adjusted pH and filled to 200ml.
12.5mg cysteine-HCl in 20ml 0.05M phosphate buffer, pH7.5
50mg potassium iodide in 10ml 0.05M phosphate buffer, pH7.5
25mg chloramine T in 10ml 0.25M phosphate buffer, pH7.5
A.5: For use in PAGE studies
Tris-glvcine electrode buffer stock solution, pH8.3
6g Tris
28.8g glycine
Made up to 900ml with distilled water, adjusted pH to 8.3, and filled up to 1





Made up to 90ml with distilled water, adjusted pH to 8.9, added 0.23ml of




Made up to 90ml with distilled water, adjusted pH to 6.7, added 0.46ml of
Temed, and filled up to 100ml.
Resolving acrvlamide stock solution
28g acrylamide
0.74g NN'-methylenebis acrylamide
Made up to 100ml with distilled water. Stored in dark bottle at 4°C for up
to 2 weeks.
Resolving gel at 5%
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5ml Tris-chloride buffer pH8.9
6.6ml resolving gel acrylamide solution
28.4ml deionised water
Mix and degas
300ul ammonium persulphate (10%w/v)
Pour immediately
Stacking gel
2.5ml Tris-chloride buffer pH6.7
3.1ml resolving gel acrylamide
14.1ml deionised water
Mix and degas
300ul ammonium persulphate (10%w/v)
Pour immediately
Sample Buffer
0.1ml l%(v/v) bromophenol blue
10ml glycerol
25ml TRIS stock pH6.7
Mix and fill to 100ml
Use in 1:4 ratio with samples
Fixative
500ml methanol
200ml glacial acetic acid
Made up to 2 litres with distilled water. Used to fix proteins to acrylamide
gels after electrophoresis - required ~500ml per gel - left for 1 hour in a





Made up to 2 litres with distilled water in a glass measuring cylinder. Used
for staining proteins on acrylamide gels after electrophoresis - left for 1





200ml glacial acetic acid
Made up to 2 litres with distilled water. Replaced fluid 3 times each time
incubating the gel for ~2 hours in a sandwich box on a shaking plate -
carried this out at 37°C and in the presence of a small piece of sponge -
these two practices improved the removal of background stain on the gels.
A. 6: For use in SDS-PAGE




Make up to 4.51itres with deionised water, check pH. Fill to 5 litres.
TRIS-SDS stock solution. pH6.8
30.29g TRIS
2g SDS
Make up to 950ml with deionised water, check pH. Fill to 1 litre.
TRIS-SDS stock solution, pH8.8
90.86g TRIS
2g SDS
Make up to 950 ml with deionised water, check pH. Fill to 1 litre.
Resolving gel solution
9.9ml acrylamide solution
30ml TRIS-SDS stock solution, pH8.3
Make up to 60ml with deionised water
Degas
15ul Temed
1.5ml l%(w/v) ammonium persulphate
Mix and pour immediately.
Stacking gel solution
2ml acrylamide solution
10ml TRIS-SDS stock solution pH6.8
Make up to 20ml
Degas
lOul Temed
lml l%(w/v) ammonium persulphate
Mix and pour immediately.
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Sample buffer




0.1ml 1% (v/v) bromophenol blue
Make up to 100ml with deionised water
A. 7: For use in development of the RIA
0.1M Sodium Acetate
13.608g made up to 1 litre.
0.1M Acetic Acid
5.72ml glacial acetic acid made up to 1 litre
0.1M Acetate. pH5.0. with 5mM sodium m-periodate
70ml 0.1M sodium acetate
30ml 0.1M acetic acid
Mixed and tested pH as 5.0. Added 5ml of sodium m-periodate prepared as




Made up to 1.9 litres, tested pH as 4.0, then filled up to 2 litres.
0.1M Sodium Bicarbonate. pH9.0
42g sodium bicarbonate
1.7g sodium hydroxide
Made up to 4.91itres, tested pH as 9.0 and filled up to 5 litres.
0.25M Tris
151.4g ofTris
Made up to 5 litres with distilled water.
A.8: For use in the RIA
Prewash solution
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0.06M PBS pH7.2, 0.15M NaCl
1% (v/v) Tween 20
Wash buffer
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Appendix CI: Calculations appertaining to the column
studies
1) The quantity of protein eluting from G200 Sepahdex, FPLC Superose
6B or zinc affinity columns was calculated thus:
Absorbance total of protein peak = Protein (g/lOOml)
Extinction coefficent
where the extinction coefficent is 12.8
Protein (g/lOOml) x 1000 = Protein (mg/ml)
100
Protein (mg/ml) x Total volume of fractions in peak (ml) = Total protein
in peak (mg)
2) The amount of 125-I cytokine eluting from the columns was calculated
thus:
cpm = nmoles 125-I cytokine
specific activity (cpm/nmole)
3) The percentage of 125-iodine eluted in any peak from the columns
was calculated thus:
cpm in peak x 100 = % eluted 125-iodine
total cpm eluted
4) The relation ship of Kav to the log of molecular weight was used to
establish the molecular weight of fractions eluting from the columns
used in Section 2.3.
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Kav was calculated thus:
Kav= V, - Vo
VfV0
where
Ve = elution volume, the volume at which an individual fraction has
eluted
V0 = void volume, the volume in which blue dextran elutes from the
column
Vt = total volume of the column
Kav is a constant value for each molecular weight provided that the
column and elution conditions remain the same
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Appendix C2: Calculation of values for RIA and zinc
affinity studies





where [RL]= concentration of complex = bound material = B
[R] = concentration of free receptor = F
[L] = concentration of free ligand
The usual assumption is:
[R] = [Total R] - [RL]
ie, that the total i-eceptor concentration (T) minus that complexed to




(T-B)F = Kd (Equation A)
B
Which implies: (T-B)F = BKd
Which implies: TF - BF = BKd
Which implies: TF = B(Kd+F)
Which implies: B = TF
Kd+F
This equation forms the usual Scatchard plot.
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However, in the present study the concenHation of a2M (R) is much
greater than that of cytokine (L), and therefore:
T»L
Therefore, the decx-ease in T (the total concentration of R) due to the
interaction with ligand is impeixeptible, and hence:
T (total a2M concentration) - B (amount of a2M bound to cytokine) = T
This simplifies Equation A thus:
(T-B)F =
B





Plotted as B vs F, the slope is m = T/Kj
Therefore, Kj = T/m
where T = total concentx-ation of a2M present
m = gradient of graph.
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Appendix C3: Statistical analysis of immunoassay
data
The mean value for each concentration of cytokine in the presence
of additional protein (eg a2Mm at 5mg/ml) was calculated with
respect to the control reading, and therefore awarded a value
that related to the 100% value of the control. From these values
the overall deviation around the control values was calculated.
Thus, for Amersham IL6 in the presence of lmg/ml a2Mm:
Control concentration % deviation in the





Thus, the overall mean for the deviation in the absorbance read in
the presence of lmg/ml a2Mm was -1.75%+/- 13.49.
This gives the investigator an indication of the effect of the added
reagent (ie cx2Mm). It is prone to a large percentage error because







Arising from these studies, there have been a number of presentations at
national and international immunology conferences. In addition, the
following publications have appeared:
James, K, Milne, I, Cunningham, A and Elliott, SF. The effect of a2
macroglobulin in commercial cytokine assays. J Immunol Meths 1994;
168: 33-37.
Cunningham, AJ, Elliott, SF, Black, JR and James, K. A simple method
for isolating a2 macroglobulin-cytokine complexes. J Immunol Meths
1994; 169:287-292.
Copies of these papers are enclosed herewith.
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A simple method for isolating a2
macroglobulin-cytokine complexes
A.J. Cunningham *, S.-F. Elliott, J.R. Black, K. James
Department of Surgery (WGH), University of Edinburgh Medical School, Teviot Place, Edinburgh EH8 9AG, UK
(Received 9 September 1993; revised received 22 November 1993; accepted 15 December 1993)
Abstract
There is the need for a simple, effective procedure for separating a2 macroglobulin-cytokine complexes from free
cytokine in order that the nature and possible immunological significance of cytokine-binding by a2 macroglobulin
(a2-M) might be further investigated. This presentation describes a method which exploits the presence of
zinc-binding sites on a2-M which permit the isolation of complexes from other proteins by zinc-affinity chromatogra¬
phy. Furthermore the method may be used in either a column or batch format.
Key words: a2 Macroglobulin; Cytokine; Complex; Isolation
1. Introduction
a2 macroglobulin (a2-M) is a highly conserved
major blood protein found at a concentration of
2-4 mg/ml in serum and extravascular fluid de¬
pending on age and sex (Coan and Roberts, 1989).
No recorded cases of a2-M gene deletion have
been demonstrated to date, suggesting a key
physiological importance. Human a2-M has a
molecular weight of 720 kDa and consists of four
180 kDa polypeptide sub-units held together by
non-covalent and interchain disulphide bonds.
a2-M exhibits the propensity to bind a wide range
of physiologically important molecules, including
all known endopeptidases (Starkey and Barratt,
1977). This interaction results in important
Corresponding author.
changes in both the a2-KI molecule and interact¬
ing enzyme (Sottrupp-Jensen 1989). Similar
changes in the properties of a2-M can also be
achieved by treatment with primary amines such
as methylamine (Gonias et al., 1982). This confor¬
mational change causes a corresponding shift in
electrophoretic mobility from a 'slow' to 'fast'
form and the subsequent exposure of a hydropho¬
bic receptor-binding site on the a2-M molecule
which readily binds to receptors on the surface of
macrophages, fibroblasts and hepatocytes result¬
ing in its rapid removal from the circulation (De-
banne et al., 1976). Recently it has become ap¬
parent that protease and methylamine-treated fast
forms of a2-M also bind a number of immunolog¬
ically important cytokines including IL-1/3, TNF-a
and IL-2 (reviewed by James, 1990; Borth, 1992;
James et al., 1992). These observations are rele¬
vant to both the assay of cytokines (James et al.,
0022-1759/94/S07.00 © 1994 Elsevier Science B.V. All rights reserved
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1994) and their therapeutic application. Further¬
more as previously stressed, they may help ex¬
plain some of the immunological effects previ¬
ously attributed to a2-M (James, 1990).
In order that the possible nature and immuno¬
logical significance of cytokine binding might be
further investigated there is the need for a sim¬
ple, effective procedure for separation of a2-M-
cytokine complexes from free cytokine. This pre¬
sentation describes one such method which ex¬
ploits the presence of a large number of low
affinity zinc-binding sites on a2-M (Gettins and
Cunningham, 1986) thus permitting the separa¬
tion of this molecule from other plasma proteins
by zinc affinity chromatography (Kurecki et al.,
1979). This simple procedure should facilitate the
study of the nature of cytokine interactions with
a2-M and permit investigations with isolated
complexes themselves rather than the compli¬
cated mixtures hitherto studied.
2. Materials and methods
2.1. Source of a2-M and cytokines
Human a2-M was prepared from frozen nor¬
mal human plasma by zinc affinity chromatogra¬
phy as previously described (Kurecki et al., 1979).
It was converted to the electrophoretically 'fast'
form by dialysis against 200 mM methylamine in
50 mM Tris-HCl buffer pH 8.2; this product is
hereafter referred to as a2-Mme. Unbound meth¬
ylamine was removed by dialysis against 0.06 M
PBS (phosphate-buffered saline pH 7.2, contain¬
ing 0.15 M NaCl). The purity of the original a2-M
and its conversion to the 'fast' form were con¬
firmed by polyacrylamide gel electrophoresis
(PAGE) under non-denaturing conditions. The
labelled cytokines used were commercially avail¬
able recombinant human products; the 1251-
labelled IL-2 (specific activity > 600 Ci/mmol)
and IFN-y (specific activity approximately 675
Ci/mmol) were labelled by the chloramine-T
procedure and were purchased from Amersham
International, (Aylesbury, Bucks, UK), while
l25I-labelled TNF-a (labelled by the Bolton-
Hunter method, specific activity > 30 /j,Ci//rg)
was purchased from DuPont (Stevenage, Herts,
UK). It should be noted that according to the
manufacturers' data sheet all the cytokines bind
specifically to their receptors on appropriate tar¬
get cells. After reconstitution in PBS containing
0.1% BSA the cytokines were aliquoted and
stored at -70°C. The percentage of counts pre¬
cipitated by 20% (w/v) tri-chloro acetic acid
(TCA) was routinely assessed and always ex¬
ceeded 85%. Complexes were prepared by incu¬
bating a2-Mme and labelled cytokines for 2 h at
37°C. Experiments designed to assess the feasibil¬
ity of the technique involved incubating 3 pmol of
«2-Mme with approximately 300 fmol of labelled
cytokine. When larger amounts of complex were
required for further investigation 150 pmol of
ci2-Mme were incubated with 1 pmol of cytokine.
2.2. Isolation of a2-M-cytokine complexes
Fast-flow chelating Sepharose 6B (Pharmacia,
Milton Keynes, UK) was washed in 0.1 M phos¬
phate buffer pH 6.5 to remove preservative and
packed into a 180 X 15 mm column. After equili¬
bration with 0.1 M phosphate buffer pH 8.0 (con¬
taining 0.8 M NaCl) the column was charged by
pumping through 0.04 M zinc chloride until free
zinc appeared in the effluent. Excess unbound
zinc was then eluted from the column with 0.1 M
phosphate buffer pH 6.5 (containing 0.8 M NaCl).
The a2-M-cytokine mixture was then applied to
the column and eluted with 0.1 M phosphate
buffer pH 6.5 (containing 0.8 M NaCl), followed
by 0.1 M acetate buffer pH 4.5 (containing 0.8 M
NaCl). The pump speed was maintained through¬
out at 12 ml/h. The protein concentration of the
effluent was determined by measuring the optical
density at 280 nm, whilst the presence of labelled
cytokine was determined by y scintillometry. On
completion of each separation columns were re¬
generated for further use by eluting with 0.05 M
EDTA (containing 0.8 M NaCl) followed by
recharging with zinc as described above. The
tube-based batch assay utilised the same proce¬
dure for equilibration and charging of the
Sepharose as indicated for column preparation,
except that the process was carried out in a 50 ml
centrifuge tube and gel washing was achieved by
centrifugation (200 Xg for 10 min). Once charged
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with zinc, 1 ml Sepharose was added to the
prepared a2-M-cytokine mixture (300 pmol a2-M
+ 150 fmol cytokine) and mixed on a rotator for 1
h to ensure the a2-Mme was thoroughly adsorbed
to the Sepharose. The resultant slurry was washed
and centrifuged, unbound cytokine was eluted in
the phosphate buffer supernatant. The buffer was
changed to 0.1 M acetate saline pH 4.5 and
incubated for a further hour to elute the a2-M
complex in the supernatant and the Sepharose
regenerated as per the schedule described above.
Phosphate buffer pH 6.5
3. Results and discussion
In these experiments we have been able to
demonstrate that a2-M-cytokine complexes can
be readily separated from free cytokine. It is
apparent (Figs, la, lb, 2a and 2b) that cytokine
in the absence of a2-M is almost completely
recovered from the column in the equilibrating
buffer (0.1 M phosphate buffer pH 6.5 containing
0.8 M NaCl), as was confirmed by enzyme im¬
munoassay (data not shown). In contrast how-





























Fig. 1. The isolation of a2-M/
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125I-IL-2 complexes from «,-M/ I25I-I-2 mixtures by zinc affinity chromatography. This figure
portrays the elution profiles of both free l25-I-IL-2 (a, h) and 25I-IL-2-a2-M mixtures (c, d). Note that the free cytokine alone was
recovered in the pH 6.5 phosphate buffer (a) while in the mixture an appreciable proportion of counts were eluted along with
a2-M by the pH 4.5 acetate buffer (d). In this experiment 3 pmol of a2-M were incubated with 300 fmol of l25I-IL-2 for 2 h at 37°C
and applied to a 180 x 15 mm zinc affinity column. Elution was carried out at 12 ml/h and 1 ml fractions collected, (cpm ( );
absorbance at 280 nm (• •)).
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ever, in the presence of a2-Mme an appreciable
proportion of the counts were eluted with the
acetate buffer used to displace the a2-M from the
column (Figs, lc, Id, 2c and 2d). The presence
of bound cytokine in the acetate recovered frac¬
tion was also confirmed by immunoprecipitation
with specific antisera to a2-M and by PAGE
analysis followed by autoradiography (data not
presented). On the basis of repeated separations
of a number of a2-M-cytokine mixtures by both
the column and batch methods, it is apparent
that the technique is highly reproducible (Table
1). Furthermore, studies have revealed as ex¬
pected, that labelled cytokines bound more effec-
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Fig. 2. The isolation of a2-M/ 125I-IFN-y complexes from a2-M/ 125I-IFN-y mixtures by zinc affinity chromatography. This figure
portrays the elution profiles of both free I25I-IFN-y (a, b) and 125I-IFN--y/a2-M mixtures (c, d). Note that the free cytokine alone
was recovered in the pFl 6.5 phosphate buffer (a) while in the mixture an appreciable proportion of counts were eluted along with
a2-M by the pH 4.5 acetate buffer (d). In this experiment 3 pmol of cr2-M were incubated with 300 fmol of I25-I-IFN--y for 2 h at
37°C and applied to a 180 X 15 mm zinc affinity column. Elution was carried out at 12 ml/h and 1 ml fractions collected, (cpm
( ); absorbance at 280 nm (• •)).
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Table 1
The reproducibility of zinc affinity chromatography for isolat¬
ing a2-M cytokine complexes from a2-M-cytokine mixtures
Cytokine 1 Run % of counts eluted
in acetate buffer pH 4.5
Column Batch
'"T-IL-2 + «2-Mme 1 34.4 28.6
0 2 35.9 29.8
3 44.9 25.9
l25I-IFN-y + a2-Mme 1 14.5 11.3
t 2 18.2 12.5
3 18.4 13.3
I25I-TNF-a + a2-Mme 1 28.3 18.4
2 30.2 18.5
3 - 19.1
-M at ratios indi¬
cated in the Materials and Methods section and separated
either by the column or batch method.
Note: an appreciable and consistent number of counts are
always eluted along with arM by both column and batch
methods, with more recovered by the column method due to
more efficient washing.
tively to methylamine-converted 'fast' form of
a2-M than to the native preparation. Neverthe¬
less some binding to the untreated form of a2-M
did occur, possibly indicating that these prepara¬
tions contained small amounts of 'fast' a2-M gen¬
erated during the original isolation procedure.
This technique for a2M-cytokine complex pro¬
duction is a logical adaptation of an existing
a2-M purification protocol and should be readily
applicable to the separation of complexes be¬
tween a2-M and other biologically important
molecules, providing that complex formation does
not block zinc binding sites on the a2-M molecule.
It does not depend on specialised equipment or
lengthy procedures for effectiveness and has also
been successfully adapted by us to a centrifuge
tube-based batch format, thus permitting the
rapid processing of multiple samples. Further¬
more it can be applied to more complex mixtures,
e.g., serum and labelled cytokine. This technique
should facilitate the study of cytokine a2-M inter¬
actions. It should be stressed that in the column
and batch procedures described an excess of solid
phase was used to ensure maximum resolution.
Studies undertaken by us indicate that columns
containing 1 ml volume of the chelating gel are
capable of binding 2 mg of isolated a2-M under
the conditions described. Furthermore columns
of the dimensions used are routinely employed by
us to completely remove the «2-M from 25 ml of
serum or plasma and have been shown to bind at
least 150 mg of a2-M. While it is possible that the
binding of a2-M may be inhibited by interaction
with cytokine we believe that any such effects will
not impair the usefulness of this procedure.
Of additional interest is the apparent hetero¬
geneity of the labelled cytokine preparation (con¬
firmed by gel permeation chromatography and
PAGE analysis - data not shown). It is obviously
important to determine how much binding is at¬
tributable to cytokine degradation products. In
this connection it should be noted that our pre¬
liminary data suggests that a2-M preferentially
binds the intact cytokine although some interac¬
tion with degradation products may also occur.
Furthermore others have shown that biologically
active cytokines can be recovered by dissociation
of a2-M complexes (O'Connor-McCourt and
Wakefield, 1987) and that complex formation it¬
self is not an artefact of the iodination process
(Gettins and Crews, 1993).
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The effect of a2 macroglobulin in commercial cytokine assays
K. James, I. Milne, A. Cunningham, S-F. Elliott *
Department of Surgery (WGH), University ofEdinburgh Medical School, Teviot Place, Edinburgh EH8 9AG, Scotland, UK
(Received 2 August 1993, accepted 17 September 1993)
Abstract
a2 macroglobulin (a2M), a 725 kDa plasma protein, has been reported to bind a range of cytokines. We have
therefore investigated its effect on a number of commercial cytokine assays. The methylamine converted fast form of
the molecule was found to reproducibly depress, by 26% or more, the standard curves obtained with certain
commercial assays for IL-2 and for tumor necrosis factor a, and had a small inhibitory effect on some IL-4 assays. In
contrast it slightly enhanced or had no effect on ELISAs for IL-1/3 and IL-6. The inhibition observed was directly
proportional to the concentration of <r2M used in the range 0.5-5 mg/ml. Studies in the IL-2 system also revealed
that it was largely attributable to the fast form of a2M. Preliminary evidence suggests that the effects observed may
be dependent on the assay source. These findings may be relevant to the assay of biological fluids in which a2M is
present.
Key words: a2 Macroglobulin; Cytokine; ELISA
1. Introduction
a2 macroglobulin (a2M) is a high molecular
weight plasma protein (725 kDa) present at 2-4
mg/ml in the blood and also in relatively high
concentrations in extravascular fluids including
lymph. To date no individuals lacking this protein
have been identified, suggesting that absence of
the appropriate gene constitutes a lethal deletion.
Furthermore, the protein is highly conserved, ho-
mologues having been identified in many lower
species (Starkey and Barrett, 1982).
* Corresponding author. Fax: 031-667-6190.
Abbreviations: ff2M, a2 macroglobulin; a2Mm, a2 macro-
=globulin methylamine.
In plasma, it exists primarily, but not exclu¬
sively as an electrophoretically 'slow', native form,
which can be converted to an electrophoretically
'fast' form by the action of proteases or primary
amines (Barrett et al., 1979). The conformational
changes which accompany conversion to the fast
form expose a hydrophobic domain on the sur¬
face of the molecule which can bind to receptors
on macrophages, hepatocytes and fibroblasts
(Roche et al., 1988; Sottrup-Jensen et al., 1986;
Van Leuven et al., 1986 a, b). Interaction of the
fast form of a2M with this receptor results in its
rapid clearance from the circulation.
The primary physiological role of a2M is that
of a pan-protease inhibitor exhibiting the ability
to bind all endopeptidases (Barrett and Starkey,
1973; Gonias et al., 1982). There have, however,
0022-1759/94/S07.00 © 1994 Elsevier Science B.V. All rights reserved
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been many reports of a2M impairing immune
responses (reviewed in James, 1980), and recently
it has been observed that a2M may bind a num¬
ber of cytokines, leading to the suggestion that
the effects of a2M on the immune system may be
linked to its interaction with cytokines (James
1990; Borth, 1993). The cytokines reported to
bind to a2M include platelet derived growth fac¬
tor (PDGF), IL-2, IL-1/3, IL-6, tumor necrosis
factor a (TNFa), and IFN-y (Huang et al., 1984;
Borth and Teodorescu, 1986; Borth and Luger,
1989; Matsuada et al., 1989; Wollenberg et al.,
1991; James et al., 1992, respectively). In almost
all cases it would appear that cytokine binding is
predominantly to the electrophoretically 'fast'
form of the molecule.
Within clinical and research environments
there is an increasing interest in the assay of
cytokines in biological fluids and tissue culture
supernatants. In view of the high concentration of
a2M in many body fluids and tissue-culture su¬
pernatants, and the a2M-cytokine interactions
referred to above, it seemed desirable to establish
the effect of a2M on a number of commercially
available cytokine ELISAs. Our studies reveal
that the 'fast' form of a2M inhibits certain cy¬
tokine assays without seriously affecting others.
2. Materials and methods
Human a2M was kindly donated by Behring-
werke, Marburg, Germany, and was 82.6% pure
as judged by electrophoresis, the principle impu¬
rities being albumin and immunoglobulins. In ad¬
dition, highly purified electrophoretically 'slow'
native a2M was prepared from fresh plasma
sources by zinc affinity chromatography (Kurecki,
1979). Electrophoretically 'fast' a2M was gener¬
ated from both a2M sources by treatment with
methylamine (Gonias et al., 1982). In brief, a2M
was dialysed against 200 mM methylamine in 50
mM Tris-HCl (pH 8.2) for 6 h. Unbound meth¬
ylamine was then removed by dialysis against
phosphate-buffered saline (pH 7.2, 0.06 M con¬
taining 0.15 M NaCl) (PBS). This product is re¬
ferred to hereafter as a2M methylamine (a2Mm)
or 'fast' asM. Conversion to the electrophoreti¬
cally fast form was confirmed by polyacrylamide
gel electrophoresis (PAGE) (King and Laemmli,
1973). Human serum albumin (98-99% purity,
Sigma Chemical Company, Poole, England) was
used as a control protein. All samples were di¬
luted in and dialysed against PBS, aliquoted and
then stored at - 70°C prior to use.
The cytokine assay kits were purchased from a
number of commercial sources as indicated in the
results; all were two-site ELISAs, and the proto¬
cols followed were as specified by the manufac¬
turer.
The effect of a2M derivatives and albumin in
the assays were determined as follows. 1 vol. of
the protein under test was added to one volume
of each standard to give a final protein concen¬
tration ranging from 0.5 to 5 mg/ml. Samples of
these preparations were incubated for 2 h at 37°C
prior to application to the ELISA plate. ELISA
assays were simultaneously performed with stan¬
dards not preincubated with these proteins. All
assays were carried out in duplicate, and where
pronounced inhibition was seen, assays were re¬
peated 2-6 times.
Table 1
A summary of the effect of methylamine converted a2M on ELISA assays for cytokines




IL-2 Amersham 6 -36.5% (±3.8) -5.5% (±6.0)
TNFa Amersham 2 -23.4% (±3.4) -10.4% (±4.5)
IL-6 Amersham 2 ±13.8% (±0.0) ±3.75% (±2.6)
IL-1/3 Medgenix 2 ±18.0% (±12.3) ±31.5% (±4.3)
IL-4 Amersham 2 -22.6% (±11.4) -11.4% (±3.0)
The methylamine treated ar2M inhibits the assays for IL-2, TNFa, and IL-4, and slightly enhanced those for IL-6 and IL-1/3.
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Unless otherwise stated, the results are pre¬
sented either as the standard curves generated in
the presence or absence of a2M or as the per¬
centage inhibition observed at the highest a2M
and standard concentrations.
3. Results
The results obtained are summarised in Tables
1 and 2, and are presented in Figs. 1-3.
It was found that a2Mm reproducibly inhib¬
ited the detection of cytokine in the Amersham
kits for IL-2, and for TNFa (Figs. 1A and IB).
This inhibition was observed with different
batches of both ELISA kits, and was directly
related to the concentration of a2Mm added. In
contrast, the inhibition of cytokine detection was
independent of the concentration of the cytokine
standard (Table 2), though the absolute level of
inhibition did increase as the cytokine concentra¬
tions increased. Further studies in the IL-2 sys¬
tem revealed that the interference was primarily
associated with the fast form of the molecule
(Fig. 2). It should be noted that in these systems
tested, a smaller inhibition was always observed
with albumin.
The effect of a2M on other assays studied
were less marked. In brief, a small increase was
seen in the Amersham ELISA for IL-6 and in the
Medgenix assay for IL-1/3 (Table 1, and Figs. 3A
Table 2
The percentage inhibition observed when a2 macroglobulin
methylamine was applied to a range of cytokine standards in




62 30.0 40.1 37.0 42.6
125 32.0 38.7 38.7 30.9
250 34.5 40.9 42.2 34.8
500 32.2 32.2 35.2 31.2
1,000 30.5 37.8 34.7 26.4
a2M methylamine was pre-incubated with standards from the
ELISA kits for 2 h at 37°C prior to application to the system.
The decrease in the detection of IL-2 across the standard
range is recorded. The inhibition observed is consistent




Fig. 1. The effect of methylamine treated a2 macroglobulin at
5 mg/ml (o) or at 1 mg/ ml (■), or of albumin at 5 mg/ml
(grey squares) on cytokine assays for IL-2 and TNFalpha was
assessed by pre-incubating assay kit standards with these
proteins for 2 h at 37°C and then applying the incubated
mixtures to the assay systems. The figure compares the in¬
hibitory effect found with the standards alone (a). Note that
n2Mm at 5 mg/ml yielded the greatest inhibitory effect.
and 3B), and a small variable inhibition was ob¬
served in an IL-4 assay (Table 1, and Fig. 3C).
However, in most of these cases the presence of
albumin yielded a similar effect to that observed
with a,Mm.
4. Discussion
In these studies we have shown that a2Mm
may influence cytokine ELISAs in different ways.
Thus, with certain IL-2 and TNFa assays the
presence of a2Mm resulted in an inhibition of
the detection of the cytokines, whereas in other
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Fig. 2. Comparative study of the effects of 'fast' (o) and 'slow'
(•) forms of a2M on the IL-2 assay. Native a2M ('slow') or
a2M methylamine ('fast') were incubated for 2 h at 37°C with
standards in an IL-2 assay. Comparison of the standard curves
derived were made against the standards alone (*). Greater
inhibition was achieved in the presence of the fast form of
r*2M.
systems a2Mm and albumin either had no effect
or caused a small increase in the apparent levels
of cytokine.
The decrease in the detected levels of IL-2
and TNFa in the presence of a2Mm may have
been due to partial or complete masking of epi¬
topes recognised by either the 'capture' or 'detec¬
tor' antibodies. The observation that the percent¬
age inhibition is independent of the concentra¬
tion of standard would seem to support this hy¬
pothesis. Such masking might result from the
binding of cytokine to residues on the outer sur¬
face of the a2M molecule or in the core of the
protein in a similar manner to proteases. An
alternative theory would be that endogenous pro¬
teases bound to a2M degrade the cytokine stan¬
dards (Borth and Teoderescu, 1986). Conversely,
the enhancement seen in some instances may be
due to improved exposure of particular epitopes
resulting from a2M-cytokine interactions, or im¬
proved stability resulting from the antiprotease
activity of a2M itself, or to a non-specific protein
effect. These various hypotheses remain to be
tested.
The limited studies that we have performed to
date suggest that the effects of a2M in cytokine
assays may be dependent on the source of the kit
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Fig. 3. The effect of a2 macroglobulin methylamine at 5
mg/ml (o) and 1 mg/ml (■), or albumin at 5 mg/ml (grey
squares) on cytokine assay kits after preincubation at 37°C for
2 h with kit standards. The incubated samples were applied to
the assay kits as normal. The figures demonstrate the effect of
the proteins on the detection of IL-6, IL-1/3, and IL-4 in assay
systems in comparison to controls, i.e., standards alone (a).
Note that the presence of a2M and albumin at 5 mg/ml
resulted in an increase in the apparent levels of IL-6 and
IL-1/3.
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laboratory reported that a2Mm did not impair an
ELISA for TNFa (James et al., 1992). Further
studies are necessary to establish whether the
effects of fast a2M on cytokine assays is indepen¬
dent of the source but such studies would be
extremely expensive. We believe that the varia¬
tion between kits and cytokines may possibly oc¬
cur due to differences in the epitopes recognised
by the antibodies in the two-site assays. In some
cases the epitopes may be partially or completely
masked following a2M-cytokine interactions,
whilst in others they remain exposed to both
capture and detector antibodies. The possibility
that a2M preferentially binds a subpopulation of
the cytokine, ie denatured protein or peptide
fragments, is also worthy of consideration.
These studies confirm and extend the reported
observations on cytokine-a2M interactions (re¬
viewed in James, 1990; Borth, 1993), and provide
evidence that in certain cases these may interfere
with cytokine assays. These results need to be
considered when precise quantitation of cy¬
tokines is required and may be especially relevant
in clinical situations where high levels of circulat¬
ing a2M are known to exist (e.g., in diabetes),
and where abnormally high levels of proteolytic
activity may also be anticipated. Finally, it may be
possible to circumvent the inhibitory effect ob¬
served in the current study by the use of combi¬
nations of antibodies recognising cytokine epi¬
topes not masked by a2M.
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